Hemophilia B

Genetic MONDO:0010604 Pathograph 45 Show in embeddings browser Bleeding Disorder Coagulation Disorder hemophilia

Hemophilia B is an X-linked disorder of functional coagulation factor IX deficiency caused by pathogenic F9 variants. Defective FIXa-FVIIIa intrinsic tenase limits factor X activation and thrombin-dependent fibrin hemostasis. Residual FIX activity, treatment, joint health, and other modifiers shape a spectrum from severe spontaneous joint and muscle bleeding to bleeding mainly after trauma or procedures. Heterozygous females can also have clinically significant disease.

Ask OpenScientist

Ask a research question about Hemophilia B. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
10
Pathophys.
21
Phenotypes
1
Hypotheses
5
Gaps
45
Pathograph
1
Genes
15
Medical Actions
4
Subtypes
4
Differentials
1
Datasets
13
Trials
9
Models
1
References
3
Deep Research
1
Hyp. Reports
👪

Inheritance

1
X-linked inheritance HP:0001417
A heterozygous mother has a 50% chance of transmitting the variant in each pregnancy. An affected father transmits it to all daughters and no sons. Females can be symptomatic with one pathogenic allele; de novo variation and parental germline mosaicism can explain simplex cases.
X-linked inheritance
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"If the mother of the proband has an F9 pathogenic variant, the chance of the mother transmitting it in each pregnancy is 50%. If the father of the proband has an F9 pathogenic variant, he will transmit it to all his daughters and none of his sons."
GeneReviews describes X-linked transmission.
PMID:20301668 SUPPORT Other
"Approximately 30% of heterozygous females have factor IX clotting activity lower than 40% and are at risk for bleeding"
This is an activity threshold among heterozygotes, not a requirement for biallelic disease.
◆

Subtypes

4
baseline FIX activity
Severe Hemophilia B
Baseline FIX activity below 1 IU/dL (<1%). Spontaneous joint and muscle bleeding is typical without prophylaxis; diagnosis is usually in the first two years.
Show evidence (2 references)
PMID:31219805 SUPPORT Other
"people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive..."
The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
PMID:20301668 SUPPORT Other
"Severe hemophilia B: Usually diagnosed during the first two years of life."
GeneReviews gives the usual diagnostic age.
Moderate Hemophilia B
Baseline FIX activity 1–5 IU/dL (1–5%). Spontaneous bleeding is less frequent and variable, with excessive or delayed bleeding after minor trauma; some patients need prophylaxis for a severe bleeding phenotype.
Show evidence (2 references)
PMID:31219805 SUPPORT Other
"people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive..."
The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
PMID:20301668 SUPPORT Other
"Moderate hemophilia B: Less frequent spontaneous bleeding, although it varies between individuals; however, individuals with moderate hemophilia B do have prolonged or delayed oozing after relatively minor trauma"
GeneReviews documents variation within the moderate activity band.
Mild Hemophilia B
Baseline FIX activity above 5 and below 40 IU/dL (>5% to <40%). Spontaneous bleeding is generally absent, but surgery, dental extraction, or major trauma can cause serious bleeding. Diagnosis may be delayed until adulthood.
Show evidence (2 references)
PMID:31219805 SUPPORT Other
"people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive..."
The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
PMID:20301668 SUPPORT Other
"Mild hemophilia B: Individuals generally do not have spontaneous bleeding episodes; however, without pre- and postoperative treatment, abnormal bleeding occurs with surgery or tooth extractions."
GeneReviews distinguishes mild disease from spontaneous bleeding in severe disease.
regulatory genotype
Hemophilia B Leyden MONDO:0850054
A promoter-variant subtype in which childhood FIX deficiency can improve after puberty. This is an age-dependent regulatory classification that overlaps baseline activity classes; not every proximal-promoter variant has a recovering Leyden phenotype.
Show evidence (2 references)
PMID:23472758 SUPPORT Other
"Mutations within the F9 promoter are associated with a remarkable hemophilia B subtype, termed hemophilia B Leyden, in which symptoms ameliorate after puberty."
Defines the clinical regulatory subtype.
PMID:23472758 SUPPORT In Vitro
"The various hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their associated clinical severities."
Direct binding perturbation links promoter variants to altered regulation.
◈

Mechanistic Hypotheses

1
Canonical F9 Deficiency / Intrinsic Coagulation Failure Model
canonical_f9_deficiency_intrinsic_coagulation_model CANONICAL
Evidence balance 4 support
Pathogenic F9 variants reduce FIX production or activity. FIX activated by FXIa or the tissue-factor/FVIIa complex normally combines with FVIIIa on activated platelet surfaces to activate factor X and support propagation of thrombin generation. Functional FIX deficiency impairs this amplification and fibrin hemostasis to a degree related to residual activity. Replacement, gene addition, and experimental gene correction support the causal role of F9; pharmacologic inhibition of anticoagulant pathways can bypass the defect.
The full OpenScientist report was reviewed against its cited sources, additional primary literature, and GeneReviews. Retain CANONICAL, but replace universal abolition of thrombin with severity-dependent impairment. Both HOPE-B and BENEGENE-2 use FIX-Padua; their lead-in comparisons and distinct follow-up cohorts must not be pooled. A separate ten-person wild-type F9 AAV cohort has median 13-year follow-up. The report overlooked direct experimental evidence for collagen-IV-bound extravascular FIX and existing definitive ClinGen curation. Leyden regulation and inhibitor risk are valid refinements. Modifier associations do not explain a measured 10–15% of HB variance; mixed HA/HB platelet and bone observations do not establish a primary platelet lesion or direct FIX-to-osteoblast pathway. Mouse synovitis and bone results remain species-qualified. See the accompanying openscientist-assessment-by-codex.yaml for claim-level adjudication and unperformed analyses.
Deep research
OpenScientist citations 44 citations 2026-05-23T21:53:07.494491
Show evidence (4 references)
PMID:32809627 SUPPORT Other
"Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX."
Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
PMID:31219805 SUPPORT In Vitro
"Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation"
Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
PMID:40499172 SUPPORT Human Clinical
"Participants were followed for a median of 13.0 years (range, 11.1 to 13.8)."
Longitudinal human intervention supports durable FIX restoration in a distinct early AAV8 cohort.
+ 1 more reference
?

Discussions and Knowledge Gaps

5
Which downstream coagulation signals connect FIX deficiency to low bone mass?
KNOWLEDGE GAP skeletal-pathway
Attached to
pathophysiology#Factor IX Deficiency phenotypes#Reduced Bone Mineral Density
Mouse F9 loss produces a skeletal phenotype without spontaneous joint bleeding, but the study did not demonstrate direct FIX binding/signaling in osteoblasts. Similar FVIII-null findings favor testing shared downstream thrombin/PAR or matrix effects. Human low-BMD studies mix HA/HB and cannot separate bleeding, mobility, or comorbidity.
Proposed experiments
Distinguish systemic FIX from direct skeletal signaling
systemic-fix-bone
First establish F9 expression and source contribution before proposing osteoblast-specific deletion; compare systemic FIX rescue with controlled thrombin-pathway perturbation.
Prospective HB-specific bone outcomes
prospective-bone-clinical
Prospectively measure bone endpoints, activity, joint bleeding, and comorbidity in HB cohorts; improved DXA alone would not identify the molecular mediator.
Show evidence (1 reference)
PMID:34117910 SUPPORT Model Organism
"Further studies are needed to explore the underlying mechanism by which a defective coagulation cascade and the resulting thrombin deficiency alters normal skeletogenesis."
The primary study explicitly leaves mechanism unresolved.
Can an adjunct inflammatory intervention protect human joints beyond optimized bleed prevention?
KNOWLEDGE GAP synovitis-translation
Attached to
pathophysiology#Blood-induced synovitis
Mouse preventive and delayed-treatment experiments have different cartilage outcomes. These data justify further evaluation, not routine MTX treatment or proof that inflammation is independent of all continuing blood exposure.
Show evidence (1 reference)
PMID:42119948 SUPPORT Model Organism
"No differences in cartilage erosion and proteoglycan loss were observed."
Delayed-treatment result limits reversal claims.
How should extravascular FIX and cross-reacting antigen status inform human prophylaxis?
KNOWLEDGE GAP extravascular-fix
Attached to
pathophysiology#Impaired fibrin hemostasis
Collagen-IV-binding perturbation in mice and localization in human liver and muscle establish that this is not a no-data gap. The unresolved issue is quantitative contribution and validated dosing implications in patients, including competition by dysfunctional CRM-positive FIX.
Show evidence (2 references)
PMID:19583826 SUPPORT Model Organism
"the binding of FIX to collagen IV probably plays a significant functional role in hemostasis."
Experimental support exists but needs human quantitative translation.
PMID:33780107 SUPPORT Model Organism
"Prophylactic protection decreases ~5X faster in CRM+ animals."
Cross-reacting antigen status modifies protection in a mouse comparison.
What predicts lifetime gene-therapy durability and feasible retreatment across vector platforms?
KNOWLEDGE GAP durability-and-retreatment
Attached to
pathophysiology#Factor IX Deficiency
Median 13-year follow-up exists in ten men given a wild-type F9 AAV8 vector; current Padua product cohorts have shorter follow-up. One liver biopsy does not resolve all vector-integration, clonal, or cancer risks. Persistently high anti-AAV antibodies limit redosing, and children have different liver-growth considerations.
Show evidence (1 reference)
PMID:40499172 SUPPORT Human Clinical
"Levels of neutralizing antibodies to AAV8 remained high throughout follow-up, thus indicating potential barriers to readministration of the vector."
Long-term human follow-up identifies a concrete retreatment barrier.
Which modifiers improve HB-specific prediction beyond FIX activity and treatment history?
KNOWLEDGE GAP severity-modifiers
Attached to
pathophysiology#Deficient thrombin propagation
FVII, thrombophilia, platelet, and endothelial reports are heterogeneous and often mix HA and HB. They do not quantify how much HB severity variance is explained. The small TGA cohort supports prospective validation, not replacement of factor assays. Matched HA/HB comparisons need genotype, prophylaxis, age, and joint-damage adjustment.
Show evidence (3 references)
PMID:19686262 SUPPORT Human Clinical
"Of the polymorphisms studied, the FVII353Q (RR = 3.5, 95% CI: 1.04-12.05, P = 0.044) allele was associated with a severe phenotype."
This is the FVII report behind the rationale's first clause, and it shows why the clause is a gap rather than a modifier to curate. The association is a single nominal result (interval barely excluding 1) selected from 53 parameters tested in 114 patients whose comparability analysis is reported as F8:c activity, so it yields no HB-specific estimate of severity variance explained. Its direction is also toward more severe disease, opposite to the milder-than-expected subgroup the 10-15% framing invokes.
PMID:28550758 SUPPORT Other
"the available evidence is currently limited and no clear correlations between platelet function parameters and clinical phenotypes have been demonstrated."
Review explicitly limits platelet-modifier inference.
PMID:18624700 SUPPORT Human Clinical
"Fifteen haemophilia patients with chronic viral hepatitis and/or HIV infection showed a significantly lower FMD than patients without active infection."
Vascular findings are confounded by comorbidity in a mixed cohort.
⚙

Pathophysiology

10
Factor IX Deficiency
Pathogenic coding, splice, deletion, and regulatory F9 variants cause absent, reduced, or dysfunctional FIX. Hepatocytes normally secrete this vitamin K-dependent zymogen. Some variants retain circulating FIX antigen despite low activity, so functional deficiency is the common lesion.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
F9 hgnc:3551 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
Animal models
F9-mutant mouse with CRISPR correction Mouse rescues Endogenous F9 correction restores functional FIX sufficiently to improve coagulation in treated mice.
Albumin-locus FIX gene-addition mouse Mouse rescues Albumin-locus gene addition restores sustained FIX expression in newborn and adult hemophilia B mice.
F9 regulatory-and-coding-defect editing mouse Mouse rescues Promoter/enhancer reconstruction and coding-sequence replacement restore FIX expression in the engineered mouse model.
F9-null mouse skeletal phenotype Mouse partially recapitulates
Downstream
Deficient intrinsic tenase activity Insufficient functional FIX limits the FIXa component of the FIXa-FVIIIa complex.
Show evidence (1 reference)
PMID:32809627 SUPPORT Other
"Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX."
Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
Deficient intrinsic tenase activity
Reduced FIXa-FVIIIa activity limits propagation on activated platelet surfaces. Tissue-factor initiation and residual FIX-dependent activity can persist; the defect does not abolish every route of thrombin production.
platelet CL:0000233 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves platelet (CL:0000233). CL:0000233 is a cell type from the Cell Ontology.
blood coagulation, intrinsic pathway GO:0007597 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves blood coagulation, intrinsic pathway (GO:0007597). GO:0007597 is a biological process from the Gene Ontology.
Experimental models
Purified and plasma FIX-Padua cofactor-dependence assays OTHER
Downstream
Impaired factor X activation Intrinsic tenase is the proteolytic activator of factor X; its deficiency reduces sustained FXa generation.
Show evidence (1 reference)
PMID:31219805 SUPPORT In Vitro
"Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation"
Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
Impaired factor X activation
Reduced sustained generation of FXa limits downstream prothrombinase function. The tissue-factor pathway is still present and can be enhanced by TFPI inhibition.
Downstream
Deficient thrombin propagation Less FXa limits conversion of prothrombin to thrombin.
Show evidence (1 reference)
PMID:31219805 SUPPORT In Vitro
"Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation"
Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
Deficient thrombin propagation
The coagulation defect reduces the amount and kinetics of thrombin generated on activated platelet surfaces. This is the functional target of rebalancing therapies and an experimental readout; thrombin-generation assays are not established universal clinical bleeding predictors.
platelet CL:0000233 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves platelet (CL:0000233). CL:0000233 is a cell type from the Cell Ontology.
Downstream
Impaired fibrin hemostasis Inadequate thrombin propagation compromises formation of an effective fibrin clot.
Show evidence (2 references)
PMID:11434702 SUPPORT Other
"propagation, in which large amounts of thrombin are generated on the platelet surface."
Foundational cell-based model places the amplification phase on platelets.
PMID:15735797 SUPPORT Human Clinical
"In a series of 46 haemophilia patients (34 haemophilia A and 12 haemophilia B patients), we found a significant correlation between plasmatic FVIII/FIX levels and endogenous thrombin potential (ETP), peak and time to peak obtained by thrombin generation measurement."
Patient-plasma measurements provide human functional evidence, with only twelve HB participants.
Impaired fibrin hemostasis
The clotting defect permits delayed, recurrent, or prolonged bleeding after vessel injury; severe disease can cause clinically spontaneous bleeding. Physiologic severity depends on residual activity, tissue context, and treatment.
blood coagulation, fibrin clot formation GO:0072378 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves blood coagulation, fibrin clot formation (GO:0072378). GO:0072378 is a biological process from the Gene Ontology.
Animal models
Collagen-IV-binding-defective FIX K5A mouse Mouse partially recapitulates
Downstream
Abnormal Bleeding Inadequate clot formation permits continued or recurrent blood loss.
Joint blood exposure Defective hemostasis permits joint-space bleeding, particularly in untreated severe disease.
Muscle Hemorrhage The clotting defect can produce spontaneous or traumatic muscle bleeding.
Postprocedural Bleeding Injuries, dental extraction, and surgery challenge the deficient coagulation system.
Intracranial Hemorrhage The inherited hemostatic defect permits bleeding at this clinically documented site.
Oral Bleeding The inherited hemostatic defect permits bleeding at this clinically documented site.
Hematoma The inherited hemostatic defect permits bleeding at this clinically documented site.
Hematuria The hemostatic defect can manifest as clinically documented urinary tract bleeding.
Show evidence (2 references)
PMID:32809627 SUPPORT Other
"Factor IX serves as a critical component of the intrinsic coagulation pathway, and its deficiency disrupts normal fibrin clot formation, predisposing affected individuals to prolonged or spontaneous bleeding."
Clinical synthesis links deficient FIX to impaired fibrin hemostasis and bleeding.
PMID:20301668 SUPPORT Other
"Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing."
GeneReviews defines the recurrent and delayed bleeding phenotype.
Joint blood exposure
Bleeding into a joint exposes synovium and cartilage to blood and its breakdown products. Repeated hemarthroses initiate chronic synovitis and cartilage injury.
Downstream
Hemarthrosis Joint-space blood is the clinical manifestation of this exposure.
Blood-induced synovitis Repeated blood exposure initiates synovial inflammatory and proliferative responses.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions."
GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
PMID:42119948 SUPPORT Other
"In severe hemophilia, recurrent hemarthroses lead to hemophilic arthropathy (HArt), characterized by chronic synovitis and cartilage destruction, reminiscent of rheumatoid arthritis."
The source separates the established clinical consequence from its mouse intervention.
Blood-induced synovitis
Chronic synovial inflammation, hyperplasia, macrophage infiltration, and abnormal vascularity accompany recurrent hemarthrosis. Mouse experiments show that these processes can be modified in addition to FIX prophylaxis; the exact contribution of each mediator in patients remains unresolved.
Animal models
Recurrent-hemarthrosis mouse with adjunctive methotrexate Mouse partially recapitulates
Downstream
Cartilage and joint damage Blood-associated synovitis contributes to cartilage remodeling through inflammatory mediators. This is not a claim that synovitis is the sole route of blood-induced cartilage injury.
Show evidence (2 references)
PMID:42119948 SUPPORT Model Organism
"Following targeted treatment of chronic synovitis, combined FIX + MTX therapy resulted in significantly reduced synovial hyperplasia, vascularity, and macrophage infiltration."
Delayed methotrexate changes synovial endpoints in mice, but does not establish a standard human therapy.
PMID:17822515 SUPPORT Other
"it is likely that iron deposition in the synovium induces an inflammatory response that causes not only immune system activation but also stimulates angiogenesis."
Mechanistic synthesis supports iron-associated amplification as a qualified model, not a proven linear human p53→p21→TRAIL pathway.
Cartilage and joint damage
Repeated joint bleeding and inflammatory tissue injury produce chronic arthropathy. Existing damage can influence later bleeding and functional outcome even when FIX activity improves.
Downstream
Hemophilic Arthropathy Structural joint damage produces chronic musculoskeletal disease.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"prophylactic treatment with factor IX concentrate infusions to maintain factor IX clotting activity higher than 1% or as needed to prevent bleeding and allow normal activity improves outcomes and prevents chronic joint disease."
GeneReviews links bleed prevention with protection from chronic joint disease.
Leyden promoter dysfunction
Selected F9 promoter variants impair binding of liver-enriched transcription factors. ONECUT binding at the -5/-6 site and HNF4-dependent regulation provide distinct mechanisms; age-dependent transcriptional compensation varies by allele.
F9 hgnc:3551 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
Experimental models
Leyden F9 promoter transactivation assays CELL LINE
Downstream
Factor IX Deficiency Reduced promoter function lowers FIX expression, with age-dependent improvement for Leyden alleles.
Show evidence (4 references)
PMID:23472758 SUPPORT In Vitro
"ONECUT transcription factors (ONECUT1 and ONECUT2) bind to the -5/-6 site."
Promoter-binding experiments identify a mechanistic regulatory subtype.
PMID:23472758 SUPPORT In Vitro
"The various hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their associated clinical severities."
Direct binding perturbation links promoter variants to altered regulation.
PMID:1631121 SUPPORT In Vitro
"Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all."
Different promoter variants have distinct functional effects; lifelong deficiency is not Leyden recovery.
+ 1 more reference
Neutralizing FIX alloantibodies
After exposure to replacement FIX, a subset of patients develops inhibitory antibodies that neutralize its coagulation activity. Risk is concentrated in severe disease with null variants, especially large deletions or nonsense alleles. This treatment complication is distinct from spontaneous acquired anti-FIX autoimmunity.
Animal models
Naturally occurring hemophilia B dogs Dog partially recapitulates
Downstream
Factor IX Deficiency Inhibitors reduce effective activity of infused FIX and can undermine replacement response.
Show evidence (2 references)
PMID:31919092 SUPPORT Human Clinical
"Nonsense mutations and deletions with large structural changes comprised all mutations among inhibitor patients and were associated with an inhibitor risk of 26.9% and 33.3%, respectively."
Prospective severe previously untreated cohort links null variants to inhibitor development.
PMID:41499759 SUPPORT Human Clinical
"The development of inhibitors in some patients further complicates clinical management, as these antibodies neutralize the coagulation activity of FVIII or FIX, negatively affecting treatment outcomes."
Clinical trial context explains the neutralizing effect of inhibitors.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hemophilia B Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Blood 12
Abnormal Bleeding HP:0001892 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal bleeding (HP:0001892). HP:0001892 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing."
GeneReviews defines the recurrent and delayed bleeding phenotype.
Hemarthrosis Joint hemorrhage HP:0005261 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hemorrhage (HP:0005261). HP:0005261 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions."
GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
Muscle Hemorrhage HP:0040242 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle hemorrhage (HP:0040242). HP:0040242 is a phenotype from the Human Phenotype Ontology.
The subtype annotation records the severe-disease context of the quoted GeneReviews passage; it does not exclude traumatic muscle bleeding in other severity classes.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions."
GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
Postprocedural Bleeding Prolonged bleeding after surgery HP:0004846 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Prolonged bleeding after surgery (HP:0004846). HP:0004846 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing."
GeneReviews defines the recurrent and delayed bleeding phenotype.
Reduced Factor IX Activity HP:0011858 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced factor IX activity (HP:0011858). HP:0011858 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity."
GeneReviews identifies the diagnostic biochemical defect.
Postpartum Hemorrhage HP:0011891 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Post-partum hemorrhage (HP:0011891). HP:0011891 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Maternal factor IX levels do not significantly increase during pregnancy and heterozygous females may need factor IX infusion support for delivery and/or to treat or prevent postpartum hemorrhage."
GeneReviews gives the factor-specific pregnancy risk.
Intracranial Hemorrhage HP:0002170 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intracranial hemorrhage (HP:0002170). HP:0002170 is a phenotype from the Human Phenotype Ontology.
The subtype annotation records the cited severe-disease case and is not a restriction of intracranial bleeding to severe hemophilia.
Show evidence (1 reference)
PMID:39609856 SUPPORT Human Clinical
"This case report outlines the management of ICH in a 7-month-old infant with severe hemophilia B, following an accidental trauma-related event, resulting in a thin compound fracture of the left occiput."
Clinical case directly documents serious intracranial bleeding; its unusual allergy regimen is not generalized.
Oral Bleeding Oral cavity bleeding HP:0030140 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Oral cavity bleeding (HP:0030140). HP:0030140 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:19245420 SUPPORT Human Clinical
"The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding)."
Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
Menorrhagia HP:0000132 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Menorrhagia (HP:0000132). HP:0000132 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33082527 SUPPORT Human Clinical
"In our cohort of haemophilia carriers, the most common bleeding symptoms were menorrhagia (74%) and cutaneous bleeding (69%)."
Selected symptomatic mixed carrier cohort; percentages are not used as HB phenotype frequencies.
PMID:39371765 SUPPORT Human Clinical
"In Group 1 (women and girls with hemophilia (WGH)), 58 and 10 were carriers of hemophilia A and B, respectively."
The newer cohort includes ten HB carriers but pooled symptom reporting does not identify HB-specific counts.
Epistaxis HP:0000421 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epistaxis (HP:0000421). HP:0000421 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33082527 SUPPORT Human Clinical
"Epistaxis was experienced in 43% of the cohort."
The denominator is a selected mixed carrier cohort, not all HB.
Bruising Susceptibility HP:0000978 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bruising susceptibility (HP:0000978). HP:0000978 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33082527 SUPPORT Human Clinical
"In our cohort of haemophilia carriers, the most common bleeding symptoms were menorrhagia (74%) and cutaneous bleeding (69%)."
Supports cutaneous bleeding in a mixed HA/HB carrier cohort; no universal frequency is assigned.
Prolonged aPTT Prolonged partial thromboplastin time HP:0003645 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Prolonged partial thromboplastin time (HP:0003645). HP:0003645 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22123568 SUPPORT Human Clinical
"an isolated prolongation of the activated partial thromboplastin time (APTT) with a reduced factor IX level"
Acquired anti-FIX case illustrates the FIX-dependent assay abnormality; inherited-disease screening limits are described by GeneReviews.
PMID:20301668 SUPPORT Other
"The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity."
GeneReviews requires factor-specific testing.
Genitourinary 2
Nephrotic Syndrome HP:0000100 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nephrotic syndrome (HP:0000100). HP:0000100 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36163649 SUPPORT Human Clinical
"Nephrotic syndrome developed in two (16.7%) patients during ITI."
The denominator is the twelve completing ITI in the Chinese inhibitor cohort.
PMID:34118102 SUPPORT Human Clinical
"all patients experiencing nephrosis either failed or were on-going."
Nephrosis complicates tolerance induction in B-Natural.
Hematuria HP:0000790 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematuria (HP:0000790). HP:0000790 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25515020 SUPPORT Human Clinical
"A seven-year-old Croatian boy with hemophilia B with high-titer inhibitors to coagulation FIX was admitted at our institution with severe hematuria."
Direct clinical observation of urinary bleeding in inhibitor-complicated HB; the treatment-associated renal thromboembolism is distinct from the presenting hemorrhage.
Immune 2
FIX Inhibitors Anti-factor IX antibody positivity HP:6000495 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anti-factor IX antibody positivity (HP:6000495). HP:6000495 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31919092 SUPPORT Human Clinical
"Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED."
Prospective severe previously untreated cohort provides exposure-day cumulative incidence, not all-patient prevalence.
PMID:29925096 SUPPORT Other
"The development of an inhibitor in HB is a rare event (1.5-3% of all patients)"
Review-level all-patient prevalence estimate is a different denominator.
FIX-Associated Anaphylaxis Drug-induced anaphylaxis HP:0410149 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Drug-induced anaphylaxis (HP:0410149). HP:0410149 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36163649 SUPPORT Human Clinical
"Allergic/Anaphylactic reactions occurred in 59.1% patients."
This applies to a selected 44-patient Chinese inhibitor cohort, not all patients with HB.
PMID:31919092 SUPPORT Human Clinical
"Allergic reactions occurred in 4 (28.6%) inhibitor patients."
A prospective cohort illustrates denominator and ascertainment differences.
Musculoskeletal 1
Reduced Bone Mineral Density HP:0004349 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22292576 SUPPORT Human Clinical
"The mean for factor replacement, the number of joint bleeding episodes in the past year, and the number of arthropathic joints were significant independent predictors of both spinal and femoral BMD."
Cross-sectional association does not isolate a direct FIX effect.
PMID:21391975 SUPPORT Human Clinical
"Bone mineral density was lower in children with haemophilia but there was no evidence for significantly increased fracture rate."
Mixed pediatric cohort separates low BMD from demonstrated fracture excess.
Constitutional 1
Joint Pain Arthralgia HP:0002829 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arthralgia (HP:0002829). HP:0002829 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions."
GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
PMID:20301668 SUPPORT Other
"standard treatments for pain with help from a pain specialist as needed"
Pain management is part of GeneReviews supportive care.
Other 3
Hemophilic Arthropathy
No exact HPO term for the combined hemophilic arthropathy entity was found in OLS on 2026-09-04; specific joint bleeding and pain are bound separately.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"improves outcomes and prevents chronic joint disease."
Prevention of bleeding protects joints.
Hematoma
HPO search on 2026-09-04 found site-specific or spontaneous hematoma terms, not an exact generic soft-tissue hematoma term; do not restrict this presentation to spontaneous events.
Show evidence (1 reference)
PMID:19245420 SUPPORT Human Clinical
"The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding)."
Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
Abdominal Hemorrhage
No exact HPO term for this broad abdominal hemorrhage grouping was found on 2026-09-04. Do not bind to gastrointestinal bleeding alone from a source that pools several abdominal compartments. The broad clinical complication is retained without forcing an anatomical causal edge from pooled cohort data.
Show evidence (1 reference)
PMID:41746495 SUPPORT Human Clinical
"Diagnoses included hemophilia A (n = 4; 75% inhibitor-positive), hemophilia B (n = 1), VWD (n = 4), and Glanzmann thrombasthenia (n = 1)."
The ten-case pediatric massive abdominal hemorrhage series includes one HB patient; the abstract does not identify that individual's GI, intraperitoneal, or pelvic compartment.
🧬

Genetic Associations

1
F9 (Pathogenic Variants)
Gene: F9 hgnc:3551 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (5 references)
CGGV:assertion_3d56d08d-48d0-4523-b433-dbd44c5b9e45-2019-05-22T190226.728Z SUPPORT Other
"F9 | HGNC:3551 | hemophilia B | MONDO:0010604 | XL | Definitive"
ClinGen classifies the F9-hemophilia B gene-disease relationship as definitive with X-linked inheritance.
PMID:32809627 SUPPORT Other
"Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX."
Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
PMID:33082527 SUPPORT Human Clinical
"HUMARA assay was performed on 73 symptomatic carriers with low clotting activity ≤50 IU/dL."
Selected mixed HA/HB carrier cohort; this is not a population penetrance estimate.
+ 2 more references
💊

Medical Actions

15
Factor IX Replacement
Action: Protein Replacement TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. NCIT:C16221
Agent: factor IX NCIT:C87741 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses factor IX, annotated with Factor IX Complex (NCIT:C87741). NCIT:C87741 is a therapeutic agent from the NCI Thesaurus.
Platform: Protein replacement
Plasma-derived or recombinant FIX treats acute bleeds and provides hemostatic cover for dental procedures, surgery, or significant trauma. A hemophilia treatment center individualizes product and exposure; inhibitor status and measured recovery can change the approach. Vitamin K and desmopressin do not correct inherited FIX deficiency.
Mechanism Target:
RESTORES Factor IX Deficiency — Provides the missing functional coagulation protein.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur."
GeneReviews supports prompt replacement for acute bleeds.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur."
GeneReviews supports prompt replacement for acute bleeds.
Prophylactic Factor IX Replacement
Action: Protein Replacement TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. NCIT:C16221
Agent: factor IX NCIT:C87741 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses factor IX, annotated with Factor IX Complex (NCIT:C87741). NCIT:C87741 is a therapeutic agent from the NCI Thesaurus.
Platform: Protein replacement
Regular individualized FIX prophylaxis is recommended for severe disease and for moderate or mild disease with frequent bleeds. Targets should prevent bleeding and allow activity; a trough just above 1% may be inadequate for some people, especially with existing joint disease.
Mechanism Target:
RESTORES Factor IX Deficiency — Maintains functional FIX to prevent spontaneous bleeding.
Show evidence (1 reference)
PMID:39043543 SUPPORT Other
"Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B."
ISTH guideline supports regular bleed prevention.
Show evidence (2 references)
PMID:39043543 SUPPORT Other
"Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B."
ISTH guideline supports regular bleed prevention.
PMID:20301668 SUPPORT Other
"For those with severe hemophilia B and those with moderate or mild hemophilia B and frequent bleeding, prophylactic treatment with factor IX concentrate infusions to maintain factor IX clotting activity higher than 1% or as needed to prevent bleeding and allow normal activity improves outcomes..."
GeneReviews emphasizes an individualized clinical goal.
Extended Half-Life Factor IX Products
Action: Protein Replacement TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. NCIT:C16221
Platform: Protein replacement
Fc fusion, albumin fusion, and PEGylation can prolong circulating FIX exposure and reduce infusion burden. Product-specific assays and pharmacokinetics require attention. Plasma half-life alone does not establish tissue hemostatic protection: mouse comparisons and human tissue localization support an extravascular collagen-IV-bound pool, without validating mouse high-dose predictions as a patient regimen.
Mechanism Target:
RESTORES Factor IX Deficiency — Supplies functional FIX with altered pharmacokinetics.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur."
GeneReviews supports prompt replacement for acute bleeds.
Show evidence (3 references)
PMID:33780107 SUPPORT Model Organism
"In mice, both Alprolix® and BeneFIX® bind Col4 with similar affinities"
Binding experiments support an extravascular compartment, not a universal dosing recommendation.
PMID:27106122 SUPPORT In Vitro
"A robust pool of extravascular FIX is clearly observed surrounding blood vessels, localized to the same region as collagen IV, in 2 representative human tissues: liver and skeletal muscle."
Ex vivo immunolocalization in human tissue sections complements the mouse hemostatic experiments; it is not a clinical treatment-response result.
PMID:41087175 SUPPORT Other
"the advent of novel therapeutic strategies-including long-acting coagulation factor products, non-factor therapies, and gene therapy-has ushered hemophilia into a new era of treatment."
Guideline identifies long-acting FIX strategies.
Etranacogene Dezaparvovec Gene Therapy
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
Agent: Etranacogene Dezaparvovec NCIT:C171798 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Etranacogene Dezaparvovec (NCIT:C171798). NCIT:C171798 is a therapeutic agent from the NCI Thesaurus.
Platform: Gene therapy
Liver-directed AAV5 gene addition supplies the hyperactive FIX-Padua transgene for selected adults. HOPE-B enrolled 54 men with baseline FIX ≤2 IU/dL: five-year mean activity was 36.1 IU/dL and ABR fell 63% against each participant's prophylaxis lead-in. Eligibility, liver health, product-specific AAV antibody interpretation, corticosteroid management, and long-term follow-up matter. It is not assured permanent cure or an established repeat-dose treatment.
Mechanism Target:
RESTORES Factor IX Deficiency — Transduced hepatocytes supply a functional FIX variant without correcting the endogenous F9 allele.
Show evidence (1 reference)
PMID:41358585 SUPPORT Human Clinical
"In the full analysis population (54 participants), the adjusted annualized bleeding rate for all bleeding events was 4.16 during the lead-in period and 1.52 during months 7 through 60 after gene therapy, a reduction of 63% (95% confidence interval, 24 to 82)."
HOPE-B five-year results compare the treated cohort with its own prophylaxis lead-in, not a parallel randomized group.
Show evidence (4 references)
PMID:41358585 SUPPORT Human Clinical
"In the full analysis population (54 participants), the adjusted annualized bleeding rate for all bleeding events was 4.16 during the lead-in period and 1.52 during months 7 through 60 after gene therapy, a reduction of 63% (95% confidence interval, 24 to 82)."
HOPE-B five-year results compare the treated cohort with its own prophylaxis lead-in, not a parallel randomized group.
PMID:41358585 SUPPORT Human Clinical
"at 5 years, the mean (±SD) factor IX activity level was 36.1±15.7 IU per deciliter"
This is the five-year value; 36.7% was the two-year value.
PMID:20301668 SUPPORT Other
"One product for adeno-associated virus (AAV)-mediated gene therapy for hemophilia B is approved and available for use in adult males with factor IX levels ≤2%."
GeneReviews describes available gene therapy and variable response.
+ 1 more reference
Fidanacogene Elaparvovec Gene Therapy
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
Agent: Fidanacogene Elaparvovec NCIT:C171800 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Fidanacogene Elaparvovec (NCIT:C171800). NCIT:C171800 is a therapeutic agent from the NCI Thesaurus.
Platform: Gene therapy
AAV gene addition with FIX-Padua reduced ABR by 71% in 45 BENEGENE-2 participants versus their prophylaxis lead-in; mean activity was 26.9% at 15 months. Sixty-two percent received glucocorticoids and anti-AAV antibodies excluded many screened men. Separate phase 1/2a follow-up involved 14 participants and median 5.5 years; it is not an extension result for all 45 phase 3 recipients. Commercial access changed after development: EU authorization was withdrawn on 15 May 2025 for commercial reasons, so trial efficacy is retained without presenting Beqvez as routinely available.
Mechanism Target:
RESTORES Factor IX Deficiency — Provides the same Padua protein variant through a distinct vector platform.
Show evidence (1 reference)
PMID:39321362 SUPPORT Human Clinical
"containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua)"
The transgene is explicitly Padua.
Show evidence (4 references)
PMID:39321362 SUPPORT Human Clinical
"Of the 45 participants who received fidanacogene elaparvovec, 44 completed at least 15 months of follow-up."
Defines the phase 3 population and follow-up.
PMID:39321362 SUPPORT Human Clinical
"The annualized rate of bleeding for all bleeding episodes decreased by 71%, from 4.42 (95% confidence interval [CI], 1.80 to 7.05) at baseline to 1.28 (95% CI, 0.57 to 1.98) after gene therapy"
Before-after phase 3 outcome supports biological activity.
PMID:39321362 SUPPORT Human Clinical
"A total of 28 participants (62%) received glucocorticoids for increased aminotransferase levels or decreased factor IX levels (or both)"
Treatment burden and immune/liver monitoring qualify the benefit.
+ 1 more reference
Fitusiran
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Fitusiran NCIT:C169984 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Fitusiran (NCIT:C169984). NCIT:C169984 is a therapeutic agent from the NCI Thesaurus.
Platform: siRNA
Subcutaneous SERPINC1-directed siRNA reduces antithrombin and increases thrombin generation in eligible patients aged ≥12 years with hemophilia A or B, with or without inhibitors. ATLAS-OLE included 213 participants on an antithrombin-guided regimen, not 213 HB-only randomized patients. The regimen targets AT 15–35% to mitigate thrombosis; breakthrough bleeding, liver and gallbladder safety, and laboratory monitoring require product-specific specialist management.
Mechanism Target:
BYPASSES Deficient thrombin propagation — Reduces anticoagulant inhibition of thrombin rather than supplying FIX.
Show evidence (1 reference)
PMID:40053895 SUPPORT Human Clinical
"Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia."
Antithrombin reduction bypasses the deficient procoagulant factor.
Show evidence (3 references)
PMID:40053895 SUPPORT Human Clinical
"Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia."
Antithrombin reduction bypasses the deficient procoagulant factor.
PMID:40053895 SUPPORT Human Clinical
"Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR..."
External parent-study comparisons do not imply 71% superiority to prophylactic FIX.
PMID:40053895 SUPPORT Human Clinical
"Persistent AT activity levels of <10% for prolonged periods of time were identified as a potential modifiable target for risk mitigation"
The low-AT risk is central to the redesigned dosing strategy.
Concizumab
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Concizumab NCIT:C166914 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Concizumab (NCIT:C166914). NCIT:C166914 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
Anti-TFPI prophylaxis increases extrinsic-pathway FXa generation for patients aged ≥12 years with hemophilia A or B with or without inhibitors. Explorer7 included 133 participants, only 52 in the randomized comparison; explorer8 had a separate HB randomized comparison (12 no prophylaxis, 24 concizumab) with a treated-bleed rate ratio of 0.21. Thromboembolic events prompted a trial pause and mitigation; current management requires drug-level-guided dosing and a breakthrough-bleed plan.
Mechanism Target:
BYPASSES Impaired factor X activation — Relieves TFPI inhibition of tissue-factor-pathway FXa generation.
Show evidence (1 reference)
PMID:33570646 SUPPORT Other
"When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis."
Mechanistic review describes a bypass through extrinsic FXa generation.
Show evidence (4 references)
PMID:33570646 SUPPORT Other
"When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis."
Mechanistic review describes a bypass through extrinsic FXa generation.
PMID:37646676 SUPPORT Human Clinical
"Of 133 enrolled patients, 19 were randomly assigned to group 1 and 33 to group 2; the remaining 81 were assigned to groups 3 and 4."
Separates randomized evidence from the full inhibitor cohort.
PMID:39521008 SUPPORT Human Clinical
"0·21 (0·10-0·45; p<0·0001) for patients with haemophilia B."
HB-specific result in explorer8 compares concizumab with no prophylaxis.
+ 1 more reference
Marstacimab
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Marstacimab NCIT:C166436 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Marstacimab (NCIT:C166436). NCIT:C166436 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
Weekly anti-TFPI prophylaxis is FDA-approved for adults and children aged six years and older with hemophilia A or B, with or without inhibitors, under the June 2026 label. In the BASIS without-inhibitor cohort, 116 treated participants were compared with their preceding six-month on-demand or prophylaxis period; pooled HA/HB ABR fell from 39.86 to 3.20 in the on-demand group and 7.90 to 5.09 in the prophylaxis group. A separate inhibitor cohort treated 51 participants; among 48 previously receiving on-demand bypassing agents, pooled ABR fell from 19.78 to 1.39. Only eight participants in that efficacy comparison had HB, so the subgroup estimate remains imprecise. These within-participant comparisons were not randomized. Thrombotic risk and breakthrough-bleed treatment still need a specialist plan.
Mechanism Target:
BYPASSES Impaired factor X activation — TFPI blockade improves generation and availability of FXa through the tissue-factor pathway.
Show evidence (1 reference)
PMID:33570646 SUPPORT Other
"When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis."
Mechanistic review describes a bypass through extrinsic FXa generation.
Show evidence (8 references)
url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf SUPPORT Other
"HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:"
June 2026 FDA prescribing information establishes the current US age threshold.
url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf SUPPORT Other
"hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors."
The expanded indication includes both inhibitor and non-inhibitor HB populations.
PMID:41351884 SUPPORT Human Clinical
"Of 60 participants with inhibitors in the OP, 51 entered the ATP and received marstacimab."
Distinguishes the inhibitor cohort from the earlier without-inhibitor publication and separates enrolled from treated participants.
+ 5 more references
Inhibitor-Directed Hemostatic Management
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: Eptacog Alfa NCIT:C81125 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Eptacog Alfa (NCIT:C81125). NCIT:C81125 is a therapeutic agent from the NCI Thesaurus.
Platform: Other
Clinically significant FIX inhibitors require specialized hemostatic treatment. Recombinant activated FVII bypasses FIX-dependent tenase and is an option for acute bleeding, especially when allergic reactions make FIX-containing products problematic. Non-factor prophylaxis offers additional options; doses and combinations depend on the specific concomitant therapy.
Mechanism Target:
BYPASSES Deficient intrinsic tenase activity — Activated FVII-based therapy can generate hemostasis without restoring the inhibited FIXa-FVIIIa complex.
Show evidence (1 reference)
PMID:22123568 SUPPORT Human Clinical
"patient received recombinant factor VIIa and corticosteroid treatment."
Clinical anti-FIX case illustrates bypass, while specific regimens require broader guideline management.
Show evidence (3 references)
PMID:22123568 SUPPORT Human Clinical
"patient received recombinant factor VIIa and corticosteroid treatment. Bleeding symptoms had completely disappeared and coagulation tests become normal."
This acquired anti-FIX case supports bypass activity, not corticosteroids as routine congenital HB prophylaxis.
PMID:37646676 SUPPORT Human Clinical
"Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis."
Trial evidence supports an inhibitor-specific non-factor option.
PMID:32133968 SUPPORT Other
"do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX."
Management review reinforces the need for bypass options in this high-risk context.
Immune Tolerance Induction for FIX Inhibitors
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Other
Selected patients undergo specialist FIX exposure-based immune tolerance induction, sometimes with immune suppression. Success is variable and allergic reactions and nephrotic syndrome can complicate therapy. B-Natural reported 11/22 successfully tolerized after one or more courses at study end, with eight still undergoing treatment; that is not a final population success probability.
Mechanism Target:
MODULATES Neutralizing FIX alloantibodies — Attempts to induce tolerance and remove inhibitory antibody activity.
Show evidence (1 reference)
PMID:34118102 SUPPORT Human Clinical
"Eight patients (36.4%) were successfully tolerized after the first course of ITI."
Initial-course efficacy is distinct from later repeat-course outcomes.
Show evidence (2 references)
PMID:34118102 SUPPORT Human Clinical
"At study end, 11 (50%) were considered successfully tolerized after one or more ITI courses, three were unsuccessful, and eight were still undergoing treatment."
Observational cohort documents incomplete follow-up and variable outcome.
PMID:36163649 SUPPORT Human Clinical
"Nephrotic syndrome developed in two (16.7%) patients during ITI."
This frequency applies to the selected Chinese ITI subgroup, not all HB.
Rehabilitation and Pain Management
Action: Physical TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Physical Therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. NCIT:C15302
Platform: Behavioral / lifestyle
Physical therapy evaluates and treats musculoskeletal disease; rehabilitation, exercise adapted to joint status, and pain care accompany bleed prevention. Established arthropathy may require orthopedic treatment and does not necessarily resolve when FIX levels rise.
Target Phenotypes: Hemophilic Arthropathy Relation: this treatment targets this phenotype This treatment targets Hemophilic Arthropathy. Joint Pain HP:0002829 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Joint Pain, annotated with Arthralgia (HP:0002829). HP:0002829 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Physical therapy for evaluation and treatment of musculoskeletal disease; standard treatments for pain with help from a pain specialist as needed"
GeneReviews recommends rehabilitation and pain management.
Mucosal and Postpartum Antifibrinolytic Support
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tranexamic acid CHEBI:48669 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tranexamic acid (CHEBI:48669). CHEBI:48669 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Tranexamic acid can support selected mucosal/procedural and postpartum bleeding management. It is not a FIX replacement and should not be extrapolated to upper urinary-tract bleeding, where clot obstruction can be hazardous. A specialist coordinates its use with factor and non-factor products.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Tranexamic acid can be used to prevent and treat postpartum hemorrhage."
GeneReviews supports this specific use.
Hemophilia Treatment Center Follow-Up
Platform: Other
Provide education, home-infusion training, joint and muscle assessment, exposure-related inhibitor surveillance, and individualized treatment adjustment. GeneReviews recommends six- to twelve-month review for young severe/moderate patients, at least annually for older severe/moderate patients, and every one to two years for mild disease, with shorter intervals for comorbidity.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"Referral to a hemophilia treatment center (HTC) for assessment, education, genetic counseling, and treatment."
Organized multidisciplinary care is a management component.
PMID:20301668 SUPPORT Other
"The assessment should include a review of bleeding episodes, adjustment of treatment plans as needed, a joint and muscle evaluation, an inhibitor screen, viral testing if indicated"
Defines surveillance content.
Genetic Counseling and Pregnancy Planning
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Platform: Other
Test at-risk relatives, establish female genetic status and baseline FIX before pregnancy where possible, and discuss prenatal or preimplantation testing. Maternal FIX does not normally increase substantially in pregnancy; coordinate delivery and postpartum hemostasis and monitor delayed bleeding. Delivery planning should minimize traumatic fetal instrumentation without assuming all pregnancies require cesarean delivery.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"It is recommended that the genetic status of at-risk females be established prior to pregnancy or as early in a pregnancy as possible."
GeneReviews identifies timing of female-risk assessment.
PMID:20301668 SUPPORT Other
"Maternal factor IX levels do not significantly increase during pregnancy and heterozygous females may need factor IX infusion support for delivery and/or to treat or prevent postpartum hemorrhage."
Corrects the research report's erroneous claim that pregnancy increases FIX.
Bleeding-Risk Precautions
Platform: Behavioral / lifestyle
Avoid unnecessary high-trauma activities and coordinate invasive procedures with hemostatic cover. Do not circumcise an at-risk newborn until hemophilia is excluded or covered. Use caution with aspirin and other platelet-active medicines; intramuscular injections require pressure, ice, and treatment planning. Modern factor products have improved infection safety, while older recipients may need evaluation for historical transfusion-related infection.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"Circumcision of at-risk males until hemophilia B is either excluded or treated with factor IX concentrate regardless of severity; activities with a high risk of trauma, particularly head injury."
GeneReviews lists circumstances to avoid.
PMID:20301668 SUPPORT Other
"Cautious use of medications and herbal remedies that affect platelet function, including aspirin. Use precaution with intramuscular injections (apply pressure and ice)"
Specifies medication and injection precautions.
🔬

Biochemical Markers

2
Factor IX Activity (Decreased)
Context: Severe less than 1%, moderate 1-5%, mild 5-40%
Reference Ranges
Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay (Narrative review of FIX Padua hyperactivity, citing the conventional severity classification)
Severe Hemophilia B (< 1 %) Moderate Hemophilia B (1–5 %) Mild Hemophilia B (5–40 %) Not classified as hemophilia B by this scale (≥ 40 %)
Severe Hemophilia B: Frequent spontaneous bleeds are characteristic at this severity.
Moderate Hemophilia B: Bleeding with minor trauma, but rarely spontaneous, is characteristic at this severity.
Mild Hemophilia B: Bleeding only during invasive procedures or trauma is characteristic at this severity.
The source's dash notation ("1%-5%", "5%-40%") does not itself resolve which band exactly 5% falls in. The half-open convention below places Moderate's upper_bound at 5 (excluding exactly 5.0%) and Mild's lower_bound at 5 (including it), so a measured value of exactly 5.0% is placed in Mild; no finer precision is stated in this source to resolve the ambiguity otherwise. The source gives no boundary statement for values at or above 40%, so the open-above tier is this entry's own placement, not a quoted assertion.
Show evidence (1 reference)
PMID:31219805 SUPPORT Other
"people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%-5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%-40% normal) bleed only during invasive..."
States the three conventional severity thresholds, reproduced below as interpretation bands.
Thrombin generation capacity (DECREASED)
Pathograph Readouts
Readout Of Deficient thrombin propagation Negative Candidate Surrogate
An exploratory functional marker; prospective HB-specific validation is required before claiming clinical surrogacy.
Show evidence (1 reference)
PMID:15735797 SUPPORT Human Clinical
"Our results suggest that TGT could be a promising tool to evaluate haemostasis capacity in patients with haemophilia."
The source itself frames the assay as promising rather than validated.
Show evidence (1 reference)
PMID:15735797 SUPPORT Human Clinical
"In addition, a correlation was found between severe clinical bleeding phenotype and ETP."
Correlation supports investigation of functional coagulation capacity, not validated individual prediction.
🔬

Diagnosis

3
FIX clotting activity and coagulation studies
Establish low FIX activity with an appropriate factor assay. Severe disease is <1%, moderate 1–5%, and mild >5% to <40%; phenotype and assay context also matter. A prolonged aPTT with normal PT and platelet count suggests intrinsic-pathway factor deficiency, but mild disease can have a normal screening aPTT. Age-adjust newborn FIX results because physiologic levels are low; molecular testing or later repeat testing may resolve equivocal results.
Show evidence (2 references)
PMID:20301668 SUPPORT Other
"The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity."
Full GeneReviews diagnosis section was reviewed, including screening-test and neonatal limitations.
PMID:31219805 SUPPORT Other
"people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive..."
The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
F9 molecular testing
Sequence F9 including the relevant proximal promoter, with deletion/duplication testing when appropriate. A hemizygous pathogenic variant confirms male disease and a heterozygous pathogenic variant can confirm female disease; a variant of uncertain significance alone is not confirmation.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Identification of a hemizygous F9 pathogenic variant by molecular genetic testing confirms the diagnosis in a male proband. Identification of a heterozygous F9 pathogenic variant by molecular genetic testing confirms the diagnosis in a female proband."
GeneReviews supplies the molecular confirmation criteria.
Inhibitor testing
Measure an inhibitor when recovery or clinical response to FIX is suboptimal and according to exposure-related surveillance. Mixing studies and Bethesda-based assays distinguish a neutralizing inhibitor from isolated inherited factor deficiency, interpreted by a specialist laboratory.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Screening for alloimmune inhibitors is performed after treatment with factor IX concentrates has been initiated and in any individual with a suboptimal clinical response to treatment."
GeneReviews gives the testing indication.
📊

Prevalence

2
Males
Point Prevalence 3.8 per 100,000 1–9 per 100,000
Meta-analysis of national registries estimated point prevalence among males; prevalence at birth was higher at 5.0 per 100,000 male births.
Show evidence (1 reference)
PMID:31499529 SUPPORT Human Clinical
"Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B."
Random-effects national-registry synthesis estimates HB point prevalence among males.
Male births
Birth Prevalence 5.0 per 100,000 1–9 per 100,000 (births)
National-registry meta-analysis estimated 5.0 cases per 100,000 male births. Birth and point prevalence are different measures; their difference does not give an individual patient's life expectancy or a contemporary treatment-specific prognosis.
Show evidence (1 reference)
PMID:31499529 SUPPORT Human Clinical
"Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, 5.0 cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B."
Birth prevalence is estimated separately from point prevalence.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Hemophilia B:

Hemophilia A
Overlapping Features Clinically similar X-linked bleeding with deficient FVIII rather than FIX.
Distinguishing Features
  • Measure both activities; normal FVIII does not exclude HB, and unusual new bleeding in known HB may warrant investigation for an acquired FVIII inhibitor.
Show evidence (1 reference)
PMID:36407152 SUPPORT Human Clinical
"This report describes the management of a patient with congenital hemophilia B and acquired hemophilia A."
A rare dual diagnosis illustrates why a known F9 diagnosis does not exclude an additional cause.
Acquired FIX inhibitor
Overlapping Features Rare autoantibody-mediated functional FIX loss without the inherited F9 disorder.
Distinguishing Features
  • New bleeding, inhibitor detection, and prior or family history distinguish acquired autoimmunity from congenital HB with an alloimmune treatment complication.
Show evidence (1 reference)
PMID:22123568 SUPPORT Human Clinical
"a 7-year-old girl with no past medical history of bleeding disorder and who present an extensive haematoma in the left calf."
Case supports a distinct acquired presentation.
Vitamin K deficiency, liver disease, or vitamin K antagonist effect
Overlapping Features Acquired reduction in several coagulation factors can include FIX.
Distinguishing Features
  • Multi-factor abnormalities and often prolonged PT distinguish these states from isolated congenital FIX deficiency; vitamin K does not correct an inherited dysfunctional F9 allele.
Show evidence (1 reference)
PMID:20301668 SUPPORT Other
"Vitamin K does not prevent or control bleeding in hemophilia B."
GeneReviews distinguishes the inherited defect from vitamin K-responsive states.
Other inherited bleeding disorders
Overlapping Features von Willebrand disease and deficiencies of factors XI, VII, or XIII can overlap clinically.
Distinguishing Features
  • FVII deficiency usually prolongs PT; HB affects FIX-dependent aPTT assays.
  • VWF/FVIII studies identify von Willebrand disease; type 2N mimics FVIII deficiency, not FIX deficiency.
  • Factor XIII deficiency can cause delayed bleeding with normal routine PT/aPTT; factor XII deficiency can prolong aPTT without causing the HB bleeding phenotype.
Show evidence (2 references)
PMID:19245420 SUPPORT Human Clinical
"Hemophilia B patients (n = 296) and FVII-deficient males (n = 109) were compared for FVII/FIX clotting activity, F7/F9 genotypes and clinical phenotypes"
Primary cohort demonstrates distinct phenotypes despite shared coagulation involvement.
PMID:20301668 SUPPORT Other
"The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity."
Factor-specific assays distinguish the diagnostic defect; the complete GeneReviews differential table was reviewed.
📊

Related Datasets

1
Single-Cell RNA sequencing reveals prophylactic Prednisone blunts cellular immunity in hemophilia B gene therapy geo:GSE190760
Blood single-cell RNA sequencing from seven BBM-H901 gene-therapy participants at four time points (28 longitudinal samples). The study relates immune-cell profiles and prednisone exposure to FIX response. These are repeated blood samples, not 28 independent patients or patient joint tissue.
human SINGLE CELL RNA SEQ n=28
PMID:35598604
GEO metadata verified with just verify-datasets on 2026-09-04; evidence is in references_cache/GEO_GSE190760.md. The linked phase 1 trial treated ten participants, whereas this transcriptomic subset contains seven. No raw-data reanalysis was performed. Without a randomized steroid comparison, immune associations do not isolate prophylactic prednisone efficacy.
🔬

Clinical Trials

13
NCT03569891 PHASE_III COMPLETED
HOPE-B, the 54-participant phase 3 etranacogene study. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03569891 SUPPORT Other
"This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03489291 PHASE_II COMPLETED
Three-participant phase 2b etranacogene study, distinct from HOPE-B. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03489291 SUPPORT Other
"This is an open-label, single-dose, single-arm, multi-center trial, with a screening, a treatment + post-treatment follow-up phase, and a long-term follow-up phase."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT05962398 NOT_APPLICABLE ENROLLING_BY_INVITATION
Long-term follow-up of participants from the phase 2b and HOPE-B etranacogene studies. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT05962398 SUPPORT Other
"The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891)."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03861273 PHASE_III ACTIVE_NOT_RECRUITING
BENEGENE-2 phase 3 fidanacogene study; the 15-month results are not the phase 1/2a extension. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03861273 SUPPORT Other
"This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less)."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03307980 PHASE_II COMPLETED
Follow-up and higher-dose substudy after the early fidanacogene program; source of the 14-participant multiyear report. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03307980 SUPPORT Other
"Long-term safety and efficacy follow-up for participants with Hemophilia B who were previously treated in the C0371005 (formerly SPK-9001-101) study, and a dose-escalation sub-study evaluating safety, tolerability, and kinetics of a higher dose with long-term safety and efficacy follow-up...."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT00979238 PHASE_I COMPLETED
Early scAAV2/8-LP1-hFIXco dose escalation; median 13-year follow-up supports durable wild-type FIX expression. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT00979238 SUPPORT Other
"The purpose of this study is to determine the safety of giving a normal factor IX gene to treat individuals who have an abnormal or no factor IX gene."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT04083781 PHASE_III ACTIVE_NOT_RECRUITING
Explorer7 concizumab in HA/HB with inhibitors; randomized and nonrandomized groups coexist. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT04083781 SUPPORT Other
"This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT04082429 PHASE_III ACTIVE_NOT_RECRUITING
Explorer8 concizumab in HA/HB without inhibitors; HB-specific randomized efficacy is reported. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT04082429 SUPPORT Other
"This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03938792 PHASE_III COMPLETED
BASIS marstacimab; separate published cohorts evaluate patients with and without inhibitors using preceding treatment periods. The inhibitor efficacy comparison predominantly comprises HA, with eight HB participants previously receiving on-demand bypassing agents. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03938792 SUPPORT Other
"Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of..."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03754790 PHASE_III ACTIVE_NOT_RECRUITING
ATLAS-OLE fitusiran; antithrombin-guided extension regimen following redesigned safety mitigation. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03754790 SUPPORT Other
"To characterize the long-term safety and tolerability of fitusiran"
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT03369444 PHASE_II TERMINATED
FLT180a gene-therapy study; registry termination does not by itself identify biological failure. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT03369444 SUPPORT Other
"Severe haemophilia B (HB) is a bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT04135300 NOT_APPLICABLE COMPLETED
BBM-H901 phase 1 pilot in ten Chinese adults; blood transcriptomic subset has seven participants. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT04135300 SUPPORT Other
"GT2019001 is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and kinetics of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual FIX levels. BBM-H901 is an adeno-associated viral (AAV) vector..."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
NCT07080905 PHASE_III RECRUITING
Adolescent etranacogene phase 3 study; registration does not establish pediatric efficacy. Registry status checked 2026-09-04.
Show evidence (1 reference)
clinicaltrials:NCT07080905 SUPPORT Other
"This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B."
Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
🧫

Experimental Models

2
Purified and plasma FIX-Padua cofactor-dependence assays OTHER
Recombinant FIX-WT and R338L activity, activation, inactivation and FVIIIa dependence were compared in purified-protein and plasma systems, including transgene-expressing patient samples. Emicizumab substitution removed Padua-specific hyperactivity.
Publication
PMID:31219805
Pathograph links
Deficient intrinsic tenase activity perturbs fidelity: high observes: molecular
Limitations: Defined biochemical systems resolve enzyme-cofactor dependence but lack organ injury, vascular compartments and patient-level bleeding outcomes.
Show evidence (1 reference)
PMID:31219805 SUPPORT In Vitro
"We observed that the high-specific-activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor."
FVIIIa perturbation identifies the requirement for Padua hyperactivity.
Show evidence (1 reference)
PMID:31219805 SUPPORT In Vitro
"We observed that the high-specific-activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor."
FVIIIa perturbation identifies the requirement for Padua hyperactivity.
Leyden F9 promoter transactivation assays CELL_LINE
Wild-type and mutant F9 promoter reporters test HNF4-dependent transactivation. Together with ONECUT binding assays, these experiments connect specific regulatory alleles with loss of expression.
Cell source
HepG2 and HeLa cell lines
Publication
PMID:1631121
Pathograph links
Leyden promoter dysfunction perturbs fidelity: moderate observes: cellular
Limitations: Reporter assays do not recapitulate puberty, liver chromatin context or all Leyden variants.
Show evidence (1 reference)
PMID:1631121 SUPPORT In Vitro
"Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all."
Promoter transactivation separates recovering and persistent regulatory defects.
Show evidence (1 reference)
PMID:1631121 SUPPORT In Vitro
"Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all."
Promoter transactivation separates recovering and persistent regulatory defects.
🐁

Animal Models

7
F9-mutant mouse with CRISPR correction
Hydrodynamic tail-vein delivery of Cas9 and donor plasmids corrected hepatocyte F9 in a subset of treated mice. The result was >1% corrected alleles in 62.5% of mice, not 62.5% allelic correction.
Species
Mouse
Genotype
F9-mutant hemophilia B
Publication
PMID:28508290
Pathograph links
Factor IX Deficiency rescues fidelity: moderate observes: organism Endogenous F9 correction restores functional FIX sufficiently to improve coagulation in treated mice.
Limitations: Hydrodynamic delivery, mosaic correction, and mouse physiology limit clinical transfer; germline experiments do not establish an acceptable human therapy.
Show evidence (1 reference)
PMID:28508290 SUPPORT Model Organism
"62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency."
Model-specific experimental support.
Show evidence (1 reference)
PMID:28508290 SUPPORT Model Organism
"62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency."
Model-specific experimental support.
Albumin-locus FIX gene-addition mouse
Site-specific transgene insertion rescued newborn and adult HB mice and persisted after partial hepatectomy; this differs from repairing endogenous F9.
Species
Mouse
Genotype
Hemophilia B with AAV/CRISPR-mediated albumin-locus insertion
Publication
PMID:32775489
Pathograph links
Factor IX Deficiency rescues fidelity: moderate observes: organism Albumin-locus gene addition restores sustained FIX expression in newborn and adult hemophilia B mice.
Limitations: Mouse stable insertion does not establish human editing efficacy or long-term insertion safety.
Show evidence (1 reference)
PMID:32775489 SUPPORT Model Organism
"FIX levels in treated mice persisted even after a two-thirds partial hepatectomy, indicating stable gene integration."
Model-specific experimental support.
Show evidence (1 reference)
PMID:32775489 SUPPORT Model Organism
"FIX levels in treated mice persisted even after a two-thirds partial hepatectomy, indicating stable gene integration."
Model-specific experimental support.
F9 regulatory-and-coding-defect editing mouse
A synthetic promoter/enhancer and long-range replacement restored expression. Single-cell analysis found hepatocyte-subset differences and treatment-related inflammatory effects.
Species
Mouse
Genotype
Complex mutant F9 with regulatory and coding defects
Publication
PMID:34649996
Pathograph links
Factor IX Deficiency rescues fidelity: moderate observes: organism Promoter/enhancer reconstruction and coding-sequence replacement restore FIX expression in the engineered mouse model.
Limitations: Synthetic promoter rescue and post-treatment inflammation are model-specific; this is not human joint-tissue omics.
Show evidence (1 reference)
PMID:34649996 SUPPORT Model Organism
"a single DNA cutting-mediated long-range replacement restored the FIX-encoding function of a mutant F9 (mF9) carrying both regulatory and coding defects in a severe mouse HB model"
Model-specific experimental support.
Show evidence (1 reference)
PMID:34649996 SUPPORT Model Organism
"a single DNA cutting-mediated long-range replacement restored the FIX-encoding function of a mutant F9 (mF9) carrying both regulatory and coding defects in a severe mouse HB model"
Model-specific experimental support.
Collagen-IV-binding-defective FIX K5A mouse
Reduced collagen-IV binding impaired injury-dependent hemostasis despite normal in vitro clotting activity. This demonstrates an extravascular dimension missing from a plasma-activity-only model.
Species
Mouse
Genotype
F9 K5A knock-in
Publication
PMID:19583826
Pathograph links
Impaired fibrin hemostasis partially recapitulates fidelity: moderate observes: organism
Limitations: The engineered binding variant is not the universal mechanism of inherited HB; assay-specific injury effects do not establish a human dose target.
Show evidence (1 reference)
PMID:19583826 SUPPORT Model Organism
"The K5A mutation dramatically reduced the affinity of FIX for collagen type IV, but had no measurable effect on platelet binding, phospholipid binding, or in vitro clotting activity. However, K5AFIX mice had a mild bleeding tendency, despite their in vitro clotting activity being normal."
Model-specific experimental support.
Show evidence (1 reference)
PMID:19583826 SUPPORT Model Organism
"The K5A mutation dramatically reduced the affinity of FIX for collagen type IV, but had no measurable effect on platelet binding, phospholipid binding, or in vitro clotting activity. However, K5AFIX mice had a mild bleeding tendency, despite their in vitro clotting activity being normal."
Model-specific experimental support.
F9-null mouse skeletal phenotype
Juvenile and adult male knockout mice had reduced BMD, cortical and cancellous bone mass, and fracture resistance despite normal somatic growth. This motivates a bone-mechanism question; it does not demonstrate direct FIX signaling in osteoblasts.
Species
Mouse
Genotype
F9 knockout
Publication
PMID:34117910
Pathograph links
Factor IX Deficiency partially recapitulates fidelity: moderate observes: organism
Limitations: These mice lack spontaneous bleeding seen in human severe disease. Bone histomorphometry and reliable RANKL/OPG measurements were unavailable; downstream thrombin signaling remains a hypothesis.
Show evidence (1 reference)
PMID:34117910 SUPPORT Model Organism
"the FIX KO mice displayed reduced bone mineral density (BMD), reduced cortical and cancellous bone mass, and diminished whole bone fracture resistance."
Model-specific experimental support.
Show evidence (1 reference)
PMID:34117910 SUPPORT Model Organism
"the FIX KO mice displayed reduced bone mineral density (BMD), reduced cortical and cancellous bone mass, and diminished whole bone fracture resistance."
Model-specific experimental support.
Recurrent-hemarthrosis mouse with adjunctive methotrexate
Preventive MTX plus EHL-FIX improved synovitis and cartilage outcomes compared with FIX alone. Delayed MTX reduced synovial endpoints but did not improve cartilage erosion or proteoglycan loss.
Species
Mouse
Genotype
Hemophilia B with repeated joint puncture
Publication
PMID:42119948
Pathograph links
Blood-induced synovitis partially recapitulates fidelity: moderate observes: organism
Limitations: Puncture-induced disease and high experimental doses do not establish human efficacy or reversal of established cartilage damage.
Show evidence (1 reference)
PMID:42119948 SUPPORT Model Organism
"Knee diameter measurements and magnetic resonance imaging scans confirmed successful induction of joint bleeding and synovitis in all injured mice in both parts."
Induced hemarthrosis produces the synovitis represented by this model link; the separate delayed-treatment cartilage result limits claims of structural reversal.
Show evidence (1 reference)
PMID:42119948 SUPPORT Model Organism
"No differences in cartilage erosion and proteoglycan loss were observed."
Model-specific experimental support.
Naturally occurring hemophilia B dogs
Canine models support sustained FIX rescue and permit evaluation of spontaneous bleeding and immunity. Null-mutation dogs developed inhibitors after muscle-directed AAV at doses tolerated by previously studied missense dogs; this is not inevitable for every route or modern vector.
Species
Dog
Genotype
F9 missense or null mutations
Publication
PMID:11545609
Pathograph links
Neutralizing FIX alloantibodies partially recapitulates fidelity: moderate observes: organism
Limitations: Species, genotype, route, and vector dose affect immunity; canine tolerance does not guarantee human safety.
Show evidence (1 reference)
PMID:11545609 SUPPORT Model Organism
"AAV-mediated canine F9 gene transfer to skeletal muscle of hemophilia B dogs carrying a null mutation of F9 (causing an early stop codon and an unstable mRNA) results in induction of inhibitory anti-canine F9"
Canine genotype affects immune response under this delivery regimen.
Show evidence (2 references)
PMID:11545609 SUPPORT Model Organism
"AAV-mediated canine F9 gene transfer to skeletal muscle of hemophilia B dogs carrying a null mutation of F9 (causing an early stop codon and an unstable mRNA) results in induction of inhibitory anti-canine F9"
Canine genotype affects immune response under this delivery regimen.
PMID:9883841 SUPPORT Model Organism
"In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months."
Distinct liver-directed preclinical context demonstrates partial correction.
{ }

Source YAML

click to show 
name: Hemophilia B
creation_date: '2026-02-02T00:16:36Z'
category: Genetic
parents:
- Bleeding Disorder
- Coagulation Disorder
- hemophilia
disease_term:
  preferred_term: hemophilia B
  term:
    id: MONDO:0010604
    label: hemophilia B
description: >-
  Hemophilia B is an X-linked disorder of functional coagulation factor IX deficiency caused by pathogenic F9 variants. Defective FIXa-FVIIIa intrinsic tenase limits factor X activation and thrombin-dependent fibrin hemostasis. Residual FIX activity, treatment, joint health, and other modifiers shape a spectrum from severe spontaneous joint and muscle bleeding to bleeding mainly after trauma or procedures. Heterozygous females can also have clinically significant disease.
prevalence:
- population: Males
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 3.8
  percentage: 3.8 per 100,000
  notes: >-
    Meta-analysis of national registries estimated point prevalence among males;
    prevalence at birth was higher at 5.0 per 100,000 male births.
  evidence:
  - reference: PMID:31499529
    reference_title: 'Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B.
    explanation: >-
      Random-effects national-registry synthesis estimates HB point prevalence among males.
- population: Male births
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 5.0
  percentage: 5.0 per 100,000
  notes: >-
    National-registry meta-analysis estimated 5.0 cases per 100,000 male births. Birth and point prevalence are different measures; their difference does not give an individual patient's life expectancy or a contemporary treatment-specific prognosis.
  evidence:
  - reference: PMID:31499529
    reference_title: 'Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, 5.0 cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B.
    explanation: >-
      Birth prevalence is estimated separately from point prevalence.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_f9_deficiency_intrinsic_coagulation_model
  hypothesis_label: Canonical F9 Deficiency / Intrinsic Coagulation Failure Model
  status: CANONICAL
  description: >-
    Pathogenic F9 variants reduce FIX production or activity. FIX activated by FXIa or the tissue-factor/FVIIa complex normally combines with FVIIIa on activated platelet surfaces to activate factor X and support propagation of thrombin generation. Functional FIX deficiency impairs this amplification and fibrin hemostasis to a degree related to residual activity. Replacement, gene addition, and experimental gene correction support the causal role of F9; pharmacologic inhibition of anticoagulant pathways can bypass the defect.
  notes: >-
    The full OpenScientist report was reviewed against its cited sources, additional primary literature, and GeneReviews. Retain CANONICAL, but replace universal abolition of thrombin with severity-dependent impairment. Both HOPE-B and BENEGENE-2 use FIX-Padua; their lead-in comparisons and distinct follow-up cohorts must not be pooled. A separate ten-person wild-type F9 AAV cohort has median 13-year follow-up. The report overlooked direct experimental evidence for collagen-IV-bound extravascular FIX and existing definitive ClinGen curation. Leyden regulation and inhibitor risk are valid refinements. Modifier associations do not explain a measured 10–15% of HB variance; mixed HA/HB platelet and bone observations do not establish a primary platelet lesion or direct FIX-to-osteoblast pathway. Mouse synovitis and bone results remain species-qualified. See the accompanying openscientist-assessment-by-codex.yaml for claim-level adjudication and unperformed analyses.
  evidence:
  - reference: PMID:32809627
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX.
    explanation: >-
      Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation
    explanation: >-
      Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
  - reference: PMID:40499172
    reference_title: Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Participants were followed for a median of 13.0 years (range, 11.1 to 13.8).
    explanation: >-
      Longitudinal human intervention supports durable FIX restoration in a distinct early AAV8 cohort.
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We observed that the high-specific-activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor.
    explanation: >-
      Perturbation shows the hyperactive transgene still depends on the intrinsic-tenase cofactor.
pathophysiology:
- name: Factor IX Deficiency
  description: >-
    Pathogenic coding, splice, deletion, and regulatory F9 variants cause absent, reduced, or dysfunctional FIX. Hepatocytes normally secrete this vitamin K-dependent zymogen. Some variants retain circulating FIX antigen despite low activity, so functional deficiency is the common lesion.
  evidence:
  - reference: PMID:32809627
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX.
    explanation: >-
      Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
  genes:
  - preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  downstream:
  - target: Deficient intrinsic tenase activity
    description: >-
      Insufficient functional FIX limits the FIXa component of the FIXa-FVIIIa complex.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32809627
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX.
      explanation: >-
        Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
    - reference: PMID:31219805
      reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation
      explanation: >-
        Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
- name: Deficient intrinsic tenase activity
  description: >-
    Reduced FIXa-FVIIIa activity limits propagation on activated platelet surfaces. Tissue-factor initiation and residual FIX-dependent activity can persist; the defect does not abolish every route of thrombin production.
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation
    explanation: >-
      Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: blood coagulation, intrinsic pathway
    term:
      id: GO:0007597
      label: blood coagulation, intrinsic pathway
  downstream:
  - target: Impaired factor X activation
    description: >-
      Intrinsic tenase is the proteolytic activator of factor X; its deficiency reduces sustained FXa generation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31219805
      reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation
      explanation: >-
        Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
- name: Impaired factor X activation
  description: >-
    Reduced sustained generation of FXa limits downstream prothrombinase function. The tissue-factor pathway is still present and can be enhanced by TFPI inhibition.
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Activated FIX (FIXa) complexes with its cofactor, FVIIIa, to form the intrinsic Xase enzyme complex (FIXa-FVIIIa), which is responsible for the proteolytic activation of coagulation factor X (FX) through the intrinsic pathway during sustained coagulation
    explanation: >-
      Biochemical study defines the FIXa-FVIIIa complex and its factor X substrate.
  downstream:
  - target: Deficient thrombin propagation
    description: >-
      Less FXa limits conversion of prothrombin to thrombin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34117910
      reference_title: 'Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Activated FX converts prothrombin to thrombin, a pivotal step necessary for clot formation.
      explanation: >-
        The source summarizes this established coagulation step; its experimental bone results are assessed separately.
- name: Deficient thrombin propagation
  description: >-
    The coagulation defect reduces the amount and kinetics of thrombin generated on activated platelet surfaces. This is the functional target of rebalancing therapies and an experimental readout; thrombin-generation assays are not established universal clinical bleeding predictors.
  evidence:
  - reference: PMID:11434702
    reference_title: A cell-based model of hemostasis.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: propagation, in which large amounts of thrombin are generated on the platelet surface.
    explanation: >-
      Foundational cell-based model places the amplification phase on platelets.
  - reference: PMID:15735797
    reference_title: Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In a series of 46 haemophilia patients (34 haemophilia A and 12 haemophilia B patients), we found a significant correlation between plasmatic FVIII/FIX levels and endogenous thrombin potential (ETP), peak and time to peak obtained by thrombin generation measurement.
    explanation: >-
      Patient-plasma measurements provide human functional evidence, with only twelve HB participants.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  downstream:
  - target: Impaired fibrin hemostasis
    description: >-
      Inadequate thrombin propagation compromises formation of an effective fibrin clot.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32809627
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Factor IX serves as a critical component of the intrinsic coagulation pathway, and its deficiency disrupts normal fibrin clot formation, predisposing affected individuals to prolonged or spontaneous bleeding.
      explanation: >-
        Clinical synthesis links deficient FIX to impaired fibrin hemostasis and bleeding.
    intermediate_mechanisms:
    - insufficient thrombin-mediated fibrinogen conversion
- name: Impaired fibrin hemostasis
  description: >-
    The clotting defect permits delayed, recurrent, or prolonged bleeding after vessel injury; severe disease can cause clinically spontaneous bleeding. Physiologic severity depends on residual activity, tissue context, and treatment.
  evidence:
  - reference: PMID:32809627
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Factor IX serves as a critical component of the intrinsic coagulation pathway, and its deficiency disrupts normal fibrin clot formation, predisposing affected individuals to prolonged or spontaneous bleeding.
    explanation: >-
      Clinical synthesis links deficient FIX to impaired fibrin hemostasis and bleeding.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing.
    explanation: >-
      GeneReviews defines the recurrent and delayed bleeding phenotype.
  biological_processes:
  - preferred_term: blood coagulation, fibrin clot formation
    term:
      id: GO:0072378
      label: blood coagulation, fibrin clot formation
  downstream:
  - target: Abnormal Bleeding
    description: >-
      Inadequate clot formation permits continued or recurrent blood loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing.
      explanation: >-
        GeneReviews defines the recurrent and delayed bleeding phenotype.
  - target: Joint blood exposure
    description: >-
      Defective hemostasis permits joint-space bleeding, particularly in untreated severe disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
      explanation: >-
        GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  - target: Muscle Hemorrhage
    description: >-
      The clotting defect can produce spontaneous or traumatic muscle bleeding.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
      explanation: >-
        GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  - target: Postprocedural Bleeding
    description: >-
      Injuries, dental extraction, and surgery challenge the deficient coagulation system.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing.
      explanation: >-
        GeneReviews defines the recurrent and delayed bleeding phenotype.
  - target: Intracranial Hemorrhage
    description: >-
      The inherited hemostatic defect permits bleeding at this clinically documented site.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39609856
      reference_title: 'Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This case report outlines the management of ICH in a 7-month-old infant with severe hemophilia B, following an accidental trauma-related event, resulting in a thin compound fracture of the left occiput.
      explanation: >-
        Clinical case directly documents serious intracranial bleeding; its unusual allergy regimen is not generalized.
  - target: Oral Bleeding
    description: >-
      The inherited hemostatic defect permits bleeding at this clinically documented site.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19245420
      reference_title: Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding).
      explanation: >-
        Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
  - target: Hematoma
    description: >-
      The inherited hemostatic defect permits bleeding at this clinically documented site.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19245420
      reference_title: Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding).
      explanation: >-
        Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
  - target: Hematuria
    description: >-
      The hemostatic defect can manifest as clinically documented urinary tract bleeding.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25515020
      reference_title: Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: A seven-year-old Croatian boy with hemophilia B with high-titer inhibitors to coagulation FIX was admitted at our institution with severe hematuria.
      explanation: >-
        Direct clinical observation of urinary bleeding in inhibitor-complicated HB; the treatment-associated renal thromboembolism is distinct from the presenting hemorrhage.
- name: Joint blood exposure
  description: >-
    Bleeding into a joint exposes synovium and cartilage to blood and its breakdown products. Repeated hemarthroses initiate chronic synovitis and cartilage injury.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
    explanation: >-
      GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  - reference: PMID:42119948
    reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In severe hemophilia, recurrent hemarthroses lead to hemophilic arthropathy (HArt), characterized by chronic synovitis and cartilage destruction, reminiscent of rheumatoid arthritis.  # codespell:ignore-line
    explanation: >-
      The source separates the established clinical consequence from its mouse intervention.
  downstream:
  - target: Hemarthrosis
    description: >-
      Joint-space blood is the clinical manifestation of this exposure.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
      explanation: >-
        GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  - target: Blood-induced synovitis
    description: >-
      Repeated blood exposure initiates synovial inflammatory and proliferative responses.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42119948
      reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hemophilia B mice underwent 3 biweekly knee joint punctures to induce recurrent hemarthroses.
      explanation: >-
        Experimentally repeated bleeding induces joint disease in an HB mouse model.
    - reference: PMID:42119948
      reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Knee diameter measurements and magnetic resonance imaging scans confirmed successful induction of joint bleeding and synovitis in all injured mice in both parts.
      explanation: >-
        Mouse intervention supports blood exposure followed by synovitis, with species limitations.
- name: Blood-induced synovitis
  description: >-
    Chronic synovial inflammation, hyperplasia, macrophage infiltration, and abnormal vascularity accompany recurrent hemarthrosis. Mouse experiments show that these processes can be modified in addition to FIX prophylaxis; the exact contribution of each mediator in patients remains unresolved.
  evidence:
  - reference: PMID:42119948
    reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Following targeted treatment of chronic synovitis, combined FIX + MTX therapy resulted in significantly reduced synovial hyperplasia, vascularity, and macrophage infiltration.
    explanation: >-
      Delayed methotrexate changes synovial endpoints in mice, but does not establish a standard human therapy.
  - reference: PMID:17822515
    reference_title: 'Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: it is likely that iron deposition in the synovium induces an inflammatory response that causes not only immune system activation but also stimulates angiogenesis.
    explanation: >-
      Mechanistic synthesis supports iron-associated amplification as a qualified model, not a proven linear human p53→p21→TRAIL pathway.
  downstream:
  - target: Cartilage and joint damage
    description: >-
      Blood-associated synovitis contributes to cartilage remodeling through inflammatory mediators. This is not a claim that synovitis is the sole route of blood-induced cartilage injury.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42119948
      reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Prophylactic MTX combined with EHL-FIX reduced the severity of the synovitis, significantly reduced the vascular density in the synovial pannus, and decreased the degree of cartilage damage compared with EHL-FIX alone.
      explanation: >-
        Prevention experiment supports an inflammatory contribution to cartilage injury in mice; delayed treatment did not reverse cartilage endpoints.
    - reference: PMID:17822515
      reference_title: 'Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A cartilage remodelling programme induced by the release of cytokines and growth factors that result in articular damage is also discussed.
      explanation: >-
        Mechanistic synthesis identifies the intervening inflammatory remodeling process while emphasizing incomplete human experimental evidence.
    intermediate_mechanisms:
    - inflammatory cytokine and growth-factor-associated cartilage remodeling
- name: Cartilage and joint damage
  description: >-
    Repeated joint bleeding and inflammatory tissue injury produce chronic arthropathy. Existing damage can influence later bleeding and functional outcome even when FIX activity improves.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: prophylactic treatment with factor IX concentrate infusions to maintain factor IX clotting activity higher than 1% or as needed to prevent bleeding and allow normal activity improves outcomes and prevents chronic joint disease.
    explanation: >-
      GeneReviews links bleed prevention with protection from chronic joint disease.
  downstream:
  - target: Hemophilic Arthropathy
    description: >-
      Structural joint damage produces chronic musculoskeletal disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42119948
      reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In severe hemophilia, recurrent hemarthroses lead to hemophilic arthropathy (HArt), characterized by chronic synovitis and cartilage destruction, reminiscent of rheumatoid arthritis.  # codespell:ignore-line
      explanation: >-
        The clinical background explicitly defines arthropathy through joint tissue damage; the intervention results remain mouse-specific.
- name: Leyden promoter dysfunction
  description: >-
    Selected F9 promoter variants impair binding of liver-enriched transcription factors. ONECUT binding at the -5/-6 site and HNF4-dependent regulation provide distinct mechanisms; age-dependent transcriptional compensation varies by allele.
  evidence:
  - reference: PMID:23472758
    reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: ONECUT transcription factors (ONECUT1 and ONECUT2) bind to the -5/-6 site.
    explanation: >-
      Promoter-binding experiments identify a mechanistic regulatory subtype.
  - reference: PMID:23472758
    reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The various hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their associated clinical severities.
    explanation: >-
      Direct binding perturbation links promoter variants to altered regulation.
  - reference: PMID:1631121
    reference_title: Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all.
    explanation: >-
      Different promoter variants have distinct functional effects; lifelong deficiency is not Leyden recovery.
  - reference: PMID:8499951
    reference_title: Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: a synergistic interaction between DBP and C/EBP responsible for the recovery of normal transcriptional activity of the -5 mutant promoter and may play a role in the resolution of other Leyden mutants.
    explanation: >-
      Specific promoter compensation does not establish one universal pubertal mechanism.
  genes:
  - preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
  subtypes:
  - Hemophilia B Leyden
  downstream:
  - target: Factor IX Deficiency
    description: >-
      Reduced promoter function lowers FIX expression, with age-dependent improvement for Leyden alleles.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:23472758
      reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The various hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their associated clinical severities.
      explanation: >-
        Direct binding perturbation links promoter variants to altered regulation.
    - reference: PMID:23472758
      reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: mice deficient in ONECUT1, ONECUT2, or both exhibit depleted levels of F9.
      explanation: >-
        In vivo TF deficiency supports dependence of F9 expression on this regulatory system.
- name: Neutralizing FIX alloantibodies
  description: >-
    After exposure to replacement FIX, a subset of patients develops inhibitory antibodies that neutralize its coagulation activity. Risk is concentrated in severe disease with null variants, especially large deletions or nonsense alleles. This treatment complication is distinct from spontaneous acquired anti-FIX autoimmunity.
  evidence:
  - reference: PMID:31919092
    reference_title: 'Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nonsense mutations and deletions with large structural changes comprised all mutations among inhibitor patients and were associated with an inhibitor risk of 26.9% and 33.3%, respectively.
    explanation: >-
      Prospective severe previously untreated cohort links null variants to inhibitor development.
  - reference: PMID:41499759
    reference_title: 'Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The development of inhibitors in some patients further complicates clinical management, as these antibodies neutralize the coagulation activity of FVIII or FIX, negatively affecting treatment outcomes.
    explanation: >-
      Clinical trial context explains the neutralizing effect of inhibitors.
  downstream:
  - target: Factor IX Deficiency
    description: >-
      Inhibitors reduce effective activity of infused FIX and can undermine replacement response.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41499759
      reference_title: 'Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: these antibodies neutralize the coagulation activity of FVIII or FIX, negatively affecting treatment outcomes.
      explanation: >-
        Neutralization creates functional replacement failure; this is an acquired complication layered onto inherited deficiency.
phenotypes:
- name: Abnormal Bleeding
  description: >-
    Prolonged, delayed, or recurrent bleeding, varying with untreated FIX activity and treatment history.
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing.
    explanation: >-
      GeneReviews defines the recurrent and delayed bleeding phenotype.
  category: Hematologic
  diagnostic: true
- name: Hemarthrosis
  description: >-
    Spontaneous or trauma-associated joint bleeding is particularly characteristic of severe untreated disease.
  phenotype_term:
    preferred_term: Joint hemorrhage
    term:
      id: HP:0005261
      label: Joint hemorrhage
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
    explanation: >-
      GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  category: Musculoskeletal
  subtypes:
  - Severe Hemophilia B
  - Moderate Hemophilia B
- name: Muscle Hemorrhage
  description: >-
    Deep muscle bleeding can cause painful swelling and functional compromise; severity and site vary.
  subtypes:
  - Severe Hemophilia B
  phenotype_term:
    preferred_term: Muscle hemorrhage
    term:
      id: HP:0040242
      label: Muscle hemorrhage
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
    explanation: >-
      GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  category: Musculoskeletal
  notes: The subtype annotation records the severe-disease context of the quoted GeneReviews passage; it does not exclude traumatic muscle bleeding in other severity classes.
- name: Postprocedural Bleeding
  description: >-
    Dental extraction and surgery can uncover mild disease as well as provoke severe bleeding in all activity classes.
  subtypes:
  - Severe Hemophilia B
  - Moderate Hemophilia B
  - Mild Hemophilia B
  phenotype_term:
    preferred_term: Prolonged bleeding after surgery
    term:
      id: HP:0004846
      label: Prolonged bleeding after surgery
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B is characterized by deficiency in factor IX clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing.
    explanation: >-
      GeneReviews defines the recurrent and delayed bleeding phenotype.
  category: Hematologic
- name: Reduced Factor IX Activity
  description: >-
    The defining laboratory abnormality is deficient clotting activity, not necessarily reduced antigen concentration.
  phenotype_term:
    preferred_term: Reduced factor IX activity
    term:
      id: HP:0011858
      label: Reduced factor IX activity
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
    explanation: >-
      GeneReviews identifies the diagnostic biochemical defect.
  category: Laboratory
  diagnostic: true
  reports_on:
  - target: Factor IX Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
      explanation: >-
        GeneReviews identifies the diagnostic biochemical defect.
- name: Hemophilic Arthropathy
  description: >-
    Chronic joint disease caused by recurrent hemarthrosis and tissue injury; disease burden depends strongly on access to effective prophylaxis.
  phenotype_term:
    preferred_term: Hemophilic arthropathy
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: improves outcomes and prevents chronic joint disease.
    explanation: >-
      Prevention of bleeding protects joints.
  category: Musculoskeletal
  notes: >-
    No exact HPO term for the combined hemophilic arthropathy entity was found in OLS on 2026-09-04; specific joint bleeding and pain are bound separately.
- name: Joint Pain
  description: >-
    Pain can accompany joint bleeding and chronic arthropathy.
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: including spontaneous joint or muscle bleeds, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.
    explanation: >-
      GeneReviews describes joint and muscle bleeding and painful swelling in untreated severe disease.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: standard treatments for pain with help from a pain specialist as needed
    explanation: >-
      Pain management is part of GeneReviews supportive care.
  category: Musculoskeletal
- name: Postpartum Hemorrhage
  description: >-
    Heterozygous females with reduced FIX can bleed at delivery or postpartum; maternal FIX does not normally rise substantially in pregnancy.
  phenotype_term:
    preferred_term: Post-partum hemorrhage
    term:
      id: HP:0011891
      label: Post-partum hemorrhage
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Maternal factor IX levels do not significantly increase during pregnancy and heterozygous females may need factor IX infusion support for delivery and/or to treat or prevent postpartum hemorrhage.
    explanation: >-
      GeneReviews gives the factor-specific pregnancy risk.
  category: Obstetric
- name: Intracranial Hemorrhage
  description: >-
    Life-threatening bleeding may be traumatic or spontaneous; it can reveal severe disease in infancy. No population frequency is inferred from a case report.
  subtypes:
  - Severe Hemophilia B
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
  evidence:
  - reference: PMID:39609856
    reference_title: 'Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This case report outlines the management of ICH in a 7-month-old infant with severe hemophilia B, following an accidental trauma-related event, resulting in a thin compound fracture of the left occiput.
    explanation: >-
      Clinical case directly documents serious intracranial bleeding; its unusual allergy regimen is not generalized.
  category: Neurologic
  notes: The subtype annotation records the cited severe-disease case and is not a restriction of intracranial bleeding to severe hemophilia.
- name: Oral Bleeding
  description: >-
    Oral mucosal bleeding and excessive bleeding after dental procedures are important presentations.
  phenotype_term:
    preferred_term: Oral cavity bleeding
    term:
      id: HP:0030140
      label: Oral cavity bleeding
  evidence:
  - reference: PMID:19245420
    reference_title: Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding).
    explanation: >-
      Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
  category: Hematologic
- name: Hematoma
  description: >-
    Soft-tissue hematomas can be an early presentation and may follow minor trauma.
  phenotype_term:
    preferred_term: Hematoma
  evidence:
  - reference: PMID:19245420
    reference_title: Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The most frequent disease-presenting symptoms in hemophilia B (hematomas and oral bleeding) differed from those in FVII deficiency (epistaxis and central nervous system bleeding).
    explanation: >-
      Retrospective study of 296 HB patients confirms hematoma and oral bleeding presentation; epistaxis and CNS prominence in this comparison refer to the FVII-deficient group.
  category: Hematologic
  notes: HPO search on 2026-09-04 found site-specific or spontaneous hematoma terms, not an exact generic soft-tissue hematoma term; do not restrict this presentation to spontaneous events.
- name: Menorrhagia
  description: >-
    Heavy menstrual bleeding can occur in heterozygous females. The cited studies combine HA and HB carriers and do not provide a general HB-only prevalence.
  phenotype_term:
    preferred_term: Menorrhagia
    term:
      id: HP:0000132
      label: Menorrhagia
  evidence:
  - reference: PMID:33082527
    reference_title: 'X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In our cohort of haemophilia carriers, the most common bleeding symptoms were menorrhagia (74%) and cutaneous bleeding (69%).
    explanation: >-
      Selected symptomatic mixed carrier cohort; percentages are not used as HB phenotype frequencies.
  - reference: PMID:39371765
    reference_title: A Comparative Analysis of the Bleeding Profile and Quality of Life Among Women With Hemophilia Genotype Compared to Other Bleeding Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In Group 1 (women and girls with hemophilia (WGH)), 58 and 10 were carriers of hemophilia A and B, respectively.
    explanation: >-
      The newer cohort includes ten HB carriers but pooled symptom reporting does not identify HB-specific counts.
  category: Gynecologic
- name: Epistaxis
  description: >-
    Nosebleeds may occur, including in symptomatic female carriers; their frequency is not established by the pooled HA/HB carrier series.
  phenotype_term:
    preferred_term: Epistaxis
    term:
      id: HP:0000421
      label: Epistaxis
  evidence:
  - reference: PMID:33082527
    reference_title: 'X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Epistaxis was experienced in 43% of the cohort.
    explanation: >-
      The denominator is a selected mixed carrier cohort, not all HB.
  category: Hematologic
- name: Bruising Susceptibility
  description: >-
    Cutaneous bleeding or bruising can occur, including in symptomatic heterozygous females.
  phenotype_term:
    preferred_term: Bruising susceptibility
    term:
      id: HP:0000978
      label: Bruising susceptibility
  evidence:
  - reference: PMID:33082527
    reference_title: 'X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In our cohort of haemophilia carriers, the most common bleeding symptoms were menorrhagia (74%) and cutaneous bleeding (69%).
    explanation: >-
      Supports cutaneous bleeding in a mixed HA/HB carrier cohort; no universal frequency is assigned.
  category: Dermatologic
- name: FIX Inhibitors
  description: >-
    Neutralizing alloantibodies are a treatment complication concentrated in severe null-variant disease. Older estimates of 1.5–3% prevalence across all HB should not replace the approximately 10% cumulative incidence in a prospective severe previously untreated cohort.
  phenotype_term:
    preferred_term: Anti-factor IX antibody positivity
    term:
      id: HP:6000495
      label: Anti-factor IX antibody positivity
  evidence:
  - reference: PMID:31919092
    reference_title: 'Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED.
    explanation: >-
      Prospective severe previously untreated cohort provides exposure-day cumulative incidence, not all-patient prevalence.
  - reference: PMID:29925096
    reference_title: Inhibitors in Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The development of an inhibitor in HB is a rare event (1.5-3% of all patients)
    explanation: >-
      Review-level all-patient prevalence estimate is a different denominator.
  category: Immunologic
  context: After exposure to therapeutic FIX
  reports_on:
  - target: Neutralizing FIX alloantibodies
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    evidence:
    - reference: PMID:31919092
      reference_title: 'Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED.
      explanation: >-
        Prospective severe previously untreated cohort provides exposure-day cumulative incidence, not all-patient prevalence.
- name: FIX-Associated Anaphylaxis
  description: >-
    Allergic and anaphylactic reactions may accompany FIX inhibitor development. Reported risk varies substantially across selected cohorts; it is not an inevitable consequence of an inhibitor.
  phenotype_term:
    preferred_term: Drug-induced anaphylaxis
    term:
      id: HP:0410149
      label: Drug-induced anaphylaxis
  evidence:
  - reference: PMID:36163649
    reference_title: 'Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Allergic/Anaphylactic reactions occurred in 59.1% patients.
    explanation: >-
      This applies to a selected 44-patient Chinese inhibitor cohort, not all patients with HB.
  - reference: PMID:31919092
    reference_title: 'Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Allergic reactions occurred in 4 (28.6%) inhibitor patients.
    explanation: >-
      A prospective cohort illustrates denominator and ascertainment differences.
  category: Immunologic
  context: Complication of FIX exposure, especially in inhibitor-positive patients
- name: Nephrotic Syndrome
  description: >-
    A recognized complication during some FIX immune tolerance regimens; it should not be depicted as a core renal manifestation in untreated inherited HB.
  phenotype_term:
    preferred_term: Nephrotic syndrome
    term:
      id: HP:0000100
      label: Nephrotic syndrome
  evidence:
  - reference: PMID:36163649
    reference_title: 'Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nephrotic syndrome developed in two (16.7%) patients during ITI.
    explanation: >-
      The denominator is the twelve completing ITI in the Chinese inhibitor cohort.
  - reference: PMID:34118102
    reference_title: The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: all patients experiencing nephrosis either failed or were on-going.
    explanation: >-
      Nephrosis complicates tolerance induction in B-Natural.
  category: Renal
  context: Immune tolerance induction complication
- name: Reduced Bone Mineral Density
  description: >-
    Low BMD is reported in mixed hemophilia cohorts, including children receiving prophylaxis. Joint disease, activity, comorbidity, and possible downstream coagulation effects require separation; a direct FIX-specific bone mechanism in people is unproven.
  phenotype_term:
    preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  evidence:
  - reference: PMID:22292576
    reference_title: Osteoporosis/osteopenia and hemophilic arthropathy in severe hemophilic patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean for factor replacement, the number of joint bleeding episodes in the past year, and the number of arthropathic joints were significant independent predictors of both spinal and femoral BMD.
    explanation: >-
      Cross-sectional association does not isolate a direct FIX effect.
  - reference: PMID:21391975
    reference_title: Hypercalciuria in children with haemophilia suggests primary skeletal pathology.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Bone mineral density was lower in children with haemophilia but there was no evidence for significantly increased fracture rate.
    explanation: >-
      Mixed pediatric cohort separates low BMD from demonstrated fracture excess.
  category: Musculoskeletal
- name: Prolonged aPTT
  description: >-
    Severe or moderate untreated FIX deficiency usually prolongs aPTT; mild disease may escape this screening test. An inhibitor or other intrinsic-pathway defect can produce the same result, so aPTT alone is not diagnostic.
  phenotype_term:
    preferred_term: Prolonged partial thromboplastin time
    term:
      id: HP:0003645
      label: Prolonged partial thromboplastin time
  evidence:
  - reference: PMID:22123568
    reference_title: '[Acquired haemophilia B: a case report and literature review].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an isolated prolongation of the activated partial thromboplastin time (APTT) with a reduced factor IX level
    explanation: >-
      Acquired anti-FIX case illustrates the FIX-dependent assay abnormality; inherited-disease screening limits are described by GeneReviews.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
    explanation: >-
      GeneReviews requires factor-specific testing.
  category: Laboratory
  reports_on:
  - target: Deficient intrinsic tenase activity
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    evidence:
    - reference: PMID:22123568
      reference_title: '[Acquired haemophilia B: a case report and literature review].'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: an isolated prolongation of the activated partial thromboplastin time (APTT) with a reduced factor IX level
      explanation: >-
        Acquired anti-FIX case illustrates the FIX-dependent assay abnormality; inherited-disease screening limits are described by GeneReviews.
- name: Hematuria
  description: >-
    Urinary tract bleeding can be severe. Underlying vascular or urologic causes and inhibitor status affect management; treatment-associated thrombosis must not be mistaken for the inherited bleeding mechanism.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  evidence:
  - reference: PMID:25515020
    reference_title: Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A seven-year-old Croatian boy with hemophilia B with high-titer inhibitors to coagulation FIX was admitted at our institution with severe hematuria.
    explanation: >-
      Direct clinical observation of urinary bleeding in inhibitor-complicated HB; the treatment-associated renal thromboembolism is distinct from the presenting hemorrhage.
  category: Renal
- name: Abdominal Hemorrhage
  description: >-
    Potentially life-threatening gastrointestinal, intraperitoneal, or pelvic bleeding is a clinical concern. A recent pediatric massive-abdominal-hemorrhage series included one HB patient; the aggregate data do not determine that patient's specific bleeding compartment or an HB prevalence.
  phenotype_term:
    preferred_term: Abdominal hemorrhage
  evidence:
  - reference: PMID:41746495
    reference_title: 'Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnoses included hemophilia A (n = 4; 75% inhibitor-positive), hemophilia B (n = 1), VWD (n = 4), and Glanzmann thrombasthenia (n = 1).
    explanation: >-
      The ten-case pediatric massive abdominal hemorrhage series includes one HB patient; the abstract does not identify that individual's GI, intraperitoneal, or pelvic compartment.
  category: Hematologic
  notes: No exact HPO term for this broad abdominal hemorrhage grouping was found on 2026-09-04. Do not bind to gastrointestinal bleeding alone from a source that pools several abdominal compartments. The broad clinical complication is retained without forcing an anatomical causal edge from pooled cohort data.
genetic:
- name: F9
  gene_term:
    preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_3d56d08d-48d0-4523-b433-dbd44c5b9e45-2019-05-22T190226.728Z
    reference_title: "F9 / hemophilia B (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "F9 | HGNC:3551 | hemophilia B | MONDO:0010604 | XL | Definitive"
    explanation: ClinGen classifies the F9-hemophilia B gene-disease relationship as definitive with X-linked inheritance.
  - reference: PMID:32809627
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Hemophilia B, also known as Christmas disease, represents the second most common form of hemophilia and results from pathogenic variants in the F9 gene that impair the production or function of coagulation factor IX.
    explanation: >-
      Clinical synthesis identifies loss of functional FIX as the lesion; reduced antigen is not required.
  - reference: PMID:33082527
    reference_title: 'X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: HUMARA assay was performed on 73 symptomatic carriers with low clotting activity ≤50 IU/dL.
    explanation: >-
      Selected mixed HA/HB carrier cohort; this is not a population penetrance estimate.
  - reference: PMID:33082527
    reference_title: 'X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In our cohort of haemophilia carriers, XCI was significantly skewed, which may contribute to the low expression of clotting factor levels and bleeding symptoms.
    explanation: >-
      Association supports an X-inactivation modifier, with tissue-specific causation unresolved.
  - reference: PMID:33656538
    reference_title: Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: This is consistent with the previous identification of hFIX-R338L as a cause of a rare X-linked thrombophilia risk factor.
    explanation: >-
      Padua is a hyperactive variant with a distinct phenotype, used therapeutically rather than as an HB allele.
  notes: >-
    F9 coding, splice, copy-number, and proximal promoter variants can cause disease. Activity rather than antigen concentration defines severity: some dysfunctional proteins retain cross-reacting antigen. Null alleles confer greater inhibitor risk than missense alleles. A single heterozygous pathogenic variant can cause disease in females; low factor levels can reflect skewed X inactivation, but blood-cell X-inactivation measurements do not directly establish hepatocyte mosaicism. The therapeutic FIX-Padua mature-protein R338L (precursor p.Arg384Leu) is a gain-of-function transgene, not a hemophilia-causing loss-of-function variant.
treatments:
- name: Factor IX Replacement
  therapeutic_modality: PROTEIN_REPLACEMENT
  description: >-
    Plasma-derived or recombinant FIX treats acute bleeds and provides hemostatic cover for dental procedures, surgery, or significant trauma. A hemophilia treatment center individualizes product and exposure; inhibitor status and measured recovery can change the approach. Vitamin K and desmopressin do not correct inherited FIX deficiency.
  treatment_term:
    preferred_term: Protein Replacement Therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
    therapeutic_agent:
    - preferred_term: factor IX
      term:
        id: NCIT:C87741
        label: Factor IX Complex
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur.
    explanation: >-
      GeneReviews supports prompt replacement for acute bleeds.
  target_mechanisms:
  - target: Factor IX Deficiency
    treatment_effect: RESTORES
    description: >-
      Provides the missing functional coagulation protein.
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur.
      explanation: >-
        GeneReviews supports prompt replacement for acute bleeds.
- name: Prophylactic Factor IX Replacement
  therapeutic_modality: PROTEIN_REPLACEMENT
  description: >-
    Regular individualized FIX prophylaxis is recommended for severe disease and for moderate or mild disease with frequent bleeds. Targets should prevent bleeding and allow activity; a trough just above 1% may be inadequate for some people, especially with existing joint disease.
  treatment_term:
    preferred_term: Protein Replacement Therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
    therapeutic_agent:
    - preferred_term: factor IX
      term:
        id: NCIT:C87741
        label: Factor IX Complex
  evidence:
  - reference: PMID:39043543
    reference_title: International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B.
    explanation: >-
      ISTH guideline supports regular bleed prevention.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For those with severe hemophilia B and those with moderate or mild hemophilia B and frequent bleeding, prophylactic treatment with factor IX concentrate infusions to maintain factor IX clotting activity higher than 1% or as needed to prevent bleeding and allow normal activity improves outcomes and prevents chronic joint disease.
    explanation: >-
      GeneReviews emphasizes an individualized clinical goal.
  target_mechanisms:
  - target: Factor IX Deficiency
    treatment_effect: RESTORES
    description: >-
      Maintains functional FIX to prevent spontaneous bleeding.
    evidence:
    - reference: PMID:39043543
      reference_title: International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B.
      explanation: >-
        ISTH guideline supports regular bleed prevention.
- name: Extended Half-Life Factor IX Products
  therapeutic_modality: PROTEIN_REPLACEMENT
  description: >-
    Fc fusion, albumin fusion, and PEGylation can prolong circulating FIX exposure and reduce infusion burden. Product-specific assays and pharmacokinetics require attention. Plasma half-life alone does not establish tissue hemostatic protection: mouse comparisons and human tissue localization support an extravascular collagen-IV-bound pool, without validating mouse high-dose predictions as a patient regimen.
  treatment_term:
    preferred_term: Protein Replacement Therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
  evidence:
  - reference: PMID:33780107
    reference_title: The Function of extravascular coagulation factor IX in haemostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In mice, both Alprolix® and BeneFIX® bind Col4 with similar affinities
    explanation: >-
      Binding experiments support an extravascular compartment, not a universal dosing recommendation.
  - reference: PMID:27106122
    reference_title: Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: 'A robust pool of extravascular FIX is clearly observed surrounding blood vessels, localized to the same region as collagen IV, in 2 representative human tissues: liver and skeletal muscle.'
    explanation: >-
      Ex vivo immunolocalization in human tissue sections complements the mouse hemostatic
      experiments; it is not a clinical treatment-response result.
  - reference: PMID:41087175
    reference_title: '[Chinese guidelines on the treatment of hemophilia (2025)].'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: the advent of novel therapeutic strategies-including long-acting coagulation factor products, non-factor therapies, and gene therapy-has ushered hemophilia into a new era of treatment.
    explanation: >-
      Guideline identifies long-acting FIX strategies.
  target_mechanisms:
  - target: Factor IX Deficiency
    treatment_effect: RESTORES
    description: >-
      Supplies functional FIX with altered pharmacokinetics.
    evidence:
    - reference: PMID:20301668
      reference_title: Hemophilia B.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Intravenous infusion of plasma-derived or recombinant factor IX for acute bleeding episodes should be given as soon as possible after symptoms occur.
      explanation: >-
        GeneReviews supports prompt replacement for acute bleeds.
- name: Etranacogene Dezaparvovec Gene Therapy
  therapeutic_modality: GENE_THERAPY
  description: >-
    Liver-directed AAV5 gene addition supplies the hyperactive FIX-Padua transgene for selected adults. HOPE-B enrolled 54 men with baseline FIX ≤2 IU/dL: five-year mean activity was 36.1 IU/dL and ABR fell 63% against each participant's prophylaxis lead-in. Eligibility, liver health, product-specific AAV antibody interpretation, corticosteroid management, and long-term follow-up matter. It is not assured permanent cure or an established repeat-dose treatment.
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
    therapeutic_agent:
    - preferred_term: Etranacogene Dezaparvovec
      term:
        id: NCIT:C171798
        label: Etranacogene Dezaparvovec
  evidence:
  - reference: PMID:41358585
    reference_title: Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the full analysis population (54 participants), the adjusted annualized bleeding rate for all bleeding events was 4.16 during the lead-in period and 1.52 during months 7 through 60 after gene therapy, a reduction of 63% (95% confidence interval, 24 to 82).
    explanation: >-
      HOPE-B five-year results compare the treated cohort with its own prophylaxis lead-in, not a parallel randomized group.
  - reference: PMID:41358585
    reference_title: Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: at 5 years, the mean (±SD) factor IX activity level was 36.1±15.7 IU per deciliter
    explanation: >-
      This is the five-year value; 36.7% was the two-year value.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: One product for adeno-associated virus (AAV)-mediated gene therapy for hemophilia B is approved and available for use in adult males with factor IX levels ≤2%.
    explanation: >-
      GeneReviews describes available gene therapy and variable response.
  - reference: PMID:40499172
    reference_title: Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seven of the 10 participants did not receive prophylaxis.
    explanation: >-
      A distinct wild-type F9 AAV8 cohort retained benefit over median thirteen years.
  target_mechanisms:
  - target: Factor IX Deficiency
    treatment_effect: RESTORES
    description: >-
      Transduced hepatocytes supply a functional FIX variant without correcting the endogenous F9 allele.
    evidence:
    - reference: PMID:41358585
      reference_title: Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In the full analysis population (54 participants), the adjusted annualized bleeding rate for all bleeding events was 4.16 during the lead-in period and 1.52 during months 7 through 60 after gene therapy, a reduction of 63% (95% confidence interval, 24 to 82).
      explanation: >-
        HOPE-B five-year results compare the treated cohort with its own prophylaxis lead-in, not a parallel randomized group.
- name: Fidanacogene Elaparvovec Gene Therapy
  therapeutic_modality: GENE_THERAPY
  description: >-
    AAV gene addition with FIX-Padua reduced ABR by 71% in 45 BENEGENE-2 participants versus their prophylaxis lead-in; mean activity was 26.9% at 15 months. Sixty-two percent received glucocorticoids and anti-AAV antibodies excluded many screened men. Separate phase 1/2a follow-up involved 14 participants and median 5.5 years; it is not an extension result for all 45 phase 3 recipients. Commercial access changed after development: EU authorization was withdrawn on 15 May 2025 for commercial reasons, so trial efficacy is retained without presenting Beqvez as routinely available.
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
    therapeutic_agent:
    - preferred_term: Fidanacogene Elaparvovec
      term:
        id: NCIT:C171800
        label: Fidanacogene Elaparvovec
  evidence:
  - reference: PMID:39321362
    reference_title: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of the 45 participants who received fidanacogene elaparvovec, 44 completed at least 15 months of follow-up.
    explanation: >-
      Defines the phase 3 population and follow-up.
  - reference: PMID:39321362
    reference_title: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The annualized rate of bleeding for all bleeding episodes decreased by 71%, from 4.42 (95% confidence interval [CI], 1.80 to 7.05) at baseline to 1.28 (95% CI, 0.57 to 1.98) after gene therapy
    explanation: >-
      Before-after phase 3 outcome supports biological activity.
  - reference: PMID:39321362
    reference_title: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A total of 28 participants (62%) received glucocorticoids for increased aminotransferase levels or decreased factor IX levels (or both)
    explanation: >-
      Treatment burden and immune/liver monitoring qualify the benefit.
  - reference: PMID:40239068
    reference_title: Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A total of 14 participants provided consent and completed at least 3 years of follow-up (median, 5.5; range 3 to 6)
    explanation: >-
      This is the separate phase 1/2a follow-up cohort.
  notes: >-
    Availability verified against https://www.ema.europa.eu/en/medicines/human/EPAR/beqvez on 2026-09-04; withdrawal was requested for commercial reasons and does not refute the clinical trial results.
  target_mechanisms:
  - target: Factor IX Deficiency
    treatment_effect: RESTORES
    description: >-
      Provides the same Padua protein variant through a distinct vector platform.
    evidence:
    - reference: PMID:39321362
      reference_title: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua)
      explanation: >-
        The transgene is explicitly Padua.
- name: Fitusiran
  therapeutic_modality: SIRNA
  description: >-
    Subcutaneous SERPINC1-directed siRNA reduces antithrombin and increases thrombin generation in eligible patients aged ≥12 years with hemophilia A or B, with or without inhibitors. ATLAS-OLE included 213 participants on an antithrombin-guided regimen, not 213 HB-only randomized patients. The regimen targets AT 15–35% to mitigate thrombosis; breakthrough bleeding, liver and gallbladder safety, and laboratory monitoring require product-specific specialist management.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Fitusiran
      term:
        id: NCIT:C169984
        label: Fitusiran
  evidence:
  - reference: PMID:40053895
    reference_title: 'Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia.
    explanation: >-
      Antithrombin reduction bypasses the deficient procoagulant factor.
  - reference: PMID:40053895
    reference_title: 'Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis.
    explanation: >-
      External parent-study comparisons do not imply 71% superiority to prophylactic FIX.
  - reference: PMID:40053895
    reference_title: 'Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Persistent AT activity levels of <10% for prolonged periods of time were identified as a potential modifiable target for risk mitigation
    explanation: >-
      The low-AT risk is central to the redesigned dosing strategy.
  target_mechanisms:
  - target: Deficient thrombin propagation
    treatment_effect: BYPASSES
    description: >-
      Reduces anticoagulant inhibition of thrombin rather than supplying FIX.
    evidence:
    - reference: PMID:40053895
      reference_title: 'Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia.
      explanation: >-
        Antithrombin reduction bypasses the deficient procoagulant factor.
- name: Concizumab
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: >-
    Anti-TFPI prophylaxis increases extrinsic-pathway FXa generation for patients aged ≥12 years with hemophilia A or B with or without inhibitors. Explorer7 included 133 participants, only 52 in the randomized comparison; explorer8 had a separate HB randomized comparison (12 no prophylaxis, 24 concizumab) with a treated-bleed rate ratio of 0.21. Thromboembolic events prompted a trial pause and mitigation; current management requires drug-level-guided dosing and a breakthrough-bleed plan.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Concizumab
      term:
        id: NCIT:C166914
        label: Concizumab
  evidence:
  - reference: PMID:33570646
    reference_title: 'Concizumab: a novel anti-TFPI therapeutic for hemophilia.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis.
    explanation: >-
      Mechanistic review describes a bypass through extrinsic FXa generation.
  - reference: PMID:37646676
    reference_title: Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 133 enrolled patients, 19 were randomly assigned to group 1 and 33 to group 2; the remaining 81 were assigned to groups 3 and 4.
    explanation: >-
      Separates randomized evidence from the full inhibitor cohort.
  - reference: PMID:39521008
    reference_title: 'Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 0·21 (0·10-0·45; p<0·0001) for patients with haemophilia B.
    explanation: >-
      HB-specific result in explorer8 compares concizumab with no prophylaxis.
  - reference: PMID:42341325
    reference_title: 'Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Low median annualized bleeding rates for treated spontaneous and traumatic bleeding episodes were maintained at the 56-week cutoff in patients receiving concizumab
    explanation: >-
      Longer follow-up maintains efficacy; HA and HB subgroup results are reported separately.
  notes: >-
    The US indication expanded to patients without inhibitors in July 2025; checked against the manufacturer announcement and current prescribing information on 2026-09-04. Earlier GeneReviews/review statements limiting use to inhibitor-positive HB are time-specific.
  target_mechanisms:
  - target: Impaired factor X activation
    treatment_effect: BYPASSES
    description: >-
      Relieves TFPI inhibition of tissue-factor-pathway FXa generation.
    evidence:
    - reference: PMID:33570646
      reference_title: 'Concizumab: a novel anti-TFPI therapeutic for hemophilia.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis.
      explanation: >-
        Mechanistic review describes a bypass through extrinsic FXa generation.
- name: Marstacimab
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: >-
    Weekly anti-TFPI prophylaxis is FDA-approved for adults and children aged six years and older with hemophilia A or B, with or without inhibitors, under the June 2026 label. In the BASIS without-inhibitor cohort, 116 treated participants were compared with their preceding six-month on-demand or prophylaxis period; pooled HA/HB ABR fell from 39.86 to 3.20 in the on-demand group and 7.90 to 5.09 in the prophylaxis group. A separate inhibitor cohort treated 51 participants; among 48 previously receiving on-demand bypassing agents, pooled ABR fell from 19.78 to 1.39. Only eight participants in that efficacy comparison had HB, so the subgroup estimate remains imprecise. These within-participant comparisons were not randomized. Thrombotic risk and breakthrough-bleed treatment still need a specialist plan.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Marstacimab
      term:
        id: NCIT:C166436
        label: Marstacimab
  evidence:
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in
      adults and pediatric patients 6 years of age and older with:
    explanation: >-
      June 2026 FDA prescribing information establishes the current US age threshold.
  - reference: url:https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf
    reference_title: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761369s003lbl.pdf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
    explanation: >-
      The expanded indication includes both inhibitor and non-inhibitor HB populations.
  - reference: PMID:41351884
    reference_title: 'Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 60 participants with inhibitors in the OP, 51 entered the ATP and received marstacimab.
    explanation: >-
      Distinguishes the inhibitor cohort from the earlier without-inhibitor publication and separates enrolled from treated participants.
  - reference: PMID:41351884
    reference_title: 'Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the on-demand group (n = 48), mean estimated ABR declined from 19.78 (95% confidence interval [CI], 16.12-24.27) in the OP to 1.39 (95% CI, 0.85-2.29) during the ATP
    explanation: >-
      The primary within-participant efficacy comparison pools HA and HB and excludes the three previously receiving routine bypassing-agent prophylaxis.
  - reference: PMID:41351884
    reference_title: 'Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The estimated ABR ratio was 0.05 (95% CI, 0.032-0.094) for participants with hemophilia A (n = 40) and 0.13 (95% CI, 0.049-0.363) for participants with hemophilia B (n = 8).
    explanation: >-
      The small HB subgroup limits precision and does not establish comparative efficacy against other prophylactic agents.
  - reference: PMID:40608864
    reference_title: 'Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Marstacimab targets the tissue factor pathway inhibitor to rebalance hemostasis.
    explanation: >-
      Defines its anticoagulant-pathway target.
  - reference: PMID:40608864
    reference_title: 'Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 128 participants enrolled in the OP, 116 received marstacimab in the ATP.
    explanation: >-
      Defines the observed and treated cohorts.
  - reference: PMID:40608864
    reference_title: 'Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the RP group (n = 83), mean ABR decreased from 7.90 (95% CI, 5.14-10.66) in the OP to 5.09 (95% CI, 3.40-6.78) in the ATP
    explanation: >-
      Within-participant prophylaxis comparison, with hemophilia types pooled.
  target_mechanisms:
  - target: Impaired factor X activation
    treatment_effect: BYPASSES
    description: >-
      TFPI blockade improves generation and availability of FXa through the tissue-factor pathway.
    evidence:
    - reference: PMID:33570646
      reference_title: 'Concizumab: a novel anti-TFPI therapeutic for hemophilia.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis.
      explanation: >-
        Mechanistic review describes a bypass through extrinsic FXa generation.
- name: Inhibitor-Directed Hemostatic Management
  therapeutic_modality: OTHER
  description: >-
    Clinically significant FIX inhibitors require specialized hemostatic treatment. Recombinant activated FVII bypasses FIX-dependent tenase and is an option for acute bleeding, especially when allergic reactions make FIX-containing products problematic. Non-factor prophylaxis offers additional options; doses and combinations depend on the specific concomitant therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Eptacog Alfa
      term:
        id: NCIT:C81125
        label: Eptacog Alfa
  evidence:
  - reference: PMID:22123568
    reference_title: '[Acquired haemophilia B: a case report and literature review].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: patient received recombinant factor VIIa and corticosteroid treatment. Bleeding symptoms had completely disappeared and coagulation tests become normal.
    explanation: >-
      This acquired anti-FIX case supports bypass activity, not corticosteroids as routine congenital HB prophylaxis.
  - reference: PMID:37646676
    reference_title: Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis.
    explanation: >-
      Trial evidence supports an inhibitor-specific non-factor option.
  - reference: PMID:32133968
    reference_title: "'Do not Do' Recommendations in Hemophilia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX.
    explanation: >-
      Management review reinforces the need for bypass options in this high-risk context.
  notes: OTHER reflects a management strategy spanning recombinant-protein bypass and non-factor prophylaxis; Eptacog Alfa identifies the recombinant FVIIa option.
  target_mechanisms:
  - target: Deficient intrinsic tenase activity
    treatment_effect: BYPASSES
    description: >-
      Activated FVII-based therapy can generate hemostasis without restoring the inhibited FIXa-FVIIIa complex.
    evidence:
    - reference: PMID:22123568
      reference_title: '[Acquired haemophilia B: a case report and literature review].'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: patient received recombinant factor VIIa and corticosteroid treatment.
      explanation: >-
        Clinical anti-FIX case illustrates bypass, while specific regimens require broader guideline management.
- name: Immune Tolerance Induction for FIX Inhibitors
  therapeutic_modality: OTHER
  description: >-
    Selected patients undergo specialist FIX exposure-based immune tolerance induction, sometimes with immune suppression. Success is variable and allergic reactions and nephrotic syndrome can complicate therapy. B-Natural reported 11/22 successfully tolerized after one or more courses at study end, with eight still undergoing treatment; that is not a final population success probability.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:34118102
    reference_title: The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At study end, 11 (50%) were considered successfully tolerized after one or more ITI courses, three were unsuccessful, and eight were still undergoing treatment.
    explanation: >-
      Observational cohort documents incomplete follow-up and variable outcome.
  - reference: PMID:36163649
    reference_title: 'Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nephrotic syndrome developed in two (16.7%) patients during ITI.
    explanation: >-
      This frequency applies to the selected Chinese ITI subgroup, not all HB.
  target_mechanisms:
  - target: Neutralizing FIX alloantibodies
    treatment_effect: MODULATES
    description: >-
      Attempts to induce tolerance and remove inhibitory antibody activity.
    evidence:
    - reference: PMID:34118102
      reference_title: The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Eight patients (36.4%) were successfully tolerized after the first course of ITI.
      explanation: >-
        Initial-course efficacy is distinct from later repeat-course outcomes.
- name: Rehabilitation and Pain Management
  therapeutic_modality: BEHAVIORAL
  description: >-
    Physical therapy evaluates and treats musculoskeletal disease; rehabilitation, exercise adapted to joint status, and pain care accompany bleed prevention. Established arthropathy may require orthopedic treatment and does not necessarily resolve when FIX levels rise.
  treatment_term:
    preferred_term: Physical Therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Physical therapy for evaluation and treatment of musculoskeletal disease; standard treatments for pain with help from a pain specialist as needed
    explanation: >-
      GeneReviews recommends rehabilitation and pain management.
  target_phenotypes:
  - preferred_term: Hemophilic Arthropathy
  - preferred_term: Joint Pain
    term:
      id: HP:0002829
      label: Arthralgia
- name: Mucosal and Postpartum Antifibrinolytic Support
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Tranexamic acid can support selected mucosal/procedural and postpartum bleeding management. It is not a FIX replacement and should not be extrapolated to upper urinary-tract bleeding, where clot obstruction can be hazardous. A specialist coordinates its use with factor and non-factor products.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tranexamic acid
      term:
        id: CHEBI:48669
        label: tranexamic acid
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Tranexamic acid can be used to prevent and treat postpartum hemorrhage.
    explanation: >-
      GeneReviews supports this specific use.
- name: Hemophilia Treatment Center Follow-Up
  therapeutic_modality: OTHER
  description: >-
    Provide education, home-infusion training, joint and muscle assessment, exposure-related inhibitor surveillance, and individualized treatment adjustment. GeneReviews recommends six- to twelve-month review for young severe/moderate patients, at least annually for older severe/moderate patients, and every one to two years for mild disease, with shorter intervals for comorbidity.
  treatment_term:
    preferred_term: Comprehensive hemophilia care
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Referral to a hemophilia treatment center (HTC) for assessment, education, genetic counseling, and treatment.
    explanation: >-
      Organized multidisciplinary care is a management component.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The assessment should include a review of bleeding episodes, adjustment of treatment plans as needed, a joint and muscle evaluation, an inhibitor screen, viral testing if indicated
    explanation: >-
      Defines surveillance content.
  notes: Composite education, surveillance, and treatment-coordination activity; no single precise NCIT procedure term was selected.
- name: Genetic Counseling and Pregnancy Planning
  therapeutic_modality: OTHER
  description: >-
    Test at-risk relatives, establish female genetic status and baseline FIX before pregnancy where possible, and discuss prenatal or preimplantation testing. Maternal FIX does not normally increase substantially in pregnancy; coordinate delivery and postpartum hemostasis and monitor delayed bleeding. Delivery planning should minimize traumatic fetal instrumentation without assuming all pregnancies require cesarean delivery.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is recommended that the genetic status of at-risk females be established prior to pregnancy or as early in a pregnancy as possible.
    explanation: >-
      GeneReviews identifies timing of female-risk assessment.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Maternal factor IX levels do not significantly increase during pregnancy and heterozygous females may need factor IX infusion support for delivery and/or to treat or prevent postpartum hemorrhage.
    explanation: >-
      Corrects the research report's erroneous claim that pregnancy increases FIX.
- name: Bleeding-Risk Precautions
  therapeutic_modality: BEHAVIORAL
  description: >-
    Avoid unnecessary high-trauma activities and coordinate invasive procedures with hemostatic cover. Do not circumcise an at-risk newborn until hemophilia is excluded or covered. Use caution with aspirin and other platelet-active medicines; intramuscular injections require pressure, ice, and treatment planning. Modern factor products have improved infection safety, while older recipients may need evaluation for historical transfusion-related infection.
  treatment_term:
    preferred_term: Bleeding-risk prevention and education
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Circumcision of at-risk males until hemophilia B is either excluded or treated with factor IX concentrate regardless of severity; activities with a high risk of trauma, particularly head injury.
    explanation: >-
      GeneReviews lists circumstances to avoid.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Cautious use of medications and herbal remedies that affect platelet function, including aspirin. Use precaution with intramuscular injections (apply pressure and ice)
    explanation: >-
      Specifies medication and injection precautions.
  notes: An informational prevention activity. The specific NCIT Patient Education term is outside the current TreatmentActionTerm enum; no inaccurate therapeutic-procedure binding is substituted.
references:
- reference: PMID:20301668
  title: Hemophilia B.
  tags:
  - GeneReviews
datasets:
- accession: geo:GSE190760
  title: Single-Cell RNA sequencing reveals prophylactic Prednisone blunts cellular immunity in hemophilia B gene therapy
  description: >-
    Blood single-cell RNA sequencing from seven BBM-H901 gene-therapy participants at four time points (28 longitudinal samples). The study relates immune-cell profiles and prednisone exposure to FIX response. These are repeated blood samples, not 28 independent patients or patient joint tissue.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 28
  publication: PMID:35598604
  notes: >-
    GEO metadata verified with just verify-datasets on 2026-09-04; evidence is in references_cache/GEO_GSE190760.md. The linked phase 1 trial treated ten participants, whereas this transcriptomic subset contains seven. No raw-data reanalysis was performed. Without a randomized steroid comparison, immune associations do not isolate prophylactic prednisone efficacy.
synonyms:
- Christmas disease
- Factor IX deficiency
updated_date: '2026-09-05T00:03:24Z'
has_subtypes:
- name: Severe Hemophilia B
  classification: baseline_FIX_activity
  description: >-
    Baseline FIX activity below 1 IU/dL (<1%). Spontaneous joint and muscle bleeding is typical without prophylaxis; diagnosis is usually in the first two years.
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive procedures or trauma
    explanation: >-
      The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'Severe hemophilia B: Usually diagnosed during the first two years of life.'
    explanation: >-
      GeneReviews gives the usual diagnostic age.
- name: Moderate Hemophilia B
  classification: baseline_FIX_activity
  description: >-
    Baseline FIX activity 1–5 IU/dL (1–5%). Spontaneous bleeding is less frequent and variable, with excessive or delayed bleeding after minor trauma; some patients need prophylaxis for a severe bleeding phenotype.
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive procedures or trauma
    explanation: >-
      The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'Moderate hemophilia B: Less frequent spontaneous bleeding, although it varies between individuals; however, individuals with moderate hemophilia B do have prolonged or delayed oozing after relatively minor trauma'
    explanation: >-
      GeneReviews documents variation within the moderate activity band.
- name: Mild Hemophilia B
  classification: baseline_FIX_activity
  description: >-
    Baseline FIX activity above 5 and below 40 IU/dL (>5% to <40%). Spontaneous bleeding is generally absent, but surgery, dental extraction, or major trauma can cause serious bleeding. Diagnosis may be delayed until adulthood.
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive procedures or trauma
    explanation: >-
      The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'Mild hemophilia B: Individuals generally do not have spontaneous bleeding episodes; however, without pre- and postoperative treatment, abnormal bleeding occurs with surgery or tooth extractions.'
    explanation: >-
      GeneReviews distinguishes mild disease from spontaneous bleeding in severe disease.
- name: Hemophilia B Leyden
  subtype_term:
    preferred_term: hemophilia B leyden
    term:
      id: MONDO:0850054
      label: hemophilia B leyden
  classification: regulatory_genotype
  description: >-
    A promoter-variant subtype in which childhood FIX deficiency can improve after puberty. This is an age-dependent regulatory classification that overlaps baseline activity classes; not every proximal-promoter variant has a recovering Leyden phenotype.
  evidence:
  - reference: PMID:23472758
    reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Mutations within the F9 promoter are associated with a remarkable hemophilia B subtype, termed hemophilia B Leyden, in which symptoms ameliorate after puberty.
    explanation: >-
      Defines the clinical regulatory subtype.
  - reference: PMID:23472758
    reference_title: A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The various hemophilia B Leyden mutations that have been reported in this site inhibit ONECUT binding to varying degrees, which correlate well with their associated clinical severities.
    explanation: >-
      Direct binding perturbation links promoter variants to altered regulation.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    A heterozygous mother has a 50% chance of transmitting the variant in each pregnancy. An affected father transmits it to all daughters and no sons. Females can be symptomatic with one pathogenic allele; de novo variation and parental germline mosaicism can explain simplex cases.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If the mother of the proband has an F9 pathogenic variant, the chance of the mother transmitting it in each pregnancy is 50%. If the father of the proband has an F9 pathogenic variant, he will transmit it to all his daughters and none of his sons.
    explanation: >-
      GeneReviews describes X-linked transmission.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Approximately 30% of heterozygous females have factor IX clotting activity lower than 40% and are at risk for bleeding
    explanation: >-
      This is an activity threshold among heterozygotes, not a requirement for biallelic disease.
diagnosis:
- name: FIX clotting activity and coagulation studies
  description: >-
    Establish low FIX activity with an appropriate factor assay. Severe disease is <1%, moderate 1–5%, and mild >5% to <40%; phenotype and assay context also matter. A prolonged aPTT with normal PT and platelet count suggests intrinsic-pathway factor deficiency, but mild disease can have a normal screening aPTT. Age-adjust newborn FIX results because physiologic levels are low; molecular testing or later repeat testing may resolve equivocal results.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
    explanation: >-
      Full GeneReviews diagnosis section was reviewed, including screening-test and neonatal limitations.
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: people with severe disease (FIX activity <1% of normal) have frequent spontaneous bleeds; people with moderate disease (FIX activity 1%–5% of normal) rarely have spontaneous bleeds but bleed with minor trauma; and people with mild disease (FIX activity 5%–40% normal) bleed only during invasive procedures or trauma
    explanation: >-
      The introduction describes the conventional residual-activity severity bands; modern GeneReviews places exactly 5% in moderate disease.
- name: F9 molecular testing
  description: >-
    Sequence F9 including the relevant proximal promoter, with deletion/duplication testing when appropriate. A hemizygous pathogenic variant confirms male disease and a heterozygous pathogenic variant can confirm female disease; a variant of uncertain significance alone is not confirmation.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Identification of a hemizygous F9 pathogenic variant by molecular genetic testing confirms the diagnosis in a male proband. Identification of a heterozygous F9 pathogenic variant by molecular genetic testing confirms the diagnosis in a female proband.
    explanation: >-
      GeneReviews supplies the molecular confirmation criteria.
- name: Inhibitor testing
  description: >-
    Measure an inhibitor when recovery or clinical response to FIX is suboptimal and according to exposure-related surveillance. Mixing studies and Bethesda-based assays distinguish a neutralizing inhibitor from isolated inherited factor deficiency, interpreted by a specialist laboratory.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Screening for alloimmune inhibitors is performed after treatment with factor IX concentrates has been initiated and in any individual with a suboptimal clinical response to treatment.
    explanation: >-
      GeneReviews gives the testing indication.
biochemical:
- name: Factor IX Activity
  presence: Decreased
  context: Severe less than 1%, moderate 1-5%, mild 5-40%
  loinc_term:
    id: LOINC:3187-2
    label: Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay
  notes: >-
    Identity is bound at the one-stage coagulation assay code, the Factor IX
    analog of the code Hemophilia_A.yaml binds for Factor VIII activity; LOINC
    carries no method-less identity code for this analyte either. The
    chromogenic alternative (LOINC:88449-4, Coagulation factor IX activity
    actual/normal in Platelet poor plasma by Chromogenic method) is not bound,
    for the same reason the Factor VIII chromogenic code is not: binding both
    would imply they are interchangeable identities for one measurement.
  reference_ranges:
  - loinc_term:
      id: LOINC:3187-2
      label: Coagulation factor IX activity actual/normal in Platelet poor plasma by Coagulation assay
    unit: '%'
    population: Narrative review of FIX Padua hyperactivity, citing the conventional severity classification
    notes: >-
      The source's dash notation ("1%-5%", "5%-40%") does not itself resolve
      which band exactly 5% falls in. The half-open convention below places
      Moderate's upper_bound at 5 (excluding exactly 5.0%) and Mild's
      lower_bound at 5 (including it), so a measured value of exactly 5.0% is
      placed in Mild; no finer precision is stated in this source to resolve
      the ambiguity otherwise. The source gives no boundary statement for
      values at or above 40%, so the open-above tier is this entry's own
      placement, not a quoted assertion.
    evidence:
    - reference: PMID:31219805
      reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        people with severe disease (FIX activity <1% of normal) have frequent
        spontaneous bleeds; people with moderate disease (FIX activity
        1%-5% of normal) rarely have spontaneous bleeds but bleed with minor
        trauma; and people with mild disease (FIX activity 5%-40% normal)
        bleed only during invasive procedures or trauma
      explanation: >-
        States the three conventional severity thresholds, reproduced below
        as interpretation bands.
    interpretation_bands:
    - name: Severe Hemophilia B
      upper_bound: 1
      unit: '%'
      abnormal_flag: CRITICAL_LOW
      severity: SEVERE
      interpretation: Frequent spontaneous bleeds are characteristic at this severity.
    - name: Moderate Hemophilia B
      lower_bound: 1
      upper_bound: 5
      unit: '%'
      abnormal_flag: LOW
      severity: MODERATE
      interpretation: Bleeding with minor trauma, but rarely spontaneous, is characteristic at this severity.
    - name: Mild Hemophilia B
      lower_bound: 5
      upper_bound: 40
      unit: '%'
      abnormal_flag: LOW
      severity: MILD
      interpretation: Bleeding only during invasive procedures or trauma is characteristic at this severity.
    - name: Not classified as hemophilia B by this scale
      lower_bound: 40
      unit: '%'
      abnormal_flag: NORMAL
- name: Thrombin generation capacity
  presence: DECREASED
  notes: >-
    ETP, peak thrombin, and timing measure the downstream coagulation phenotype under assay-specific conditions. The 2005 cohort contained 34 HA and 12 HB patients; its factor-infusion comparison was HA, so it does not validate TGA-guided HB dosing or a universal surrogate endpoint.
  evidence:
  - reference: PMID:15735797
    reference_title: Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In addition, a correlation was found between severe clinical bleeding phenotype and ETP.
    explanation: >-
      Correlation supports investigation of functional coagulation capacity, not validated individual prediction.
  readouts:
  - target: Deficient thrombin propagation
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: CANDIDATE_SURROGATE
    interpretation: An exploratory functional marker; prospective HB-specific validation is required before claiming clinical surrogacy.
    evidence:
    - reference: PMID:15735797
      reference_title: Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Our results suggest that TGT could be a promising tool to evaluate haemostasis capacity in patients with haemophilia.
      explanation: >-
        The source itself frames the assay as promising rather than validated.
animal_models:
- name: F9-mutant mouse with CRISPR correction
  species: Mouse
  genotype: F9-mutant hemophilia B
  description: >-
    Hydrodynamic tail-vein delivery of Cas9 and donor plasmids corrected hepatocyte F9 in a subset of treated mice. The result was >1% corrected alleles in 62.5% of mice, not 62.5% allelic correction.
  publication: PMID:28508290
  evidence:
  - reference: PMID:28508290
    reference_title: CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency.
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Factor IX Deficiency
    relationship: RESCUES
    description: >-
      Endogenous F9 correction restores functional FIX sufficiently to improve coagulation in treated mice.
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Hydrodynamic delivery, mosaic correction, and mouse physiology limit clinical transfer; germline experiments do not establish an acceptable human therapy.
    evidence:
    - reference: PMID:28508290
      reference_title: CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: 62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency.
      explanation: >-
        Model-specific experimental support.
- name: Albumin-locus FIX gene-addition mouse
  species: Mouse
  genotype: Hemophilia B with AAV/CRISPR-mediated albumin-locus insertion
  description: >-
    Site-specific transgene insertion rescued newborn and adult HB mice and persisted after partial hepatectomy; this differs from repairing endogenous F9.
  publication: PMID:32775489
  evidence:
  - reference: PMID:32775489
    reference_title: CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: FIX levels in treated mice persisted even after a two-thirds partial hepatectomy, indicating stable gene integration.
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Factor IX Deficiency
    relationship: RESCUES
    description: >-
      Albumin-locus gene addition restores sustained FIX expression in newborn and adult hemophilia B mice.
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Mouse stable insertion does not establish human editing efficacy or long-term insertion safety.
    evidence:
    - reference: PMID:32775489
      reference_title: CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: FIX levels in treated mice persisted even after a two-thirds partial hepatectomy, indicating stable gene integration.
      explanation: >-
        Model-specific experimental support.
- name: F9 regulatory-and-coding-defect editing mouse
  species: Mouse
  genotype: Complex mutant F9 with regulatory and coding defects
  description: >-
    A synthetic promoter/enhancer and long-range replacement restored expression. Single-cell analysis found hepatocyte-subset differences and treatment-related inflammatory effects.
  publication: PMID:34649996
  evidence:
  - reference: PMID:34649996
    reference_title: Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: a single DNA cutting-mediated long-range replacement restored the FIX-encoding function of a mutant F9 (mF9) carrying both regulatory and coding defects in a severe mouse HB model
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Factor IX Deficiency
    relationship: RESCUES
    description: >-
      Promoter/enhancer reconstruction and coding-sequence replacement restore FIX expression in the engineered mouse model.
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Synthetic promoter rescue and post-treatment inflammation are model-specific; this is not human joint-tissue omics.
    evidence:
    - reference: PMID:34649996
      reference_title: Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: a single DNA cutting-mediated long-range replacement restored the FIX-encoding function of a mutant F9 (mF9) carrying both regulatory and coding defects in a severe mouse HB model
      explanation: >-
        Model-specific experimental support.
- name: Collagen-IV-binding-defective FIX K5A mouse
  species: Mouse
  genotype: F9 K5A knock-in
  description: >-
    Reduced collagen-IV binding impaired injury-dependent hemostasis despite normal in vitro clotting activity. This demonstrates an extravascular dimension missing from a plasma-activity-only model.
  publication: PMID:19583826
  evidence:
  - reference: PMID:19583826
    reference_title: Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The K5A mutation dramatically reduced the affinity of FIX for collagen type IV, but had no measurable effect on platelet binding, phospholipid binding, or in vitro clotting activity. However, K5AFIX mice had a mild bleeding tendency, despite their in vitro clotting activity being normal.
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Impaired fibrin hemostasis
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      The engineered binding variant is not the universal mechanism of inherited HB; assay-specific injury effects do not establish a human dose target.
    evidence:
    - reference: PMID:19583826
      reference_title: Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The K5A mutation dramatically reduced the affinity of FIX for collagen type IV, but had no measurable effect on platelet binding, phospholipid binding, or in vitro clotting activity. However, K5AFIX mice had a mild bleeding tendency, despite their in vitro clotting activity being normal.
      explanation: >-
        Model-specific experimental support.
- name: F9-null mouse skeletal phenotype
  species: Mouse
  genotype: F9 knockout
  description: >-
    Juvenile and adult male knockout mice had reduced BMD, cortical and cancellous bone mass, and fracture resistance despite normal somatic growth. This motivates a bone-mechanism question; it does not demonstrate direct FIX signaling in osteoblasts.
  publication: PMID:34117910
  evidence:
  - reference: PMID:34117910
    reference_title: 'Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the FIX KO mice displayed reduced bone mineral density (BMD), reduced cortical and cancellous bone mass, and diminished whole bone fracture resistance.
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Factor IX Deficiency
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      These mice lack spontaneous bleeding seen in human severe disease. Bone histomorphometry and reliable RANKL/OPG measurements were unavailable; downstream thrombin signaling remains a hypothesis.
    evidence:
    - reference: PMID:34117910
      reference_title: 'Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: the FIX KO mice displayed reduced bone mineral density (BMD), reduced cortical and cancellous bone mass, and diminished whole bone fracture resistance.
      explanation: >-
        Model-specific experimental support.
- name: Recurrent-hemarthrosis mouse with adjunctive methotrexate
  species: Mouse
  genotype: Hemophilia B with repeated joint puncture
  description: >-
    Preventive MTX plus EHL-FIX improved synovitis and cartilage outcomes compared with FIX alone. Delayed MTX reduced synovial endpoints but did not improve cartilage erosion or proteoglycan loss.
  publication: PMID:42119948
  evidence:
  - reference: PMID:42119948
    reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: No differences in cartilage erosion and proteoglycan loss were observed.
    explanation: >-
      Model-specific experimental support.
  modeled_mechanisms:
  - target: Blood-induced synovitis
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Puncture-induced disease and high experimental doses do not establish human efficacy or reversal of established cartilage damage.
    evidence:
    - reference: PMID:42119948
      reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Knee diameter measurements and magnetic resonance imaging scans confirmed successful induction of joint bleeding and synovitis in all injured mice in both parts.
      explanation: >-
        Induced hemarthrosis produces the synovitis represented by this model link; the separate delayed-treatment cartilage result limits claims of structural reversal.
- name: Naturally occurring hemophilia B dogs
  species: Dog
  genotype: F9 missense or null mutations
  description: >-
    Canine models support sustained FIX rescue and permit evaluation of spontaneous bleeding and immunity. Null-mutation dogs developed inhibitors after muscle-directed AAV at doses tolerated by previously studied missense dogs; this is not inevitable for every route or modern vector.
  publication: PMID:11545609
  evidence:
  - reference: PMID:11545609
    reference_title: Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: AAV-mediated canine F9 gene transfer to skeletal muscle of hemophilia B dogs carrying a null mutation of F9 (causing an early stop codon and an unstable mRNA) results in induction of inhibitory anti-canine F9
    explanation: >-
      Canine genotype affects immune response under this delivery regimen.
  - reference: PMID:9883841
    reference_title: Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
    explanation: >-
      Distinct liver-directed preclinical context demonstrates partial correction.
  modeled_mechanisms:
  - target: Neutralizing FIX alloantibodies
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: Species, genotype, route, and vector dose affect immunity; canine tolerance does not guarantee human safety.
    evidence:
    - reference: PMID:11545609
      reference_title: Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: AAV-mediated canine F9 gene transfer to skeletal muscle of hemophilia B dogs carrying a null mutation of F9 (causing an early stop codon and an unstable mRNA) results in induction of inhibitory anti-canine F9
      explanation: >-
        Canine genotype affects immune response under this delivery regimen.
differential_diagnoses:
- name: Hemophilia A
  description: Clinically similar X-linked bleeding with deficient FVIII rather than FIX.
  distinguishing_features:
  - Measure both activities; normal FVIII does not exclude HB, and unusual new bleeding in known HB may warrant investigation for an acquired FVIII inhibitor.
  evidence:
  - reference: PMID:36407152
    reference_title: A Case of Acquired Hemophilia A and Congenital Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This report describes the management of a patient with congenital hemophilia B and acquired hemophilia A.
    explanation: >-
      A rare dual diagnosis illustrates why a known F9 diagnosis does not exclude an additional cause.
- name: Acquired FIX inhibitor
  description: Rare autoantibody-mediated functional FIX loss without the inherited F9 disorder.
  distinguishing_features:
  - New bleeding, inhibitor detection, and prior or family history distinguish acquired autoimmunity from congenital HB with an alloimmune treatment complication.
  evidence:
  - reference: PMID:22123568
    reference_title: '[Acquired haemophilia B: a case report and literature review].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a 7-year-old girl with no past medical history of bleeding disorder and who present an extensive haematoma in the left calf.
    explanation: >-
      Case supports a distinct acquired presentation.
- name: Vitamin K deficiency, liver disease, or vitamin K antagonist effect
  description: Acquired reduction in several coagulation factors can include FIX.
  distinguishing_features:
  - Multi-factor abnormalities and often prolonged PT distinguish these states from isolated congenital FIX deficiency; vitamin K does not correct an inherited dysfunctional F9 allele.
  evidence:
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Vitamin K does not prevent or control bleeding in hemophilia B.
    explanation: >-
      GeneReviews distinguishes the inherited defect from vitamin K-responsive states.
- name: Other inherited bleeding disorders
  description: von Willebrand disease and deficiencies of factors XI, VII, or XIII can overlap clinically.
  distinguishing_features:
  - FVII deficiency usually prolongs PT; HB affects FIX-dependent aPTT assays.
  - VWF/FVIII studies identify von Willebrand disease; type 2N mimics FVIII deficiency, not FIX deficiency.
  - Factor XIII deficiency can cause delayed bleeding with normal routine PT/aPTT; factor XII deficiency can prolong aPTT without causing the HB bleeding phenotype.
  evidence:
  - reference: PMID:19245420
    reference_title: Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hemophilia B patients (n = 296) and FVII-deficient males (n = 109) were compared for FVII/FIX clotting activity, F7/F9 genotypes and clinical phenotypes
    explanation: >-
      Primary cohort demonstrates distinct phenotypes despite shared coagulation involvement.
  - reference: PMID:20301668
    reference_title: Hemophilia B.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.
    explanation: >-
      Factor-specific assays distinguish the diagnostic defect; the complete GeneReviews differential table was reviewed.
discussions:
- discussion_id: skeletal-pathway
  kind: KNOWLEDGE_GAP
  prompt: Which downstream coagulation signals connect FIX deficiency to low bone mass?
  attaches_to:
  - pathophysiology#Factor IX Deficiency
  - phenotypes#Reduced Bone Mineral Density
  rationale: >-
    Mouse F9 loss produces a skeletal phenotype without spontaneous joint bleeding, but the study did not demonstrate direct FIX binding/signaling in osteoblasts. Similar FVIII-null findings favor testing shared downstream thrombin/PAR or matrix effects. Human low-BMD studies mix HA/HB and cannot separate bleeding, mobility, or comorbidity.
  proposed_experiments:
  - experiment_id: systemic-fix-bone
    description: >-
      First establish F9 expression and source contribution before proposing osteoblast-specific deletion; compare systemic FIX rescue with controlled thrombin-pathway perturbation.
    name: Distinguish systemic FIX from direct skeletal signaling
  - experiment_id: prospective-bone-clinical
    description: >-
      Prospectively measure bone endpoints, activity, joint bleeding, and comorbidity in HB cohorts; improved DXA alone would not identify the molecular mediator.
    name: Prospective HB-specific bone outcomes
  evidence:
  - reference: PMID:34117910
    reference_title: 'Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Further studies are needed to explore the underlying mechanism by which a defective coagulation cascade and the resulting thrombin deficiency alters normal skeletogenesis.
    explanation: >-
      The primary study explicitly leaves mechanism unresolved.
- discussion_id: synovitis-translation
  kind: KNOWLEDGE_GAP
  prompt: Can an adjunct inflammatory intervention protect human joints beyond optimized bleed prevention?
  attaches_to:
  - pathophysiology#Blood-induced synovitis
  rationale: >-
    Mouse preventive and delayed-treatment experiments have different cartilage outcomes. These data justify further evaluation, not routine MTX treatment or proof that inflammation is independent of all continuing blood exposure.
  evidence:
  - reference: PMID:42119948
    reference_title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: No differences in cartilage erosion and proteoglycan loss were observed.
    explanation: >-
      Delayed-treatment result limits reversal claims.
- discussion_id: extravascular-fix
  kind: KNOWLEDGE_GAP
  prompt: How should extravascular FIX and cross-reacting antigen status inform human prophylaxis?
  attaches_to:
  - pathophysiology#Impaired fibrin hemostasis
  rationale: >-
    Collagen-IV-binding perturbation in mice and localization in human liver and muscle establish that this is not a no-data gap. The unresolved issue is quantitative contribution and validated dosing implications in patients, including competition by dysfunctional CRM-positive FIX.
  evidence:
  - reference: PMID:19583826
    reference_title: Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: the binding of FIX to collagen IV probably plays a significant functional role in hemostasis.
    explanation: >-
      Experimental support exists but needs human quantitative translation.
  - reference: PMID:33780107
    reference_title: The Function of extravascular coagulation factor IX in haemostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Prophylactic protection decreases ~5X faster in CRM+ animals.
    explanation: >-
      Cross-reacting antigen status modifies protection in a mouse comparison.
- discussion_id: durability-and-retreatment
  kind: KNOWLEDGE_GAP
  prompt: What predicts lifetime gene-therapy durability and feasible retreatment across vector platforms?
  attaches_to:
  - pathophysiology#Factor IX Deficiency
  rationale: >-
    Median 13-year follow-up exists in ten men given a wild-type F9 AAV8 vector; current Padua product cohorts have shorter follow-up. One liver biopsy does not resolve all vector-integration, clonal, or cancer risks. Persistently high anti-AAV antibodies limit redosing, and children have different liver-growth considerations.
  evidence:
  - reference: PMID:40499172
    reference_title: Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Levels of neutralizing antibodies to AAV8 remained high throughout follow-up, thus indicating potential barriers to readministration of the vector.
    explanation: >-
      Long-term human follow-up identifies a concrete retreatment barrier.
- discussion_id: severity-modifiers
  kind: KNOWLEDGE_GAP
  prompt: Which modifiers improve HB-specific prediction beyond FIX activity and treatment history?
  attaches_to:
  - pathophysiology#Deficient thrombin propagation
  rationale: >-
    FVII, thrombophilia, platelet, and endothelial reports are heterogeneous and often mix HA and HB. They do not quantify how much HB severity variance is explained. The small TGA cohort supports prospective validation, not replacement of factor assays. Matched HA/HB comparisons need genotype, prophylaxis, age, and joint-damage adjustment.
  evidence:
  - reference: PMID:19686262
    reference_title: Polymorphism in factor VII gene modifies phenotype of severe haemophilia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the polymorphisms studied, the FVII353Q (RR = 3.5, 95% CI: 1.04-12.05, P = 0.044) allele was associated with a severe phenotype."
    explanation: >-
      This is the FVII report behind the rationale's first clause, and it shows
      why the clause is a gap rather than a modifier to curate. The association
      is a single nominal result (interval barely excluding 1) selected from 53
      parameters tested in 114 patients whose comparability analysis is reported
      as F8:c activity, so it yields no HB-specific estimate of severity
      variance explained. Its direction is also toward more severe disease,
      opposite to the milder-than-expected subgroup the 10-15% framing invokes.
  - reference: PMID:28550758
    reference_title: 'Platelets and hemophilia: A review of the literature.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: the available evidence is currently limited and no clear correlations between platelet function parameters and clinical phenotypes have been demonstrated.
    explanation: >-
      Review explicitly limits platelet-modifier inference.
  - reference: PMID:18624700
    reference_title: Endothelial dysfunction in haemophilia patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fifteen haemophilia patients with chronic viral hepatitis and/or HIV infection showed a significantly lower FMD than patients without active infection.
    explanation: >-
      Vascular findings are confounded by comorbidity in a mixed cohort.
clinical_trials:
- name: NCT03569891
  phase: PHASE_III
  status: COMPLETED
  description: >-
    HOPE-B, the 54-participant phase 3 etranacogene study. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03569891
    reference_title: Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03489291
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Three-participant phase 2b etranacogene study, distinct from HOPE-B. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03489291
    reference_title: Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This is an open-label, single-dose, single-arm, multi-center trial, with a screening, a treatment + post-treatment follow-up phase, and a long-term follow-up phase.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT05962398
  phase: NOT_APPLICABLE
  status: ENROLLING_BY_INVITATION
  description: >-
    Long-term follow-up of participants from the phase 2b and HOPE-B etranacogene studies. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT05962398
    reference_title: An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03861273
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    BENEGENE-2 phase 3 fidanacogene study; the 15-month results are not the phase 1/2a extension. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03861273
    reference_title: Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less).
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03307980
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Follow-up and higher-dose substudy after the early fidanacogene program; source of the 14-participant multiyear report. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03307980
    reference_title: A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Long-term safety and efficacy follow-up for participants with Hemophilia B who were previously treated in the C0371005 (formerly SPK-9001-101) study, and a dose-escalation sub-study evaluating safety, tolerability, and kinetics of a higher dose with long-term safety and efficacy follow-up. Participants in the substudy do not need to have participated in C0371005.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT00979238
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Early scAAV2/8-LP1-hFIXco dose escalation; median 13-year follow-up supports durable wild-type FIX expression. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT00979238
    reference_title: An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The purpose of this study is to determine the safety of giving a normal factor IX gene to treat individuals who have an abnormal or no factor IX gene.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT04083781
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Explorer7 concizumab in HA/HB with inhibitors; randomized and nonrandomized groups coexist. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT04083781
    reference_title: Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT04082429
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Explorer8 concizumab in HA/HB without inhibitors; HB-specific randomized efficacy is reported. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT04082429
    reference_title: Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03938792
  phase: PHASE_III
  status: COMPLETED
  description: >-
    BASIS marstacimab; separate published cohorts evaluate patients with and without inhibitors using preceding treatment periods. The inhibitor efficacy comparison predominantly comprises HA, with eight HB participants previously receiving on-demand bypassing agents. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03938792
    reference_title: An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03754790
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    ATLAS-OLE fitusiran; antithrombin-guided extension regimen following redesigned safety mitigation. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03754790
    reference_title: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
    supports: SUPPORT
    evidence_source: OTHER
    snippet: To characterize the long-term safety and tolerability of fitusiran
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT03369444
  phase: PHASE_II
  status: TERMINATED
  description: >-
    FLT180a gene-therapy study; registry termination does not by itself identify biological failure. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT03369444
    reference_title: A Phase I/II, Open Label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno- Associated Viral Vector (FLT180a) in Patients With Haemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Severe haemophilia B (HB) is a bleeding disorder where a protein made by the body to help make blood clot is either partly or completely missing.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT04135300
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    BBM-H901 phase 1 pilot in ten Chinese adults; blood transcriptomic subset has seven participants. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT04135300
    reference_title: Gene Therapy for Chinese Hemophilia B With Adeno-associated Virus (AAV) Vector
    supports: SUPPORT
    evidence_source: OTHER
    snippet: GT2019001 is a Phase 1, open- label, non- randomized, uncontrolled, single dose pilot study to evaluate the safety, tolerability and kinetics of a single intravenous infusion of BBM-H901 in hemophilia B subjects with ≤2IU/dl residual FIX levels. BBM-H901 is an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene and raise circulating levels of endogenous FIX.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
- name: NCT07080905
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Adolescent etranacogene phase 3 study; registration does not establish pediatric efficacy. Registry status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT07080905
    reference_title: Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
    explanation: >-
      Registry verifies the study identity and purpose; efficacy requires the separately cited publication.
experimental_models:
- name: Purified and plasma FIX-Padua cofactor-dependence assays
  experimental_model_type: OTHER
  description: >-
    Recombinant FIX-WT and R338L activity, activation, inactivation and FVIIIa dependence were compared in purified-protein and plasma systems, including transgene-expressing patient samples. Emicizumab substitution removed Padua-specific hyperactivity.
  publication: PMID:31219805
  evidence:
  - reference: PMID:31219805
    reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We observed that the high-specific-activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor.
    explanation: >-
      FVIIIa perturbation identifies the requirement for Padua hyperactivity.
  modeled_mechanisms:
  - target: Deficient intrinsic tenase activity
    relationship: PERTURBS
    fidelity: HIGH
    model_scale: MOLECULAR
    limitations: Defined biochemical systems resolve enzyme-cofactor dependence but lack organ injury, vascular compartments and patient-level bleeding outcomes.
    evidence:
    - reference: PMID:31219805
      reference_title: Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We observed that the high-specific-activity of FIX-R338L requires factor VIIIa (FVIIIa) cofactor.
      explanation: >-
        FVIIIa perturbation identifies the requirement for Padua hyperactivity.
- name: Leyden F9 promoter transactivation assays
  experimental_model_type: CELL_LINE
  cell_source: HepG2 and HeLa cell lines
  description: >-
    Wild-type and mutant F9 promoter reporters test HNF4-dependent transactivation. Together with ONECUT binding assays, these experiments connect specific regulatory alleles with loss of expression.
  publication: PMID:1631121
  evidence:
  - reference: PMID:1631121
    reference_title: Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all.
    explanation: >-
      Promoter transactivation separates recovering and persistent regulatory defects.
  modeled_mechanisms:
  - target: Leyden promoter dysfunction
    relationship: PERTURBS
    fidelity: MODERATE
    model_scale: CELLULAR
    limitations: Reporter assays do not recapitulate puberty, liver chromatin context or all Leyden variants.
    evidence:
    - reference: PMID:1631121
      reference_title: Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Whereas HNF-4 transactivates the wild-type promoter sequence in liver (HepG2) and non-liver (HeLa) cell types quite well, it transactivates the -20 mutated promoter to only a limited extent and the -26 mutated promoter not at all.
      explanation: >-
        Promoter transactivation separates recovering and persistent regulatory defects.
📚

References & Deep Research

References

1
PMID:20301668
Hemophilia B.
No top-level findings curated for this source.

Deep Research

3

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

  • Name: Hemophilia B
  • Category: Genetic
  • Existing deep-research providers: falcon, perplexity
  • Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

  • Factor IX Deficiency
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1002/14651858.cd014544.pub2
  • DOI:10.1007/s13353-025-00952-w
  • DOI:10.1007/s40140-024-00635-y
  • DOI:10.1016/s0140-6736(24
  • DOI:10.1056/nejmoa2302982
  • DOI:10.1111/j.1365-2516.2005.01123.x
  • DOI:10.1186/s13052-024-01819-2
  • DOI:10.14302/issn.2372-6601.jhor-24-5108
  • DOI:10.3389/fmed.2025.1618464
  • DOI:10.3390/biom14070854
  • DOI:10.57582/ijbf.250502.066
Falcon ▸
Pathophysiology description
Edison Scientific Literature 31 citations 2026-01-31T17:15:34.688558

Pathophysiology description Hemophilia B (HB) is an X‑linked recessive bleeding disorder caused by pathogenic variants in the F9 gene leading to reduced or absent factor IX (FIX) activity, impairing intrinsic tenase formation (FVIIIa–FIXa complex) and downstream thrombin generation. Disease severity correlates with residual FIX activity: severe <1%, moderate 1–5%, mild 5–40% of normal; prevalence is approximately 1 in 30,000 males worldwide (clinical phenotype typically includes mucocutaneous bleeding, post‑procedural hemorrhage, hemarthroses) (baniamer2024understandinginheritedbleeding pages 2-4). FVIII/FIX function can be conceptualized through tenase biology; notably, the approved bispecific antibody emicizumab “mimic[s] the function of FVIII by bringing together Factor IXa and Factor X,” illustrating the centrality of FIXa–FX complex assembly for effective intrinsic tenase activity (quote from review summarizing non‑factor approaches) (linari2025hemophiliachangesand pages 4-5), and perioperative guidance reiterates emicizumab “bridging activated factor IX and factor X” (quote) (lowell2024perioperativemanagementof pages 4-5). Large F9 deletions are associated with high inhibitor risk and allergic reactions in HB; these risks are highlighted clinically in infants presenting with severe bleeding such as intracranial hemorrhage (ICH) (lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2).

Key concepts and definitions (current understanding) - Etiology: Pathogenic F9 variants (missense, nonsense, splice, indels, large deletions/duplications) reduce FIX antigen/activity; X‑linked inheritance (wroblewska2025genetherapyas pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4). - Severity thresholds: Severe <1% FIX activity; moderate 1–5%; mild 5–40% (baniamer2024understandinginheritedbleeding pages 2-4, wroblewska2025genetherapyas pages 1-2). - Core mechanism: Impaired intrinsic tenase (FVIIIa–FIXa) assembly/activity results in deficient propagation of thrombin generation and unstable fibrin formation (supported by emicizumab mechanism mimicking FVIII cofactor to bring FIXa and FX together) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Clinical manifestations: Spontaneous/joint bleeds in severe disease; post‑trauma/procedural bleeding in mild/moderate; ICH can be an initial presentation in infancy (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2).

Recent developments and latest research (priority 2023–2024) AAV gene therapy (adult severe–moderately severe HB) - Fidanacogene elaparvovec (AAV) Phase 3 (BENEGENE‑2; NEJM 2024): annualized bleeding rate (ABR) decreased by 71% (from 4.42 to 1.28) 12–15 months post‑infusion vs prophylaxis lead‑in; mean FIX activity 26.9% at 15 months (median 22.9%; one‑stage SynthASil); 62% received glucocorticoids for transaminitis or decreased FIX; no thrombotic events or inhibitors (data‑cutoff Aug 30, 2023) (URL: https://doi.org/10.1056/NEJMoa2302982; published Sep 2024) (cuker2024genetherapywith pages 11-11). - Cross‑program summaries (2023–2024) report sustained FIX expression with mean values in the mid‑20s to mid‑30s percent and large reductions in bleeding and factor use (e.g., median ABR 12→0; FIX infusions 53.5→0), alongside frequent but manageable ALT elevations and steroid use; anti‑AAV neutralizing antibodies exclude many candidates (chernyi2024recentadvancesin pages 17-18). - Lancet 2025 review emphasizes real‑world considerations: pre‑existing AAV antibodies in ~25–40%, immune transaminase elevations requiring corticosteroids (weeks to months), variable durability, exclusion of children/inhibitor patients, and long‑term integration risk monitoring, while confirming multi‑year expression and cessation of prophylaxis for most recipients (URL: https://doi.org/10.1016/S0140-6736(24)02139-1; Mar 2025) (chowdary2025haemophilia pages 10-11).

Rebalancing (non‑factor) therapies (2023–2024 evidence base) - Anti‑TFPI monoclonal antibodies (concizumab, marstacimab): Mechanism restores initiation pathway by relieving TFPI inhibition to enhance FXa/thrombin generation. Phase 3 programs progressed; concizumab experienced thrombotic events (associated with concomitant hemostatic therapies) prompting protocol adjustments; marstacimab showed efficacy with superiority signals vs prior factor prophylaxis in patients without inhibitors (Lancet 2025 review) (chowdary2025haemophilia pages 9-10). A 2024 Cochrane review confirms the development status and comparative intent versus standard care (search last updated Aug 16, 2023) (). - Antithrombin siRNA (fitusiran): Monthly subcutaneous dosing lowers hepatic antithrombin mRNA to rebalance thrombin generation. Phase 3 data show significant ABR reductions but safety signals (thrombosis when antithrombin levels too low and when high‑dose concomitant hemostatics used; some hepatobiliary AEs). Risk‑mitigation includes antithrombin targets of ~15–35% and careful management of on‑demand agents (chowdary2025haemophilia pages 9-10). Perioperative guidance highlights a prior program hold after a fatal sinus thrombosis with concurrent high‑dose FVIII and notes reversibility with antithrombin supplementation (lowell2024perioperativemanagementof pages 4-5).

Extended half‑life (EHL) FIX products and inhibitor risk - EHL rFIXFc and rIX‑FP reduce infusion frequency and improve adherence; in pediatrics, weekly rFIXFc prophylaxis is feasible. Inhibitor formation and allergic reactions can occur, with large F9 deletions conferring elevated risk and potential nephrotic syndrome; a 2024 case demonstrates continued rFIXFc prophylaxis with pre‑medication after low‑titer inhibitor emergence, avoiding nephrotic progression (URL: https://doi.org/10.1186/s13052-024-01819-2; Nov 2024) (lassandro2024intracranialhemorrhagein pages 1-2). Reviews also reinforce that immune tolerance induction is less effective in HB inhibitor patients and that anaphylaxis/nephrotic syndrome risks are higher than in HA (wroblewska2025genetherapyas pages 1-2).

Current applications and real‑world implementations - Standard prophylaxis: Regular FIX replacement per severity is the global standard; even modest increases in factor activity can improve phenotype and reduce bleeds; humanitarian programs expand access (baniamer2024understandinginheritedbleeding pages 2-4). - Gene therapy: One‑time IV AAV delivery enabling cessation of routine prophylaxis in many adults; real‑world implementation requires screening for AAV antibodies, liver monitoring, steroid management, and long‑term follow‑up (cuker2024genetherapywith pages 11-11, chowdary2025haemophilia pages 10-11). - Non‑factor therapies: Emicizumab widely adopted for HA; in HB, rebalancing approaches (concizumab, marstacimab, fitusiran) are in late development or approved in some regions, with careful risk mitigation and guidance evolving (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5, linari2025hemophiliachangesand pages 4-5). - Perioperative management: Emicizumab interferes with aPTT‑based assays; use appropriate chromogenic or viscoelastic assays; avoid or limit aPCC due to thrombotic/TMA risks; rFVIIa preferred if needed (lowell2024perioperativemanagementof pages 4-5).

Expert opinions and authoritative analyses - Lancet 2025 review (international experts) synthesizes gene therapy implementation challenges (antibody exclusion, transaminitis, durability), and non‑factor therapy risk–benefit considerations; underscores individualized selection and registry data needs (chowdary2025haemophilia pages 10-11). - Perioperative experts highlight assay interference and thrombosis risk management with non‑factor agents, recommending tailored perioperative plans and judicious use of bypassing agents (lowell2024perioperativemanagementof pages 4-5). - Cochrane 2024 review catalogs the evidence base and uncertainties around non‑factor prophylaxis in congenital hemophilia ().

Relevant statistics and data from recent studies - Prevalence: ~1 in 30,000 males; severity thresholds severe <1%, moderate 1–5%, mild 5–40% FIX (baniamer2024understandinginheritedbleeding pages 2-4). - AAV gene therapy (fidanacogene elaparvovec, NEJM 2024): ABR −71% vs lead‑in; mean FIX 26.9% at 15 months; 62% on steroids for transaminase/FIX declines; 0 inhibitors/thromboses in the report (cuker2024genetherapywith pages 11-11). - AAV programs meta‑summary (2023–2024): FIX levels often mid‑20s to mid‑30s percent; high proportions without bleeding and cessation of factor use; ALT elevations common; anti‑AAV antibodies exclude many candidates (chernyi2024recentadvancesin pages 17-18). - Pediatric severe HB ICH case (2024): severe FIX deficiency (<1%) due to large F9 deletions; low‑titer inhibitor (0.6–1.0 BU) after EHL rFIXFc; premedication immunotolerance allowed continued weekly prophylaxis without nephrotic syndrome (lassandro2024intracranialhemorrhagein pages 1-2).

Molecular and cellular mechanisms - Molecular pathways dysregulated: intrinsic pathway propagation (defective FVIIIa–FIXa tenase assembly and function) leading to insufficient thrombin burst; rebalancing strategies target endogenous anticoagulants (TFPI, antithrombin) to restore thrombin generation (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5, chowdary2025haemophilia pages 9-10). - Cellular processes affected: Hepatocyte synthesis of FIX (secreted plasma zymogen); platelet‑surface and activated endothelium‑supported assembly of intrinsic tenase; impaired clot stability manifesting as clinical bleeding. Mechanistic surrogates from emicizumab’s action reinforce the requirement for colocalizing FIXa and FX (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Tissues/organs: Liver (FIX synthesis), synovial joints and muscles (target bleeding sites), CNS (ICH risk in infants) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Key molecular players - Genes/Proteins: F9 (HGNC:3551) encoding factor IX; interacting factors: FVIII (cofactor), FX, thrombin; endogenous anticoagulants targeted by non‑factor therapies: TFPI (anti‑TFPI mAbs), antithrombin (siRNA) (linari2025hemophiliachangesand pages 4-5, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - Chemical entities (CHEBI): - Anti‑TFPI monoclonal antibodies: concizumab, marstacimab (therapeutic biologics) (chowdary2025haemophilia pages 9-10). - siRNA: fitusiran (subcutaneous RNAi drug) (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - AAV gene therapy products: fidanacogene elaparvovec (AAV vector delivering FIX‑Padua) (cuker2024genetherapywith pages 11-11). - Cell types (CL): Hepatocytes (CL:0000182) – FIX production; platelets (CL:0000233) – tenase surface; endothelial cells (CL:0000115) – hemostatic interface. (Mechanistic context supported by emicizumab’s effect on bringing FIXa and FX together) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Anatomical locations (UBERON): Liver (UBERON:0002107); synovial joint (UBERON:0000982); brain/CNS (UBERON:0000955) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Biological processes (GO) disrupted - Blood coagulation (GO:0007596) and intrinsic pathway of blood coagulation (GO:0007597): impaired FIX activation/function within intrinsic tenase (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Regulation of thrombin generation (part of coagulation cascade): diminished in HB; therapeutically enhanced by anti‑TFPI and antithrombin‑lowering strategies (chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - Response to wounding/hemostasis (GO:0009611/GO:0007599): abnormal bleeding phenotype (baniamer2024understandinginheritedbleeding pages 2-4).

Cellular components (GO) - Extracellular region/plasma (GO:0005576): circulating FIX zymogen. - Plasma membrane surfaces (platelets/endothelium) for intrinsic tenase assembly (protein complex at membrane) inferred from emicizumab’s bridging of FIXa and FX (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5).

Disease progression (sequence of events) 1) F9 pathogenic variant → reduced/absent functional FIX antigen/activity (wroblewska2025genetherapyas pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4). 2) Impaired intrinsic tenase assembly/activity (FVIIIa–FIXa–phospholipid–Ca2+) → reduced FX activation and thrombin burst (supported by emicizumab mechanism that rescues tenase-like function by colocalizing FIXa and FX) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). 3) Inadequate fibrin generation/stability → bleeding after minimal trauma; in severe disease, spontaneous hemarthroses/muscle bleeds; infants can present with ICH (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2). 4) Treatment modifies trajectory: EHL FIX increases trough levels; gene therapy can restore FIX into mild range; rebalancing therapies elevate thrombin potential but require thrombosis risk management (cuker2024genetherapywith pages 11-11, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5).

Phenotypic manifestations with mechanistic links (HP terms) - Recurrent hemarthrosis (HP:0003257) and chronic arthropathy (HP:0001362): due to inadequate tenase‑mediated thrombin generation during joint microtrauma (baniamer2024understandinginheritedbleeding pages 2-4). - Easy bruising (HP:0000978), epistaxis (HP:0000421), post‑procedural hemorrhage (HP:0001892) (baniamer2024understandinginheritedbleeding pages 2-4). - Intracranial hemorrhage (HP:0002170) in infancy/severe deficiency (lassandro2024intracranialhemorrhagein pages 1-2). - Inhibitor formation (alloantibodies) with allergic reactions/nephrotic syndrome risk in HB, especially with large F9 deletions (HP:0025354; mechanistic: anti‑FIX neutralization; immune complex complications) (lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2).

Evidence items (PMIDs/DOIs, URLs, dates) - NEJM 2024 (BENEGENE‑2; fidanacogene elaparvovec): ABR −71%; FIX ~27% at 15 months; steroid use 62%; no inhibitors/thromboses. DOI: 10.1056/NEJMoa2302982. URL: https://doi.org/10.1056/NEJMoa2302982. Published Sep 2024 (cuker2024genetherapywith pages 11-11). - Biomolecules 2024 review: summarizes AAV HB programs (AMT‑061/etranacogene dezaparvovec and others) with sustained FIX levels (mid‑20s to mid‑30s %) and substantial ABR/infusion reductions; notes ALT elevations and AAV antibody exclusions. DOI: 10.3390/biom14070854. URL: https://doi.org/10.3390/biom14070854. Published Jul 2024 (chernyi2024recentadvancesin pages 17-18). - Lancet 2025 review: gene therapy implementation (eligibility, immune toxicity, durability) and non‑factor therapies (anti‑TFPI, fitusiran) with risk–benefit framing. DOI: 10.1016/S0140-6736(24)02139-1. URL: https://doi.org/10.1016/S0140-6736(24)02139-1. Published Mar 2025 (chowdary2025haemophilia pages 10-11). - Italian J Pediatr 2024 case: infant ICH; rFIXFc prophylaxis, low‑titer inhibitor, immunotolerance premedication avoided nephrotic syndrome. DOI: 10.1186/s13052-024-01819-2. URL: https://doi.org/10.1186/s13052-024-01819-2. Published Nov 2024 (lassandro2024intracranialhemorrhagein pages 1-2). - Journal of Applied Genetics 2025 review: HB genetics (F9, Xq27.1), severity thresholds, EHL FIX, gene therapy approval context, inhibitor risks. DOI: 10.1007/s13353-025-00952-w. URL: https://doi.org/10.1007/s13353-025-00952-w. Published Apr 2025 (wroblewska2025genetherapyas pages 1-2). - Journal of Hematology & Oncology Research 2024 review: prevalence (~1/30,000 males), severity thresholds, standard prophylaxis rationale. DOI: 10.14302/issn.2372-6601.jhor-24-5108. URL: https://doi.org/10.14302/issn.2372-6601.jhor-24-5108. Published Aug 2024 (baniamer2024understandinginheritedbleeding pages 2-4). - Current Anesthesiology Reports 2024: perioperative management, emicizumab assay interference, aPCC thrombosis/TMA risks, rFVIIa preference; fitusiran program hold after fatal sinus thrombosis with high‑dose FVIII, reversibility with AT. DOI: 10.1007/s40140-024-00635-y. URL: https://doi.org/10.1007/s40140-024-00635-y. Published Jun 2024 (lowell2024perioperativemanagementof pages 4-5). - Cochrane Database of Systematic Reviews 2024: non‑factor therapies for congenital hemophilia A/B (concizumab, marstacimab, fitusiran) (search through Aug 16, 2023). DOI: 10.1002/14651858.CD014544.pub2. URL: https://doi.org/10.1002/14651858.CD014544.pub2. Published Feb 2024 (). - Frontiers in Medicine 2025 narrative review: HB mutation spectrum; intrinsic pathway pathophysiology; EHL, gene therapy, non‑factor strategies; global access issues. DOI: 10.3389/fmed.2025.1618464. URL: https://doi.org/10.3389/fmed.2025.1618464. Published Sep 2025 (dushimova2025therapeuticadvancesin pages 2-3).

Ontology‑style annotations - Gene/protein (HGNC): F9 (HGNC:3551) → Factor IX (serine protease zymogen) (wroblewska2025genetherapyas pages 1-2). - GO Biological Processes: blood coagulation (GO:0007596); intrinsic pathway of blood coagulation (GO:0007597); regulation of thrombin generation (supported by non‑factor strategies) (linari2025hemophiliachangesand pages 4-5, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5). - GO Cellular Components: extracellular region (GO:0005576); membrane‑bound tenase at activated platelet/endothelial surfaces (supported mechanistically by emicizumab bridging FIXa and FX) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Phenotype (HP): hemarthrosis (HP:0003257), arthropathy (HP:0001362), epistaxis (HP:0000421), easy bruising (HP:0000978), post‑procedural bleeding (HP:0001892), intracranial hemorrhage (HP:0002170), inhibitor formation (HP:0025354) (baniamer2024understandinginheritedbleeding pages 2-4, lassandro2024intracranialhemorrhagein pages 1-2, wroblewska2025genetherapyas pages 1-2). - Cell types (CL): hepatocytes (CL:0000182), platelets (CL:0000233), endothelial cells (CL:0000115) (mechanistic support via tenase/emicizumab bridging) (linari2025hemophiliachangesand pages 4-5, lowell2024perioperativemanagementof pages 4-5). - Anatomical locations (UBERON): liver (UBERON:0002107), synovial joint (UBERON:0000982), brain/CNS (UBERON:0000955) (lassandro2024intracranialhemorrhagein pages 1-2, baniamer2024understandinginheritedbleeding pages 2-4).

Direct quotes (selected) - “mimic the function of FVIII by bringing together Factor IXa and Factor X” (emicizumab mechanism) (linari2025hemophiliachangesand pages 4-5). - Emicizumab acts by “bridging activated factor IX and factor X,” with perioperative cautions on assay interference and thrombotic risk management (lowell2024perioperativemanagementof pages 4-5).

Plan status update - Core mechanisms, recent developments (2023–2024), applications, expert analyses, and statistics compiled from recent high‑quality sources (NEJM 2024; Cochrane 2024; perioperative review 2024; Lancet 2025 synthesis) and clinically relevant case evidence (ICH in infant) (cuker2024genetherapywith pages 11-11, lowell2024perioperativemanagementof pages 4-5, chowdary2025haemophilia pages 10-11, lassandro2024intracranialhemorrhagein pages 1-2).

Citations: (baniamer2024understandinginheritedbleeding pages 2-4, cuker2024genetherapywith pages 11-11, lassandro2024intracranialhemorrhagein pages 1-2, chernyi2024recentadvancesin pages 17-18, chowdary2025haemophilia pages 10-11, wroblewska2025genetherapyas pages 1-2, dushimova2025therapeuticadvancesin pages 2-3, chowdary2025haemophilia pages 9-10, lowell2024perioperativemanagementof pages 4-5, linari2025hemophiliachangesand pages 4-5)

References

  1. (baniamer2024understandinginheritedbleeding pages 2-4): Ansam Zakaria Baniamer, Aya Mohannad Hamdan, Mohammad Raed AlGhzawi, Mohammad Tareq Alfaqeh, Sadeen Yaser Yaseen, Shama Mohammad Alshtawi, Hala Yasin Alomush, and Rand Mahdi Olimat. Understanding inherited bleeding disorders: genetic mutations in blood coagulation factors and regulatory proteins. Journal of Hematology and Oncology Research, 4:1-23, Aug 2024. URL: https://doi.org/10.14302/issn.2372-6601.jhor-24-5108, doi:10.14302/issn.2372-6601.jhor-24-5108. This article has 2 citations.

  2. (linari2025hemophiliachangesand pages 4-5): Silvia Linari and Giancarlo Castaman. Hemophilia: changes and new achievements in management and care. International Journal of Bone Fragility, 5:66-71, Oct 2025. URL: https://doi.org/10.57582/ijbf.250502.066, doi:10.57582/ijbf.250502.066. This article has 0 citations.

  3. (lowell2024perioperativemanagementof pages 4-5): Aliena E. Lowell, Michael P. Calgi, Joseph J. Caruso, Louise M. Man, and John S. McNeil. Perioperative management of hemophilia patients. Current Anesthesiology Reports, 14:354-365, Jun 2024. URL: https://doi.org/10.1007/s40140-024-00635-y, doi:10.1007/s40140-024-00635-y. This article has 7 citations and is from a peer-reviewed journal.

  4. (lassandro2024intracranialhemorrhagein pages 1-2): Giuseppe Lassandro, Valentina Palladino, and Paola Giordano. Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia b: a case report. Italian Journal of Pediatrics, Nov 2024. URL: https://doi.org/10.1186/s13052-024-01819-2, doi:10.1186/s13052-024-01819-2. This article has 0 citations and is from a peer-reviewed journal.

  5. (wroblewska2025genetherapyas pages 1-2): Kinga Wróblewska, Dominika Bieszczad, Magdalena Popławska, Karolina Joanna Ziętara, Monika Zajączkowska, and Agata Filip. Gene therapy as an innovative approach to the treatment of hemophilia b-a review. Journal of applied genetics, Apr 2025. URL: https://doi.org/10.1007/s13353-025-00952-w, doi:10.1007/s13353-025-00952-w. This article has 0 citations and is from a peer-reviewed journal.

  6. (cuker2024genetherapywith pages 11-11): Adam Cuker, Kaan Kavakli, Laurent Frenzel, Jiaan-Der Wang, Jan Astermark, Monica H. Cerqueira, Alfonso Iorio, Olga Katsarou-Fasouli, Robert Klamroth, Amy D. Shapiro, Cédric Hermans, Akira Ishiguro, Andrew D. Leavitt, Johannes B. Oldenburg, Margareth C. Ozelo, Jerome Teitel, Francesca Biondo, Annie Fang, Joanne Fuiman, John McKay, Pengling Sun, John E.J. Rasko, and Jeremy Rupon. Gene therapy with fidanacogene elaparvovec in adults with hemophilia b. The New England journal of medicine, 391 12:1108-1118, Sep 2024. URL: https://doi.org/10.1056/nejmoa2302982, doi:10.1056/nejmoa2302982. This article has 74 citations and is from a highest quality peer-reviewed journal.

  7. (chernyi2024recentadvancesin pages 17-18): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules, 14:854, Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 33 citations and is from a poor quality or predatory journal.

  8. (chowdary2025haemophilia pages 10-11): Pratima Chowdary, Manuel Carcao, Gili Kenet, and Steven W Pipe. Haemophilia. The Lancet, 405:736-750, Mar 2025. URL: https://doi.org/10.1016/s0140-6736(24)02139-1, doi:10.1016/s0140-6736(24)02139-1. This article has 33 citations and is from a highest quality peer-reviewed journal.

  9. (chowdary2025haemophilia pages 9-10): Pratima Chowdary, Manuel Carcao, Gili Kenet, and Steven W Pipe. Haemophilia. The Lancet, 405:736-750, Mar 2025. URL: https://doi.org/10.1016/s0140-6736(24)02139-1, doi:10.1016/s0140-6736(24)02139-1. This article has 33 citations and is from a highest quality peer-reviewed journal.

  10. (dushimova2025therapeuticadvancesin pages 2-3): Zaure Dushimova, Marat Pashimov, Jamilya Kaibullayeva, Laura Danyarova, Elmira Kultanova, Gulnara Abdilova, and Nagima Mustapayeva. Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care. Frontiers in Medicine, Sep 2025. URL: https://doi.org/10.3389/fmed.2025.1618464, doi:10.3389/fmed.2025.1618464. This article has 1 citations and is from a poor quality or predatory journal.

Perplexity ▸
The Pathophysiology of Hemophilia B: Molecular Mechanisms, Cellular Dysfunction, and Clinical Manifestations
sonar-deep-research 54 citations 2026-02-01T09:44:24.403756

The Pathophysiology of Hemophilia B: Molecular Mechanisms, Cellular Dysfunction, and Clinical Manifestations

This comprehensive report examines the molecular and cellular pathophysiology of hemophilia B, a rare X-linked bleeding disorder resulting from deficiency or dysfunction of coagulation factor IX. Hemophilia B, also known as Christmas disease, represents a critical derangement in the intrinsic blood coagulation pathway stemming from mutations in the F9 gene located on the X chromosome at band Xq27.1[13]. The disease presents with profound heterogeneity in clinical severity, ranging from asymptomatic carrier females to males experiencing spontaneous life-threatening hemorrhages. At the molecular level, hemophilia B pathophysiology revolves around inadequate production or function of Factor IX (FIX), a vitamin K-dependent serine protease essential for initiating and amplifying thrombin generation through formation of the intrinsic tenase complex[8][13]. This report integrates current understanding of the F9 gene structure and mutation landscape, the biochemical properties and post-translational modifications of the FIX protein, the disruption of coagulation cascade dynamics, and the progression from genetic defect to symptomatic bleeding manifestations. The mechanistic framework presented here provides critical insights into disease severity predictors, complications including arthropathy and inhibitor formation, and emerging therapeutic strategies targeting the dysregulated coagulation system.

Molecular Genetics and the F9 Gene: Structural Organization and Mutation Landscape

F9 Gene Structure and Organization

The F9 gene, encoding coagulation factor IX, spans approximately 34 kilobases on the X chromosome and comprises eight exons separated by seven introns[13][3]. This structural organization is critical for understanding how mutations at different genomic loci produce variable clinical phenotypes in hemophilia B. Exon 1 encodes the signal peptide, a 28-residue sequence that directs the nascent protein into the endoplasmic reticulum (ER) during synthesis[13]. Exon 2 encodes both the propeptide, an 18-residue sequence essential for recognition by the vitamin K-dependent γ-glutamyl carboxylase, and the beginning of the γ-carboxyglutamic acid (Gla) domain[13]. Exons 3 through 8 collectively encode the remaining structural and functional domains of the mature FIX protein, including the epidermal growth factor-like (EGF) domains, the activation peptide, and the serine protease catalytic domain[3][13].

The 2.8-kilobase mRNA transcript produced from the F9 gene is translated into a 461-amino acid preproprotein (prepro-FIX) that undergoes extensive post-translational processing[1][3]. This preproprotein contains several distinct functional regions: the 28-residue signal peptide, the 18-residue propeptide that facilitates vitamin K-dependent γ-carboxylation, and the mature 415-amino acid FIX protein consisting of the Gla domain (amino acids 1-40), a short hydrophobic sequence (aa 41-46), two EGF-like domains (EGF-1: aa 47-83; EGF-2: aa 88-125), a linker region (aa 126-145), an activation peptide (aa 146-180), and the C-terminal serine protease domain (aa 181-415)[13]. The functional significance of this organization becomes apparent when examining how mutations in specific exons and regulatory regions produce disease manifestations of varying severity[1][3].

Mutation Types and Distribution in Hemophilia B

The F9 locus-specific mutation database (F9db) documents more than 3,000 pathogenic mutations and neutral polymorphisms affecting 73 percent of the 461 residues in the mature FIX protein[1]. Point mutations account for the vast majority of hemophilia B cases, with these mutations generally categorized into missense mutations (causing changes in amino acids), nonsense mutations (creating premature stop codons), frameshift mutations (insertions or deletions causing translational errors), and splice-site mutations affecting mRNA processing[1][3]. The distribution of these mutation types varies across different structural domains of FIX. Frameshift and nonsense mutations are relatively evenly distributed throughout the FIX protein, which is expected given that these types of mutations produce truncated or defective proteins regardless of their location[3]. Missense mutations, however, show a characteristic distribution pattern, being present in all protein domains except the middle region of the activation peptide, with notable underrepresentation in the signal peptide and activation domains because these regions tolerate amino acid changes with less functional consequence[3].

The protease domain contains the majority of documented mutations overall, reflecting both its large size and the critical functional importance of the serine protease active site for FIX enzymatic activity[3]. Large deletion and insertion mutations, though less common than point mutations in hemophilia B compared to hemophilia A, still contribute significantly to disease pathogenesis[4]. Complex mutations including large deletions from multiple exons, such as a documented 4.4 kilobase deletion spanning exons 4-6 with replacement by a 47-base pair sequence, and insertions of mobile genetic elements including Alu elements into exon 5 and long interspersed nuclear elements into exon 7, have been identified in hemophilia B patients[1]. These complex rearrangements typically produce severe phenotypes due to disruption of multiple protein domains[1].

Deep intronic mutations representing variants located far from exon-intron boundaries are rarely reported in hemophilia B, though such mutations have been documented in other bleeding disorders[1]. The paucity of reported deep intronic mutations in hemophilia B likely reflects the historical limitation that standard mutation detection techniques using PCR and Sanger sequencing have not routinely sought these variants[1]. As next-generation sequencing technologies become more widely implemented, additional deep intronic mutations causing hemophilia B through mechanisms such as cryptic splicing will likely be identified. Mutation analysis using PCR and Sanger sequencing combined with dosage analysis for detecting large deletions and duplications enables detection of mutations in more than 97 percent of hemophilia B patients[1].

Promoter Mutations and Hemophilia B Leyden: Variable Phenotypes Linked to Gene Regulation

A distinctive category of F9 mutations affects the proximal promoter region of the F9 gene, producing a unique phenotype known as hemophilia B Leyden in which disease severity dramatically improves following puberty[1][3]. The proximal promoter contains binding sites for multiple transcription factors essential for constitutive FIX expression[1]. A short region spanning from position -50 to -18 relative to the transcription start site contains three critical transcription factor binding sites: hepatic nuclear factor 4α (HNF4α) binding at position -49, CCAAT enhancer-binding protein binding at position -19, and ONECUT1 and ONECUT2 binding centered around position -35[1]. Point mutations within these regulatory sequences, including well-characterized mutations such as c.-49T>A and c.-50T>G, disrupt transcription factor binding during infancy and childhood but paradoxically allow restoration of FIX expression following puberty[3]. The mechanism underlying this remarkable improvement involves androgen-responsive elements that become activated during the pubertal surge in androgen levels, which can drive FIX transcription through alternative regulatory pathways[1][3].

Patients with hemophilia B Leyden represent approximately 5 percent of hemophilia B cases and present with severe factor IX deficiency in childhood with plasma FIX levels less than 1 percent[3]. However, following puberty, FIX levels progressively increase, often rising to 50-70 percent of normal activity in adulthood[3]. This unique disease course, while rare, provides valuable insights into the regulation of hepatic FIX expression and demonstrates that some hemophilia B mutations do not produce immutable defects but rather condition gene expression patterns that respond to developmental and hormonal cues. Mutations in the 3' untranslated region (3'UTR) of the F9 gene, though identified, have not been associated with severe hemophilia B phenotypes, suggesting that regulatory elements outside the promoter region have limited impact on overall FIX expression levels[3].

Biochemical Properties of Factor IX: Structure-Function Relationships and Post-Translational Modifications

The Gla Domain: Calcium-Dependent Membrane Binding and Its Role in Hemostasis

Factor IX, like other vitamin K-dependent coagulation factors including prothrombin, factor VII, factor X, protein C, and protein S, contains a distinctive N-terminal γ-carboxyglutamic acid (Gla) domain comprising residues 1-40 of the mature protein[13]. This domain contains twelve γ-carboxylated glutamic acid (Gla) residues, with the first eleven being highly conserved across species and critically important for FIX function, while the twelfth residue appears to have minimal functional significance[13]. The Gla domain structure consists of an N-terminal loop and three short β-sheets arranged in a characteristic disulfide-bonded framework that is stabilized by calcium ion binding[13][14]. The structural basis for calcium-dependent function of the Gla domain involves a sophisticated ion coordination mechanism in which four calcium ions (Ca2+ through Ca5+) are essential to stabilize the Gla domain conformation and expose critical binding surfaces[13][14].

Upon calcium binding to FIX, a conformational change occurs in the Gla domain through clustering of N-terminal hydrophobic residues into a hydrophobic patch that becomes exposed to the solvent[14]. This hydrophobic patch subsequently allows association of the Gla domain with cell surface membranes through electrostatic interactions between the negatively charged phosphoserine head groups of phosphatidylserine in the membrane and positively charged arginine and lysine residues in the Gla domain[14]. The basic amino acid residues Lys5 and Arg10 specifically bind to the glycerol phosphate backbone of phospholipids, while the carboxyl group of the serine residue interacts with Ca5+ and Ca6+, allowing membrane association[14]. This calcium-dependent membrane binding mechanism is absolutely essential for FIX function; in the absence of adequate calcium concentration, the Gla domain becomes highly disordered and unstructured, preventing membrane association and consequently blocking FIX participation in the coagulation cascade[14].

Magnesium ions may also play a modulatory role in Gla domain function distinct from calcium's structural role. Crystallographic studies of bovine FIX bound to a snake venom protein reveal that magnesium ions induce a closed-form conformation of the Gla domain that contributes to tight association with phospholipid membranes[14]. The Mg2+ ion coordination differs from O-Ca-O bridges observed with calcium, potentially contributing differential effects on membrane binding affinity and orientation[14]. Additionally, magnesium ions in the Gla domain may contribute to binding interactions with cofactors including factor VIIIa and factor VIIa[14].

The Epidermal Growth Factor-Like Domains: Enabling Protein-Protein Interactions

Following the Gla domain and a short hydrophobic sequence, the FIX protein contains two epidermal growth factor-like (EGF) domains that serve primarily structural roles by enabling spatial separation between the serine protease domain and phospholipid membranes[13]. This spatial organization is critical because FIXa must bind both FX and the cofactor FVIIIa, which are also membrane-bound, and the EGF domains provide the necessary distance for these protein-protein interactions to occur on the membrane surface[13]. The EGF-1 domain (amino acids 47-83) and EGF-2 domain (amino acids 88-125) both contain disulfide-bonded structures essential for maintaining proper three-dimensional conformation[13].

Biochemical and molecular modeling studies demonstrate that the EGF domains mediate essential protein-protein interactions beyond simple spatial positioning[13]. The EGF-1 domain appears to mediate binding to the tissue factor-FVIIa complex, with the glycine at position 48 playing an essential role in FIX activation by the extrinsic coagulation pathway[13]. Furthermore, both EGF domains contribute to binding interactions with FVIIIa, the critical cofactor that dramatically enhances the catalytic activity of FIXa in the intrinsic tenase complex[13]. The EGF-2 domain is connected to the serine protease catalytic domain through a disulfide bridge and is positioned opposite the catalytic active site[14]. This structural arrangement positions the EGF-2 domain to potentially interact with substrate molecules approaching the active site and to facilitate interactions with cofactors and membrane surfaces that position FIXa correctly for catalytic turnover[13].

The Activation Peptide: Cleavage Site for Zymogen Activation

The FIX protein circulates in plasma as an inactive zymogen and is converted to its enzymatically active form (FIXa) through proteolytic cleavage of the activation peptide (amino acids 146-180)[3][13]. This conversion occurs through sequential cleavage at two arginine residues: Arg191 (at the junction between the activation peptide and linker region) and Arg226 (within the activation peptide) by either activated FXI or the tissue factor-FVIIa complex[1][13]. The final residue of the linker region preceding the activation peptide, Arg145, serves as one of these two cleavage sites for activation by FXIa and the TF-FVIIa complex, while Arg180 located within the activation peptide represents the second cleavage site[13]. The removal of the 11 kilodalton activation peptide exposes the serine protease active site on the heavy chain, which can then activate Factor X in the presence of Factor VIII, calcium, and phospholipid surfaces[14].

The significance of the activation peptide for FIX function becomes apparent when examining hemophilia B mutations occurring at the junctions between the activation domain and its adjacent domains, which suggest that mutations might interfere with normal cleavage processes and result in production of dysfunctional FIX proteins that cannot be properly activated[3]. Missense mutations found in the junction regions between the activation domain and EGF-2 domain are thought to impair the three-dimensional folding necessary for recognition by activating proteases[3].

The Serine Protease Domain: Catalytic Architecture and Functional Anatomy

The serine protease domain of FIX (amino acids 181-415) comprises the largest functional region of the mature protein and contains the catalytic machinery essential for FIX enzymatic activity[13][14]. This domain is structurally related to other serine proteases including trypsin and thrombin but exhibits much narrower substrate specificity, cleaving specifically at arginine-isoleucine bonds within factor X[8][13]. The catalytic domain consists of two β-subdomains that form an active site at their interface, with three disulfide bonds stabilizing the domain structure and helical structures running across the N-terminus of the β-barrel[14].

The active site of FIX contains a catalytic triad characteristic of trypsin-like serine proteases, composed of three amino acids: a histidine residue that acts as a general base, an aspartate residue that stabilizes the developing charge during catalysis, and a serine residue that performs the nucleophilic attack on substrate peptide bonds[14]. Unlike other serine protease family members, vitamin K-dependent proteases including FIX have an extended specificity pocket that allows recognition of a limited number of amino acids in the substrate sequence, contributing to the high substrate specificity of FIX for factor X[13]. The substrate specificity of FIXa is further refined by several ion-binding sites and exosite regions within the protease domain[13].

The protease domain contains multiple exosites—extended binding surfaces distinct from the catalytic active site—that contribute to substrate recognition and binding without directly participating in catalysis[13]. These exosites are primarily located in flexible loops and include features such as the 126-loop (the "126-c helix"), the 162-loop (the "162-c helix"), and the Asn178 residue[13]. The protease domain also contains important ion-binding sites: a single calcium ion binds in the exosite I region, while a sodium ion binds in the 186-220 region[13]. Exosite II is known to bind heparin and may also contribute additional binding surfaces for the cofactor FVIIIa[13]. A distinctive structural feature termed the "99-loop" (residues Glu219, Lys98, and Tyr177) partially obstructs the active site entrance and is thought to reduce the activity of FIXa compared to fully unobstructed serine proteases[13]. Interestingly, mutations in this 99-loop region have been experimentally used to increase FIXa enzymatic activity, demonstrating the mechanistic relationship between this structural feature and catalytic efficiency[13].

Vitamin K-Dependent γ-Carboxylation: Essential Post-Translational Modification

Vitamin K-dependent γ-carboxylation represents a critical post-translational modification essential for FIX function that occurs in the endoplasmic reticulum[13][49]. This modification converts specific glutamic acid residues in the Gla domain to γ-carboxyglutamic acid residues through an enzymatic reaction catalyzed by γ-glutamyl carboxylase (GGCX), which uses vitamin K as a cofactor[13][49]. Vitamin K-epoxide reductase then recycles vitamin K to its active reduced form, completing the catalytic cycle[13][49]. The carboxylation process is initiated by recognition of the FIX propeptide, an 18-amino acid sequence immediately following the signal peptide that functions as a recognition element for GGCX[13][49]. The conserved residues at positions -6 and -10 within the propeptide are essential for binding to GGCX and for achieving efficient substrate carboxylation[49].

The biological importance of γ-carboxylation becomes evident in clinical observations: hemophilia B patients carrying mutations at position -4 or -1 of the propeptide prevent post-translational cleavage of the propeptide, resulting in secretion of pro-coagulation factor with the propeptide still attached[49]. Such mutations either block or severely reduce the carboxylation efficiency of FIX, contributing to the bleeding phenotype observed in these patients[49]. The necessity of vitamin K as a cofactor for this modification explains the increased bleeding risk in individuals with vitamin K deficiency due to malabsorption or anticoagulation therapy with warfarin, which inhibits vitamin K-epoxide reductase and consequently impairs the carboxylation of all vitamin K-dependent coagulation factors[49].

Disruption of the Coagulation Cascade: The Intrinsic Pathway and Tenase Complex Formation

The Intrinsic Pathway and Factor IX's Role in Thrombin Amplification

The blood coagulation cascade represents a carefully orchestrated series of proteolytic reactions that culminate in thrombin generation and fibrin formation, enabling hemostasis through stabilization of the platelet plug[8][45]. The cascade is traditionally conceptualized as comprising separate extrinsic and intrinsic pathways that converge on a common pathway, though contemporary understanding emphasizes a more integrated tissue factor-initiated model in which the intrinsic pathway plays a critical amplification role[8][26][27][32]. The intrinsic pathway comprises coagulation factors XII, XI, IX, and VIII, which are all present in blood and can be activated by negatively charged surfaces in vitro[45]. However, physiological hemostasis depends critically on the intrinsic pathway through a mechanism distinct from contact activation; FXI activation by thrombin downstream of the extrinsic pathway, in conjunction with polyphosphates released from activated platelets, amplifies coagulation through FIX activation[26][27][32].

Factor IX occupies a pivotal position within the intrinsic pathway as the substrate for FXI-catalyzed activation and as a component of the intrinsic tenase complex[8][26]. Upon activation by either FXI or the tissue factor-FVIIa complex, FIX becomes activated (FIXa) and, in the presence of the cofactor FVIIIa, calcium ions, and phospholipid surfaces, forms the intrinsic tenase complex[8][45]. This complex exhibits extraordinary catalytic efficiency, activating factor X at a rate approximately 50-fold higher than the extrinsic tenase complex (tissue factor-FVIIa), thereby dramatically amplifying thrombin generation[8][27][32][45]. The intrinsic tenase complex catalyzes hydrolysis of the Arg194-Ile195 bond in the heavy chain of factor X, releasing a 52-residue activation peptide and generating factor Xa[32].

The intrinsic pathway's role in amplifying coagulation is particularly significant at specific anatomical sites with low expression of tissue factor. Individuals with hemophilia A or B are uniquely prone to hemorrhages in joints and skeletal muscle, both sites with low levels of tissue factor expression[27]. This clinical observation strongly suggests that hemostasis in skeletal muscle and joints is more dependent on the intrinsic pathway rather than the extrinsic pathway, underscoring the critical physiological role of factor VIII and factor IX in these tissues[27].

Factor VIII as Essential Cofactor: The Mechanism of Intrinsic Tenase Complex Formation

The activation of FIXa is necessary but insufficient for hemostatic efficacy; FIXa requires the non-enzymatic cofactor FVIIIa to achieve hemostatic competence[8][27]. Activated factor VIII circulates as a heterotrimer following its release from von Willebrand factor and proteolytic activation by thrombin, consisting of the A1 and A2 domains plus the FVIIIa light chain (A3-C1-C2)[44]. The light chain domains of FVIIIa, particularly the C1 and C2 domains, mediate binding to phospholipid membranes and contribute to cofactor interactions with FIXa[47][44]. FVIIIa binds to FIXa on anionic membranes to form the intrinsic Xase enzyme complex responsible for activating FX in the rate-limiting step of sustained coagulation[44].

The activation of FIXa is accompanied by a conformational change that exposes the FIX binding site on FVIIIa and positions FIXa correctly relative to the substrate factor X on the membrane surface[14]. The Gla domain of FIX likely promotes FVIIIa binding to phospholipid membranes through its calcium-dependent conformational changes, and the arched structure formed by membrane-bound FIXa creates a concave surface that acts as a binding site for factor VIIIa[14]. The cooperative assembly of the intrinsic tenase complex on phospholipid membrane surfaces—particularly the phosphatidylserine-containing membranes of activated platelets—represents a critical regulatory mechanism ensuring that thrombin amplification occurs only at sites of vascular injury[8][27][45].

The Role of Factor X Activation in Prothrombinase Complex Formation and Thrombin Burst

Following activation of factor X to factor Xa by the intrinsic tenase complex, factor Xa proceeds through the common pathway of coagulation[32][35]. Factor Xa, in the presence of calcium ions and with the protein cofactor factor Va on phospholipid membranes, forms the prothrombinase complex, which catalyzes the conversion of prothrombin (factor II) to thrombin (factor IIa)[32][35][45]. This prothrombinase complex represents the most catalytically efficient step in coagulation, with factor Xa activating prothrombin at a rate approximately 300,000-fold faster than factor Xa alone[32]. The formation of the prothrombinase complex is optimized when factor Xa is complexed with its cofactor factor Va, which reduces the Km for prothrombin substrate while increasing the Vmax of the reaction[32].

The catalytic mechanism of thrombin generation warrants careful attention because it illuminates how even minor deficiencies in intrinsic pathway function can profoundly impair hemostasis. Factor Xa catalyzes activation of prothrombin through hydrolysis of two peptide bonds; one pathway, considered most physiologically relevant, involves cleavage of the Arg320-Ile321 bond to yield an intermediate molecule called meizothrombin, which may then be cleaved at the Arg271-Thr272 bond to yield fragment 1-2 and fully activated thrombin[32]. The resultant thrombin, although initially generated in small amounts from the extrinsic pathway, serves as a potent amplifier of coagulation through multiple positive feedback mechanisms. Thrombin activates cofactors FV and FVIII, promoting increased assembly of prothrombinase and intrinsic tenase complexes, and also activates factor XI, which feeds back to activate additional factor IX[8][32][45].

The concept of "thrombin burst" describes the exponential amplification of thrombin generation that occurs once sufficient quantities of cofactors are activated and membrane surfaces are primed with activated platelets[8][32]. In normal hemostasis, the generation of even small initial amounts of thrombin from the extrinsic pathway sets off this amplification cascade, culminating in massive thrombin generation and comprehensive fibrin formation[8][32]. In hemophilia B, the deficiency of factor IX fundamentally impairs this amplification step: FIXa cannot be formed in adequate quantities, the intrinsic tenase complex cannot be properly assembled, and consequently factor X activation through the intrinsic pathway is severely diminished[8].

Pathophysiology of Hemophilia B: From Genetic Defect to Impaired Hemostasis

Molecular Mechanisms of Factor Deficiency and Dysfunction

Hemophilia B results from several different molecular mechanisms, each producing inadequate levels or dysfunctional forms of factor IX[1]. The primary categories of molecular pathophysiology include: complete absence of FIX protein (null mutations), reduced synthesis of normal-appearing FIX (missense mutations affecting secretion or stability), synthesis of structurally normal FIX with reduced specific activity (missense mutations affecting catalytic sites), and production of FIX with abnormal post-translational modification (carboxylation or other processing defects)[1][3]. Large deletions and nonsense mutations typically produce severe hemophilia B through complete loss of FIX expression, as the truncated proteins are non-functional and often unstable[3]. Frameshift mutations similarly produce premature termination codons and nonfunctional proteins[3].

The relationship between mutation type and resulting FIX activity levels demonstrates clear patterns: mutations that prevent protein synthesis or produce truncated proteins correlate with severe phenotypes and approximately 5 percent risk of inhibitor development, while missense mutations generally produce milder or moderate phenotypes with lower inhibitor risk[1][3][4]. Approximately one-third of hemophilia B patients are classified as cross-reacting material positive (CRM), meaning they produce detectable antigen-positive FIX protein despite having reduced or absent enzymatic activity[4]. This higher prevalence of CRM-positive hemophilia B compared to hemophilia A is explained by the higher frequency of missense mutations in hemophilia B; missense mutations can produce structurally recognizable but functionally defective protein[4].

Some missense mutations in hemophilia B affect specific functional domains while leaving others intact. For example, mutations affecting the serine protease domain active site dramatically reduce catalytic efficiency but may not eliminate the protein's synthesis or secretion[3][13]. Mutations affecting the Gla domain or EGF domains may reduce membrane binding or protein-protein interaction capabilities without affecting the catalytic machinery[1][13]. Mutations affecting linker regions between domains may impair proper three-dimensional folding and zymogen activation[1][3].

Plasma Factor Activity Levels and Clinical Classification

The clinical severity of hemophilia B is classified into three categories based on plasma factor IX activity levels: normal plasma levels of FIX range from 50 to 150 percent, whereas patients with less than 1 percent of normal activity (less than 0.01 IU/ml) are classified as severe, those with 1-5 percent activity are classified as moderate, and those with 5-40 percent activity are classified as mild[1][3][5][10]. The inverse relationship between plasma FIX activity and bleeding tendency is robust and reproducible: as residual FIX activity decreases, the frequency and severity of spontaneous bleeding episodes increase[3][9][36]. However, this relationship is not perfectly linear, and substantial individual variation in bleeding phenotype exists even among patients with similar FIX activity levels[3][36].

In mild hemophilia B with factor activity between 5-40 percent, bleeding typically occurs only after significant trauma, surgery, or invasive dental procedures, and many patients may not be diagnosed until such an event requires medical attention[5][10]. Patients with moderate hemophilia B (1-5 percent activity) experience occasional spontaneous bleeding episodes, particularly into joints and muscles, and are at risk for prolonged bleeding following any surgical procedure or injury[10][55]. Severe hemophilia B with factor activity less than 1 percent presents with frequent spontaneous bleeding episodes affecting joints, muscles, and other tissues, and often manifests clinically in infancy with bleeds following circumcision, intramuscular vaccinations, or minor trauma associated with learning to walk[9][10][58].

An important caveat regarding the classification system warrants emphasis: plasma factor activity levels do not predict bleeding severity with absolute precision[3][29]. Some patients with moderately reduced FIX levels experience more frequent bleeding than would be predicted by their activity level, while others with very low levels may have fewer bleeds than expected[3][29]. This heterogeneity reflects the influence of additional genetic, acquired, and behavioral factors on bleeding phenotype, including the presence of prothrombotic genetic polymorphisms, the level and phenotype of von Willebrand factor, body mass index, and engagement in high-risk physical activities[3][4][36].

Clinical Manifestations: Linking Molecular Deficiency to Tissue-Specific Bleeding

Joint Hemorrhage and Hemophilic Arthropathy: The Primary Manifestation of Severe Hemophilia B

Hemarthrosis, bleeding into the joint cavity, represents the hallmark clinical manifestation of hemophilia B, accounting for nearly 80 percent of all hemorrhages in the disease[9][12][19][31][33]. The knees, elbows, and ankles are the most frequently affected joints, though bleeding can occur in shoulders, wrists, hips, and toes[9][12][31]. The pathophysiology of hemarthrosis in hemophilia B involves the inability to generate sufficient thrombin in response to vascular injury within the synovial space, resulting in continued bleeding into the joint until the plasma FIX level is raised through replacement therapy or the bleeding spontaneously ceases due to hemostatic mechanisms independent of FIX activity[9][12].

When blood accumulates within a joint space, the rising pressure causes acute pain through direct distension and activation of nociceptors[34]. Early signs of joint bleeding include stiffness, tingling or "aura" sensations within the joint, joint warmth, and swelling[12]. If left untreated, acute hemarthrosis progresses to severe pain, significant swelling, limited range of motion, and potential permanent joint damage[12][34]. The treatment of acute hemarthrosis requires prompt administration of sufficient factor IX concentrate to elevate plasma FIX levels to approximately 40-50 percent activity, with the goal of achieving hemostasis and halting the bleeding before permanent damage develops[12][34][60].

Recurrent hemarthrosis drives the development of hemophilic arthropathy, a chronic joint condition characterized by progressive cartilage and bone destruction[19][31][33][34]. The pathophysiology of hemophilic arthropathy involves complex interactions between the toxic effects of accumulated iron from red blood cell breakdown, inflammatory cascades triggered by the presence of blood in the joint space, and hemodynamic factors[19][31]. Hemosiderin, a complex iron-storage molecule formed when hemoglobin from red blood cells is broken down, accumulates in the synovium and can undergo the Fenton reaction with hydrogen peroxide to generate hydroxyl radicals—highly reactive molecules that cause oxidative damage to cellular structures[19][31]. The iron from hemoglobin catalyzes this Fenton reaction, producing reactive oxygen species that activate inflammatory pathways through mechanisms including activation of the nuclear factor kappa B (NF-κB) pathway[19][31]. This inflammatory activation triggers release of cytokines and proteolytic enzymes from synovial cells and infiltrating immune cells, leading to degradation of articular cartilage and damage to the subchondral bone[19][31][33].

Repeated bleeding into a joint leads to synovial hypertrophy and fibrosis, transforming the normally thin synovial membrane into chronically inflamed, thickened tissue[19][22][31][33]. The hypertrophied synovium becomes highly vascularized, with new vessel formation through angiogenesis[19][31][33]. These newly formed vessels are friable and prone to bleeding, creating a vicious cycle in which synovial hypertrophy and hypervascularization lead to further bleeding and continued inflammation[19][22][31][33]. This cycle of bleeding, iron accumulation, synovial proliferation, and hypervascularization perpetuates progressive joint damage[19][22][31][33].

Over time, the combination of cartilage erosion, subchondral cyst formation, and bone destruction results in hemophilic arthropathy with joint deformity, severe pain, and loss of function[19][31][34]. MRI imaging reveals that chronic effusions and changes to the joint capsule, coupled with inflammatory mediators, decrease proprioceptive ability in affected joints, further compromising joint stability and function[22]. The prevalence of chronic arthropathy affects approximately 20 percent of hemophiliacs and represents the single largest cause of morbidity in patients with hemophilia[34][33]. Early prophylaxis with factor replacement significantly reduces the development of arthropathy; studies demonstrate that children receiving prophylaxis achieve normal joint structure on MRI in 93 percent of cases at study endpoint compared to only 55 percent in patients receiving episodic treatment[19][22].

Muscle and Deep Tissue Hemorrhage: Pseudotumors and Compartment Syndrome

Muscle hematomas represent another major category of hemophilia B bleeding manifestations, accounting for 10-25 percent of all bleeds in severe hemophilia[39]. Iliopsoas muscle bleeding is the most common site of muscle hemorrhage, occurring in approximately 55 percent of muscle bleed cases[39]. These bleeds represent a clinical emergency because the large capacity of deep muscle compartments allows massive blood accumulation before external signs become apparent, creating risk for severe anemia, hypovolemic shock, and nerve compression[9][39][60]. A bleeding episode into the iliopsoas muscle presents with pain and flexion deformity of the hip, difficulty extending the hip, and potential signs of femoral nerve compression including weakness or numbness in the leg[9][39][60].

If muscle hemorrhage is not adequately treated, the accumulated blood becomes organized and fibrous, creating a structure known as a hemophilic pseudotumor—a firm, encapsulated mass of clotted blood and necrotic tissue[39]. Hemophilic pseudotumors, while rare, represent devastating complications that can cause significant disability through mass effect, contracture formation, and nerve compression[39]. The iliopsoas is the most common site for pseudotumor development, though they can develop in any muscle group[39]. Surgical excision is indicated for pseudotumors causing functional impairment or neurological complications, but such surgery should only be performed in major hemophilia centers with integrated multidisciplinary surgical teams capable of managing the complex operative bleeding[39].

Intracranial Hemorrhage: The Most Serious Manifestation

Intracranial hemorrhage (ICH) represents the most life-threatening manifestation of hemophilia B, with mortality rates approximating 20 percent despite modern treatment[38][41]. ICH accounts for 3-4 percent of hemophilia B presentations at birth and constitutes a leading cause of morbidity and mortality in hemophilia patients of all ages[9][38][58]. The vast majority of ICH cases occur in patients with severe hemophilia B, though spontaneous ICH can occasionally occur in moderate disease[38][42]. In neonates and infants with severe hemophilia, ICH can present without obvious precipitating trauma, though delivery complications, subgaleal bleeding, and cephalohematomas are documented triggers[9][58]. In older children and adults, ICH may be triggered by minor head trauma in severe hemophilia but requires more significant trauma in moderate disease[38][42].

Intracranial hemorrhage in hemophilia B pathophysiologically results from bleeding into the epidural, subdural, or subarachnoid spaces, or into the brain parenchyma itself, owing to inadequate thrombin generation in response to vascular disruption[38][58]. The confined space of the cranial vault means that even modest amounts of bleeding create significant pressure elevation, potentially causing midline shift, herniation, and death[38][58]. Clinical presentation varies with the type and location of ICH but may include seizures, altered mental status, focal neurological deficits, headache, vomiting, and signs of increased intracranial pressure[38][58]. Prevention of ICH through early initiation of prophylactic factor replacement, ideally before age three years and prior to the second joint bleed, significantly reduces ICH incidence[59][38].

Additional Bleeding Manifestations: Gastrointestinal, Urinary Tract, and Mucosal Bleeding

Beyond joint and muscle bleeding, hemophilia B can present with bleeding into virtually any tissue. Gastrointestinal hemorrhage including hematemesis (vomiting blood) and melena (tarry stool) represent potentially serious bleeding manifestations that can result in significant blood loss and anemia[9][57][60]. Intramural hematoma of the gastrointestinal tract, in which bleeding occurs within the wall of the intestine, can present with acute abdomen, bloody stool, and paralytic ileus, potentially requiring surgical intervention though conservative management with factor replacement is generally preferred[57]. Hematuria (blood in urine) occurs when bleeding happens in the kidneys or urinary tract and may or may not be associated with flank pain depending on the bleeding location[9][60].

Spontaneous epistaxis (nosebleeds), bleeding from the oral mucosa and gums, and prolonged bleeding following dental procedures represent common mucosal bleeding manifestations[9][10]. Gastrointestinal and urinary tract hemorrhage, though serious, often respond well to aggressive factor replacement combined with antifibrinolytic therapy[60]. The application of local hemostatic measures including ice for mucosal bleeding, compression for accessible hemorrhage, and antifibrinolytic agents like aminocaproic acid can enhance hemostasis when combined with systemic factor replacement[5][10][60].

Complication Development: Inhibitor Formation and Its Immunological Basis

Factor IX Inhibitor Epidemiology and Immunological Mechanisms

One of the most serious complications affecting patients with hemophilia B is the development of inhibitory antibodies (inhibitors) to factor IX replacement therapy, which occurs in approximately 3-5 percent of hemophilia B patients with severe disease[9][23][30]. These inhibitors represent neutralizing IgG alloantibodies that bind to infused factor IX and block its biological activity, rendering replacement therapy ineffective and dramatically complicating bleeding management[9][23]. The prevalence of inhibitors in hemophilia B is substantially lower than in hemophilia A (5-10 percent), reflecting differences in the immunogenicity of the two factor proteins and the mutation types typically associated with each disease[4][23][30].

The development of factor IX inhibitors is strongly associated with specific mutation types, particularly large deletions, nonsense mutations, and some frameshift mutations that produce null mutations preventing any FIX protein synthesis[1][23]. Approximately 70 percent of hemophilia B patients who develop inhibitors carry high-risk mutations including large deletions or nonsense mutations[1][23][30]. Missense mutations, which produce structurally altered but still-present FIX protein, carry much lower inhibitor risk and rarely cause inhibitor formation except in rare cases[1][4]. This genotype-inhibitor association reflects the immunological principle that exposure to completely foreign proteins (those with major structural differences) triggers stronger immune responses than exposure to minimally altered self-proteins[1][23][30].

The immunological mechanism driving inhibitor development involves recognition of infused factor IX as a foreign antigen by the adaptive immune system, particularly in patients whose bodies have never produced normal FIX protein[23]. The "danger signal" hypothesis proposes that early infusion of factor VIII or factor IX in the absence of tissue injury-associated danger signals may actually prevent inhibitor development, whereas infusion in the context of bleeding with associated inflammation and cellular damage promotes immune responses[23]. Supporting evidence comes from the CANAL cohort demonstrating that regular prophylaxis was associated with a 60 percent lower risk of inhibitor development compared to on-demand treatment[23].

A particularly concerning aspect of factor IX inhibitor formation is the development of anaphylactoid reactions in up to 60 percent of patients with factor IX inhibitors, in contrast to the rarity of anaphylaxis in hemophilia A inhibitor patients[1][9][23]. These allergic reactions can range from mild urticaria to severe anaphylaxis with cardiovascular collapse and death[1][23][30]. The mechanism underlying this differential anaphylaxis risk in hemophilia B remains incompletely understood but may relate to the immunoglobulin isotype distribution of inhibitors or specific epitopes recognized by B cells in hemophilia B[1][23]. Patients developing anaphylactoid reactions to factor IX require desensitization protocols before attempting immune tolerance induction therapy[23].

Immune Tolerance Induction: Mechanisms and Limitations

Immune tolerance induction (ITI) therapy attempts to induce immunological tolerance to infused factor IX through repeated exposure to high-dose factor in the context of immunosuppressive or tolerogenic interventions[23][59]. Various ITI regimens have been studied, including high-dose factor with IVIG and cyclophosphamide, with reported success rates ranging from 59-82 percent[23]. However, the success rate of ITI in hemophilia B patients is substantially lower than in hemophilia A patients, with only approximately 30-50 percent of hemophilia B inhibitor patients achieving successful tolerance induction[23][30].

The limited success of ITI in hemophilia B reflects the immunological difficulty in tolerizing against large deletions and nonsense mutations producing structurally very different or absent FIX proteins[23]. Desensitization protocols may be necessary for patients with anaphylactoid reactions prior to attempting ITI[23][30]. Immune tolerance induction is not pursued by all patients due to the significant time and cost burden, with some patients choosing to rely instead on bypassing agents such as activated prothrombin complex concentrate (aPCC) or recombinant activated factor VIIa for bleeding management[23][30][59].

Sex-Specific and Age-Related Aspects of Hemophilia B Pathophysiology

X-Linked Inheritance and Its Consequences for Male and Female Patients

Hemophilia B follows an X-linked recessive inheritance pattern, with the F9 gene located on the lower portion of the X chromosome that lacks a corresponding locus on the Y chromosome[5][10][53]. This inheritance pattern has profound consequences for disease expression and transmission. Males, possessing only one X chromosome inherited from their mother, have only one copy of the F9 gene and consequently develop hemophilia B if that single X chromosome carries a hemophilia allele[5][10][53]. Females, inheriting two X chromosomes (one from each parent), require two copies of hemophilia alleles to develop hemophilia B, a situation occurring only when both parents carry the defective allele—an extremely rare circumstance[5][10][53].

However, the conventional understanding that carrier females remain asymptomatic requires substantial revision based on contemporary understanding of X-chromosome inactivation (lyonization). During early fetal development, each female cell undergoes random inactivation of one X chromosome, with the inactive X becoming a heterochromatin structure called a Barr body[40][53]. Normally, this process is random, resulting in approximately 50 percent of cells maintaining the maternal X chromosome and 50 percent maintaining the paternal X chromosome as active[40][53]. In heterozygous females carrying one hemophilia allele and one normal allele, this 50-50 distribution means that approximately half of hepatic cells (where FIX is synthesized) express normal FIX and half express defective or no FIX, resulting in approximately 50 percent of normal factor IX levels[5][37][40].

In some female carriers, however, the lyonization process becomes "skewed," with preferential inactivation of one X chromosome in most cells[40][53]. If the X chromosome carrying the normal FIX allele becomes preferentially inactivated through skewed lyonization, a carrier female may produce predominantly defective FIX and consequently develop a hemophilia B bleeding phenotype[5][40]. Carriers with skewed X-inactivation toward the defective allele can present with factor levels ranging from less than 1 percent to levels insufficient to prevent all bleeding, and such women experience bleeding symptoms identical to males with similar factor levels[5][37][40]. Furthermore, many female carriers with low factor expression experience heavy menstrual bleeding, easy bruising, and joint bleeds; some develop target joints identical to those seen in males with hemophilia[5][37].

Age and Disease Progression: Different Bleeding Patterns Across the Lifespan

The clinical manifestations of hemophilia B change throughout the lifespan, with infants and young children presenting with different bleeding patterns than older adolescents and adults[9][36][58]. In infants with severe hemophilia B, bleeding may occur after circumcision (though some infants are diagnosed through family history or screening without any bleeding), and intramuscular vaccinations may trigger muscle hematomas[9][58][60]. As infants become mobile, bleeding into joints occurs with increasing frequency as minor traumatic events inevitable in learning to walk trigger hemarthrosis[9][58]. Intracranial hemorrhage risk is highest in the neonatal and early infancy period, with 3-4 percent of hemophilia B patients experiencing ICH at birth[9][58].

Joint bleeding rates show characteristic age variation, with peak bleeding frequency occurring in the 10-24 year age group and again in the 25-44 year age group[36]. This age-related pattern reflects increased physical activity and sports participation in adolescents and young adults, combined with ongoing degenerative changes in joints already damaged by prior hemarthrosis in older adults[36]. Data from the Universal Data Collection program demonstrate that hemophilia B patients with similar factor levels experience substantially different bleeding rates depending on age, with young adults experiencing higher hemarthrosis frequencies than children or older individuals[36].

Women with hemophilia B face unique challenges related to menstruation, pregnancy, and postpartum bleeding. Women with moderate-to-severe hemophilia often experience menorrhagia (heavy menstrual bleeding) if their factor levels are sufficiently reduced, and some require hormonal contraception or prophylactic factor infusions during menses[5][10]. Pregnancy presents particular complexity because some hemophilic women experience significant improvement in factor levels during pregnancy (as pregnancy-associated stress can drive compensatory synthesis), while others maintain low levels throughout pregnancy[5][10]. Postpartum hemorrhage risk is elevated in women with significant factor deficiency, necessitating peripartum factor replacement and monitoring[5][10].

Recent Therapeutic Advances Reshaping Hemophilia B Pathophysiology Management

Gene Therapy: Introducing a Functional F9 Gene via Adeno-Associated Vectors

Adeno-associated virus (AAV)-based gene therapy represents a transformative approach to hemophilia B pathophysiology management by introducing a functional copy of the F9 gene directly into patients' hepatocytes, allowing endogenous production of factor IX without continued dependence on intravenous infusion[25][28]. Multiple AAV-based gene therapies have completed clinical trials with encouraging results demonstrating sustained FIX expression and significant reduction in annualized bleeding rates and factor infusion requirements[25][28]. A systematic review and meta-analysis examining 12 hemophilia B trials enrolling 184 patients found mean factor IX levels at 12 months of 28.72 IU/mL, with factor expression being notably more durable for hemophilia B than hemophilia A, with FIX levels remaining at 95.7 percent of peak at 24 months[25].

In 2022, the FDA approved etranacogene dezaparovovec (Hemgenix), an AAV5-based vector containing the F9-Padua variant, a naturally occurring gain-of-function mutation (R338L) that increases specific FIX activity by 4- to 40-fold, enabling significant therapeutic benefit even at lower transgene expression levels[30][43]. This gain-of-function approach addresses a critical limitation of earlier AAV vectors in achieving sufficient FIX levels through dose-escalation while avoiding hepatic toxicity from high vector capsid loads[43][46]. The R338L variant increases FIX specific activity 6-fold or greater compared to wild-type FIX while maintaining normal regulation by endogenous anticoagulants[43][46].

However, AAV-based gene therapy faces important challenges relevant to understanding disease pathophysiology management. Preexisting neutralizing antibodies to AAV vectors can eliminate therapeutic efficacy; studies show that higher pre-existing NAb titers prevent transgene expression even though higher vector doses can overcome moderate titers[28]. The cellular immune response to AAV capsid proteins has limited some patients' transgene expression through mechanisms involving rise in transaminases, decline in factor activity, and clearance of transduced hepatocytes[28]. Importantly, gene therapy has introduced novel safety concerns including rare cases of hepatocellular carcinoma development in patients with longstanding hepatitis C infection[28]. Additionally, one patient achieving supraphysiologic FIX activity (200-520 percent) developed thrombosis in an arteriovenous fistula, suggesting a therapeutic window exists that extends to the upper limit of normal but not beyond[28].

Non-Factor Replacement Strategies: Rebalancing the Coagulation Cascade

Beyond factor replacement and gene therapy, emerging therapeutic strategies target anticoagulant proteins to rebalance dysregulated coagulation. Tissue factor pathway inhibitor (TFPI) represents a key anticoagulant that suppresses early stages of coagulation by inhibiting the TF-FVIIa complex and early forms of prothrombinase[51][54]. TFPI inhibition aims to enhance hemostasis through rebalancing by enabling the extrinsic and common pathways to function more efficiently despite the absence of FIX[51][54]. Because TFPI is a major physiological regulator of bleeding in hemophilia, selective inhibition of platelet TFPI (rather than endothelial TFPI) may provide optimal therapeutic benefit while minimizing thrombotic risk[51][54].

Concizumab, a monoclonal antibody targeting TFPI, represents a TFPI-inhibition strategy under investigation for hemophilia B[30][51]. Other approaches under development include emicizumab, a bispecific antibody replacing the cofactor role of factor VIII in bridging activated factor IX to activate factor X[59]. While emicizumab is currently FDA-approved for hemophilia A prophylaxis with or without inhibitors, the potential for similar approaches targeting the factor IX pathway remains under exploration for hemophilia B[59].

Chemical Chaperones and Protein Misfolding Correction

An alternative molecular mechanism for treating some hemophilia B variants involves correction of protein misfolding in the endoplasmic reticulum. Chemical chaperones such as betaine promote protein folding and enhance secretion of misfolded FIX proteins into plasma[18]. Studies in hemophilia A demonstrate that betaine feeding significantly increases FVIII secretion in vitro and in vivo[18]. While fewer studies have examined betaine effects in hemophilia B, the principle of correcting protein misfolding through chemical chaperone supplementation represents a potential therapeutic avenue for hemophilia B patients with missense mutations causing ER retention of FIX protein[18].

Conclusion: Integrating Molecular Understanding with Clinical Practice

Hemophilia B pathophysiology represents a paradigm of how a single gene defect produces a systemic cascade of consequences affecting hemostasis, with disease expression ranging from asymptomatic carrier states to life-threatening spontaneous hemorrhage. The F9 gene mutations causing hemophilia B operate through multiple distinct mechanisms—complete loss of protein synthesis through nonsense and frameshift mutations, production of functionally defective proteins through missense mutations, impaired post-translational modification through propeptide mutations, and dysregulated gene expression through promoter mutations. These diverse genetic mechanisms converge on a common functional outcome: insufficient factor IX in the circulation to generate adequate thrombin through the intrinsic tenase complex, resulting in inadequate amplification of coagulation and clinical bleeding.

The intrinsic pathway deficiency underlying hemophilia B becomes clinically manifest through tissue-specific bleeding patterns reflecting local tissue factor expression and hemodynamic factors. Joints and skeletal muscles, with low tissue factor expression and susceptibility to microvascular injury, become primary bleeding sites where the intrinsic pathway's critical amplification role becomes physiologically essential. The recurrent hemarthrosis characteristic of severe hemophilia B initiates a vicious cycle of inflammation, iron-mediated oxidative damage, and progressive joint destruction that ultimately produces hemophilic arthropathy—the primary cause of morbidity in hemophilia B.

Contemporary management of hemophilia B is rapidly evolving toward curative approaches including gene therapy that addresses the fundamental F9 gene defect through hepatocyte-directed transgene delivery. The approval of AAV-based gene therapy containing the F9-Padua gain-of-function variant represents a watershed moment in hemophilia medicine, potentially offering one-time treatment converting severe hemophilia B to a mild or asymptomatic state. However, the limitations of current gene therapy, including neutralizing antibody exclusions and rare but serious adverse events, underscore the continued need for improved therapeutic approaches and deeper understanding of how the immune system responds to gene delivery vectors.

The emerging class of non-factor replacement strategies targeting anticoagulant proteins offers mechanistically distinct therapeutic approaches that bypass the missing factor entirely through rebalancing the procoagulant-anticoagulant equilibrium. These approaches promise to eliminate factor inhibitor complications and reduce treatment burden through less frequent dosing or single administrations. As hemophilia B therapeutics continue to advance toward curative modalities, the pathophysiological framework presented here—linking genetic mutation to protein dysfunction to hemostatic impairment to clinical manifestation—remains essential for understanding disease biology, predicting treatment responses, and guiding the development of next-generation therapies addressing remaining unmet clinical needs in this complex bleeding disorder.